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Abstract  
Von Willebrand Factor (VWF) is a large multi-domain plasma glycoprotein that is 
critical for normal platelet tethering during haemostasis. ADAMTS13 is a plasma 
metalloprotease that regulates VWF multimeric size/function by cleaving the 
Tyr1605-Met1606 bond in the VWF A2 domain. Deficiency of ADAMTS13 causes 
microvascular thrombosis. The only reported cleavage of VWF by ADAMTS13 is 
that of the Tyr1605-Met1606 bond. How this high substrate specificity is conferred 
remains unclear. To date, all the interactions between these molecules that have been 
described involve VWF residues C-terminal to the scissile bond and the non-catalytic 
domains of ADAMTS13. I hypothesised that VWF also contains an interaction site 
for ADAMTS13 N-terminal of the cleavage site to aid both in positioning of the 
scissile bond in the active site and substrate specificity. Previous studies have 
suggested that the VWF sequence between Asp1596 and Val1604, N-terminal to the 
cleavage site, is essential for cleavage by ADAMTS13. My aim was to identify the 
residues in this region that are important determinants for ADAMTS13 proteolysis. A 
panel of mutations were introduced into the substrate VWF 115 (VWF residues 1554-
1668). The mutants were expressed purified and their proteolysis by ADAMTS13 
analysed. It was found that the proteolysis of VWF 115 variants (L1603A, L1603S, 
L1603N or L1603K) were all substantially impaired (up to >400 fold reduction). The 
importance of VWF Leu1603 was confirmed using a synthetic 
peptide 1596DREQAPNLVY1605, which competitively inhibited proteolysis of VWF 
115 by ADAMTS13. A mutant peptide containing the L1603A 
mutation, 1596DREQAPNAVY1605, had minimal effect. When the VWF L1603A 
substitution was introduced into the full-length recombinant VWF, proteolysis by 
ADAMTS13 was again substantially reduced. These findings implied the presence of 
a subsite (S3) in the ADAMTS13 metalloprotease (MP) domain that interacts with 
VWF Leu1603. Using molecular modelling, the distance between VWF Leu1603 and 
the scissile bond was estimated as ~10Å. Structural homology modelling of the MP 
domain, mutagenesis of 11 candidate residues and functional characterisation of these 
variants identified two clusters, Leu198/Leu232/Leu274 and Val195/Leu151, as 
possible subsites interacting with VWF. It is suggested that VWF Leu1603 interacts 
with Leu198/Leu232/Leu274, while Val195/Leu151 may interact with VWF Tyr1605. 
I propose a mechanism for VWF cleavage involving remote C-terminal domain 
interactions that assist initial orientation of the VWF scissile bond within the active 
site of ADAMTS13, but in which N-terminal hydrophobic interactions between VWF 
Leu1603 and the S3 subsite in the MP domain of ADAMTS13 are critical for the 
positioning required for cleavage of the Tyr1605-Met1606 scissile bond.  
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CHAPTER 1: INTRODUCTION 
1.1 Overview of haemostasis  
Haemostasis is the physiological process which prevents blood loss following injury 
to blood vessels. There are four basic mechanisms that form the haemostatic response: 
vasoconstriction, platelet plug formation, blood coagulation and fibrinolysis [1]. The 
vascular endothelial cells, platelets, coagulation factors, fibrinolytic factors and 
various inhibitors that control the activities of proteolytic enzymes are the components 
that are involved in haemostasis. 
1.1.1 Vasoconstriction 
Instant constriction of injured vessels is the first stage of haemostasis.  
Vasoconstriction arises from a local contractile response, but may also be triggered by 
vasoconstrictive cytokines (such as endothelin) released by the endothelial cells lining 
the vessel wall [2]. Vasoconstriction causes a decrease in blood flow to the site of 
vessel damage and consequently mechanically limits blood loss. 
1.1.2 Platelet plug formation 
Platelet plug formation is the second process involved in haemostasis and occurs 
independent of vasoconstriction. Platelets are cellular fragments derived from 
megakaryocytes, that circulate in plasma [3]. Once the subendothelial layers are 
exposed due to the damage to the endothelium, platelets immediately adhere to the 
revealed collagen, which begins a process of cellular activation [4]. The activated 
platelets release a variety of granule substances (such as adenosine diphosphate, 
serotonin, von Willebrand factor (VWF) [see section 1.2]) [5], which positively 
activate and recruit more platelets to the area around the injury and form an unstable 
platelet plug. The formation of platelet plug is sometimes termed primary haemostasis. 
The platelet plug temporarily blocks the blood loss at the site of vessel damage. 
1.1.3 Blood coagulation  
A series of proteolytic reactions, which forms a coagulation cascade, is initiated in the 
third stage of haemostasis. The coagulation cascade is initiated by tissue factor, 
exposed at the site of injury. Tissue factor is a lipoprotein mainly in membranes of 
cell present in subendothelial tissue [6]. It interacts with factor VII(a), and this 
complex can activate factor X and factor IX through separate pathways, termed the 
extrinsic and intrinsic pathways. Both of these pathways result in formation of factor 
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Xa, which is able to proteolytically activate prothrombin to thrombin. Thrombin is a 
key protease generated during coagulation, as it has numerous functions including 
activating platelet and proteolysing fibrinogen. Because of the amplication nature of 
the coagulation cascade, there is potential for excess proteases generation. To regulate 
this, at least three inhibitory systems are present, involving the protease inhibitors, 
antithrombin and tissue factor pathway inhibitor (TFPI), as well as a protease 
generated by thrombin, activated protein C. The coagulation cascade leads ultimately 
to the conversion of fibrinogen to fibrin which forms a fiber mesh, which stabilises 
the haemostatic plug. This stage of haemostasis is sometimes termed secondary 
haemostasis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
1.1.4 Fibrinolysis 
The final stage of haemostasis is fibrinolysis. This breaks down the blood clot. 
Fibrinolysis is mediated by a specific enzyme, plasmin, which proteolyses fibrin at 
arginine and lysine residues [7]. Plasmin is converted from plasminogen, which is 
activated by tissue plasminogen activator (t-PA) and urokinase (also named 
urokinase-type plasminogen activator (u-PA)) [8, 9]. Both t-PA and u-PA are 
inhibited by plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 
(PAI-1 and PAI-2) [10]. The activity of plasmin is also inhibited by thrombin-
activatable fibrinolysis inhibitor (TAFI), which limits plasminogen binding to fibrin 
as well as the formation of plasmin [11].  
1.1.5 The balance of haemostasis 
The balance of haemostasis plays an essential role in maintaining normal blood 
circulation. While inadequate haemostasis can lead to bleeding disorders such as those 
seen in the haemophilia and  von Willebrand disease (VWD) (see section 1.2.4), 
excessive haemostasis can cause obstructive thrombotic disorders, such as deep vein 
thrombosis, stroke, myocardial infarction, and thrombotic thrombocytopenic purpura 
(TTP) (see section 1.3.5) [12]. The haemostatic balance is regulated by numerous 
factors, including those involved in controlling platelet activation, coagulation, and 
fibrinolysis. My thesis is focused on mechanisms involved in the control of the 
primary haemostasis when the platelet first recognizes the damaged endothelium. 
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 1.2 Platelet recognition of the damaged endothelium 
In normal circulation, the adhesive glycoprotein VWF does not interact with the 
platelet. However, injury to the endothelium induces VWF to bind to exposed 
subendothelial matrix proteins, primarily collagen. Upon binding to collagen, VWF 
unravels into a “string-like” conformation from an original globular form. This 
conformational change exposes multiple platelet GpIbα binding sites [13, 14]. VWF 
acts as a bridge between platelets and the damaged endothelium that otherwise would 
have difficulty interacting under the conditions of high shear stress that prevails in 
vivo [15]. The ability of VWF to bind to collagen, unfold and capture platelets is 
highly dependent upon its multimeric size, with larger VWF multimers more able to 
capture platelets. Shear stress in vessels also increases the transport of platelets 
towards the vessel wall, enhancing their interaction with VWF [16]. The initial 
contact and interaction between platelet GpIbα and VWF is rapid but reversible.  
1.3 Von Willebrand Factor 
VWF is a large multi-domain multimeric glycoprotein that plays an essential role in 
regulating the balance between blood clotting and bleeding [17]. Abnormalities 
affecting VWF can lead to health problems, such as bleeding disorders and 
thrombosis. The haemostatic properties of circulating VWF are dependent upon its 
molecular size. 
1.3.1 Synthesis and secretion of VWF 
The VWF gene is located at the tip of the short arm of chromosome 12 (region 12p12-
12pter), and contains 52 exons [18]. It is approximately 180kb in length [17]. 
Expression of the VWF gene is mainly in vascular endothelial cells and 
megakaryocytes. The VWF cDNA translation product is a 2813-residue pre-pro-VWF 
which then enters the endoplasmic reticulum, where the signal peptide is 
proteolytically cleaved [19]. With the addition of N-linked and O-linked 
oligosaccharides, the pro-VWF is glycosylated in the endoplasmic reticulum. VWF 
dimerisation subsequently occurs through disulphide bond formation close to its 
carboxyl terminus. These dimers are transported to the Golgi apparatus, where 
multimerisation through disulphide bond formation between the amino-termini of 
adjacent dimers occurs. Multimerisation is promoted by the VWF propeptide. 
Additional modifications in the Golgi include the removal of the propeptide the paired 
dibasic amino acid-cleaving enzyme furin and the completion of glycosylation. 
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Eventually, multimerisation gives rise to VWF with a molecular weight ranging from 
500kDa to 20,000kDa, or more [16]. The majority of newly synthesised VWF 
multimers undergo basal secretion into the plasma and the sub-endothelial matrix; the 
rest are stored either in the Weibel-Palade bodies of endothelial cells or in the α 
granules of platelets. These storage granules contain ultra large multimers, whereas 
plasma VWF is composed of a range of smaller multimers arising in part from 
proteolytic cleavage [20].   
1.3.2 Structure of VWF 
A mature VWF subunit consists of 2050 amino acids, lacking the signal peptide of 22 
residues and a propeptide of 741 residues, when compared to the 2813-residues pre-
pro-VWF subunit [19]. The mature VWF is extensively glycosylated and greatly rich 
in cysteines. A schematic domain structure of VWF composed of five D domains (D1, 
D2, D3, D4, and D’), three A domains (A1, A2 and A3), three B domains (B1-3), two 
C domains (C1 and C2) and CK domain, is shown in Figure 1.1 [16].  
 
Figure 1.1 Structural domain organization of VWF. The diagram shows the order and 
positions of the repeated domains (five D domains, three A domains, three B domains and 
two C domains). Major binding sites and regions involved in multimerisation are highlighted 
below the diagram. The red arrow in the middle indicates the ADAMTS13 cleavage site, 
while the red arrow above the residue 763 shows where pro-sequence is cleaved by furin. This 
figure was adapted from [16]. 
1.3.2.1 D domains 
Following the signal peptide, the 22 amino acids N-terminal part of the nascent VWF, 
the D1 and D2 domains comprise the propeptide which is cleaved by the enzyme furin 
at the residue 763 in mature VWF [21]. The Dl and D2 domains are required for 
assembly of pro-VWF dimers into multimers. Expression of a variant VWF gene 
lacking the cDNA encoding the propeptide, generated only VWF dimers [22] and 
 22 
VWF dimers lacking the propeptide do not form multimers in vitro [23]. Moreover, 
one mutation (Y87S) in the D1 domain resulted in failure of N-terminal 
multimerisation [24]. In addition to the Dl and D2 domains, both the D' and the D3 
domain are also required for multimer assembly. This conclusion is evidenced by the 
findings that the multimeric pattern of the mutant VWF proteins were unable to form 
multimers when the D' or D3 domain or both domains were deleted. However, the 
role of these two domains in the VWF multimerisation is different in that the D3 
domain functions through the formation of intermolecular disulphide bonds from the 
cysteine residues in this domain [23]. In contrast, the D' domain does not contain free 
sulphydryl groups for disulphide bonding and therefore it performs an unknown 
function essential for the assembly of multimers. Using a VWF truncation mutant that 
lacked the A, D4, B, C and CK domains, Voorberg et al. [23] identified that the C-
terminal dimerisation of VWF was not required for the formation of intermolecular 
disulphide bonds at the N-terminus of the molecule, suggesting multimerisation of 
VWF is independent of its dimerisation. 
The D’ and the D3 domains contain binding sites for factor VIII [25-27]. Takahashi et 
al. [26] established that the region for factor VIII binding to VWF was located on a 
34kDa fragment of the N-terminus of VWF, between residues 1 and 910. Applying 
two-dimensional crossed immunoelectrophoresis, Foster et al. [27] further identified 
such a binding region for factor VIII to VWF on the N-terminal 272 residues of the 
mature VWF subunit, located on the D’ and the D3 domains. Using a centrifugation 
binding assay, the binding kinetics of VWF- factor VIII association was characterized 
[28]. Based on the kinetic parameters, it was estimated that the time required for 
plasma VWF (50nmol/L) to bind 50% of factor VIII was approximately two seconds 
[28]. 
No function for the VWF D4 domain was described until recently, when using surface 
plasmon resonance and plate binding assays, Zanardelli et al. [29] identified a binding 
site (KD ~ 86nM) for the VWF-cleaving protease (see section 1.4) in the region of this 
domain.  
1.3.2.2 A domains 
The VWF A1, A2 and A3 domains are homologous and span residues ranging from 
Asp1260 to Gly1874. Two cysteine residues in both the A1 domain (Cys1272 and 
Cys1458) and A3 domain (Cys1686 and Cys1872) form intramolecular disulphide 
bonds and stabilise loops of identical length [30, 31]. In contrast, it is adjacent 
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cysteine residues (Cys1669 and Cys1670) in VWF A2 domain that form a vicinal 
disulphide bond plug that is thought to stabilize this domain [32, 33]. Crystal 
structures for all the three A domains have been determined by X-ray crystallography 
and these show that the domains are characterised by several central ß-sheets flanked 
on both sides with α-helices [30-32]. 
1.3.2.2.1 A1 domain 
The A1 domain contains binding sites for platelet GpIbα receptor (one component of 
the platelet GpIb-IX-V complex), heparin and collagen [34-36]. The interaction 
between the A1 domain and platelet GpIbα receptor supports the tethering of 
circulating platelets to the VWF multimers. The residues of the A1 domain interacting 
with GpIbα were first demonstrated by using one specific VWF fragment (residues 
1212-1491) which was able to inhibit the ristocetin induced platelet aggregation [37]. 
In addition, a similar VWF fragment (residues 1208-1496) was also found able to 
inhibit platelet aggregation and competitively inhibit the binding of anti-GpIbα 
monoclonal antibody to platelets [38]. Furthermore, a deletion mutant of VWF 
lacking the A1 domain was unable to initiate the ristocetin induced platelet 
aggregation [36]. Using recombinant A1 domain with a series of deletion mutations at 
the region of GpIbα binding, it was revealed that the A1 domain contains multiple 
interaction sites for GpIbα binding and integrity of the residues between the 
intramolecular disulphide bond (Cys1272 and Cys1458) was important for their 
interaction [39]. Using a series of synthetic VWF peptides, it was demonstrated that 
the VWF sequence Asp1277-Glu1305 was the major site of VWF binding to GpIbα 
[40]. These findings were further confirmed by crystal structure of the A1 domain and 
its complex with GpIbα [34]. As shown in Figure 1.2, the structure of the A1 domain 
contains central parallel ß-sheets flanked on two sides by α-helices. A disulphide bond 
formed between Cys1272 and Cys1458 connects the N- and C-terminus. The crystal 
structure of the A1 domain-GpIbα complex indicates that the A1 domain interacts 
with the concave side of the GpIbα, involving two distinct contact areas. The first 
contact site is located at the top of the A1 domain (Figure 1.2), where the interaction 
between the A1 (α3-helix, α3ß4-loop, and ß3 strand) and GpIbα (leucine rich repeats 
5-8 and its C-terminal residues) occurs. The second contact site is located at the 
bottom of the A1 domain (Figure 1.2), involving the interaction of the A1 (loops α1ß2, 
ß3α2 and α3ß4) with GpIbα (the first leucine rich repeat and its N -terminal ß finger). 
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This structural information can explain the effects of specific gain-of-function 
mutations related to von Willebrand disease (section 1.3.4). 
Heparin was found to competitively inhibit the binding of the VWF A1 domain to 
GpIbα [41]. Binding to heparin was almost abolished if a deletion mutant of VWF 
lacking the A1 domain was used [36]. Using site-directed mutagenesis and heparin-
Sepharose beads binding assays, it was further demonstrated that VWF residues 
Lys1362, Arg1395, and clusters 1332KDRKR1336 and 1405KKKK1408
1.3.2.2.2 A2 domain 
, are important 
residues for heparin binding to the VWF A1 domain [41]. While a collagen binding 
site was also identified within the VWF A1 domain, it is only a minor binding site, 
with the major collagen binding site located within the VWF A3 domain [36, 42] 
(section 1.3.2.2.3) 
The crystal structure of the VWF A2 domain has recently been determined [32]. As 
shown in Figure 1.3, the VWF A2 domain folds with α-helices and ß-sheets in a 
somewhat different structure to that of the VWF A1 domain. Although the central ß-
sheets are flanked on both sides with α-helices in the VWF A1 (and the A3) domains, 
the VWF A2 domain lacks an α4-helix. A loop and cis-proline replace the position of 
the α4-helix. The hydrophobic ß-sheet core contains ß-strands in the order ß3, ß2, ß1, 
ß4, ß5, and ß6, with ß3 antiparallel to the other five ß-strands (Figure 1.3).  
The VWF A2 domain contains a cleavage site at Tyr1605-Met1606, which is 
recognized and proteolyzed by the specific cleaving protease of VWF, ADAMTS13 
(see section 1.3). The ADAMTS13 cleavage site is present in the middle of the ß4-
strand, which is buried deep in the hydrophobic ß-sheet core of the A2 domain. The 
side chain of cleavage site residue Tyr1605 points to the C-terminus of the VWF A2 
domain and also contacts the side chain of residue Leu1603 at the ß4-strand. The 
other cleavage site residue, Met1606, is located on the opposite side of the ß-sheet.  
1.3.2.2.3 A3 domain 
Many groups have independently reported the crystal structure of the VWF A3 
domain [31, 43-45]. As shown in Figure 1.4, the VWF A3 domain consists of a 
central ß-sheet core containing six ß-strands, surrounded by seven α-helices. Except 
the ß3-strand, all other ß-strands are parallel. The disulphide bond formed by Cys1686 
and Cys1872 connects the N-terminus and C-terminus of the VWF A3 domain, which 
stabilises its conformation.   
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Figure 1.2 Crystal structure of the complex of the VWF A1 domain with GpIbα. The 
complex of the VWF A1 domain with GpIbα is shown in a cartoon view. The disulphide bond 
formed by Cys1458 (magenta) and Cys1272 (magenta), the contact site I and II residues 
shown in stick representation, are highlighted using Pymol. The original structural 
information was taken from PDB file 1M10 [34]. 
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VWF A2 domain 
 
Figure 1.3 Crystal structure of VWF A2 domain. The VWF A2 domain is shown in a 
cartoon view. The C-terminus (magenta) and the N-terminus (red) of this domain, and the 
proteolytic site (Tyr1605-Met1606) (yellow) buried within the core ß-sheet of this domain are 
highlighted using Pymol. The original structural information was taken from PDB file 3GXB 
[32].  
Collagen binding sites have been identified at both the VWF A3 domain and A1 
domain. It has been shown that VWF variant with the deletion of the A1 domain still 
binds to collagen type III, suggesting that the VWF A3 domain is sufficient for the 
interaction [36]. Indeed, a VWF variant with the deletion of the A3 domain, when 
preincubated on collagen type III, failed to support platelet adhesion under flow 
conditions [46]. These finding demonstrate that the VWF A3 domain contains the 
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major collagen binding site. Site-directed mutagenesis studies demonstrated that 
residues Asp1742, Ser1783 and His1786 in the VWF A3 domain (Figure 1.4) are 
essential for collagen binding [47, 48]. Other residues, Ile1738, Thr1740, Val1760, 
Glu1764, Arg1726 and Arg1779 have also claimed to be important, as mutation of 
these residues resulted in about 10-fold reduction in collagen-binding affinity [48]. 
The crystal structure of the VWF A3 domain suggests that its binding to collagen is 
achieved through interactions between negatively charged residues on the VWF A3 
domain and positively charged residues on collagen [31].  
 
 
VWF A3 domain 
 
Figure 1.4 Crystal structure of VWF A3 domain. A carton view of the VWF A3 domain is 
shown. The disulphide bond formed by Cys1686 (blue) and Cys1872 (yellow), and the 
collagen binding residues (Asp1742, Ser1783 and His1786) (green) in this domain are 
highlighted using Pymol. The original structural information was taken from PDB file 1AO3 
[31]. 
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1.3.2.3 C domains and CK domain 
Following the D4 domain, the C domains and CK domain are located at the C-
terminal part of the VWF monomer.  The C1 domain contains an Arg-Gly-Asp (RGD) 
motif, through which it binds to the platelet αIIbß3 receptor on the surface of the 
activated platelets [49]. The CK domain contains the cysteines that are involved in the 
process of dimerisation between the VWF monomers. The CK domains are 
characterized by 6 conserved cysteines (Cys2724, Cys2750, Cys2754, Cys2774, 
Cys2804 and Cys2806) [50]. Treatment by partial reduction alkylation, chemical and 
proteolytic digestion, and analysis by mass spectrometry and amino acid sequencing, 
these intramolecular disulphide bonds were identified: Cys2724–Cys2774 (1-4), 
Cys2750–Cys2804 (2-5), Cys2754–Cys2806 (3-6), and Cys2739–Cys2788 [50]. 
Disulphide bonds between Cys2750 and Cys2804 and between Cys2754 and Cys2806 
form a ring that is penetrated by the third disulphide bond between Cys2724 and 
Cys2774. Dimerisation is normally mediated by additional non-conserved cysteines 
that differ among CK domain subfamilies. Site-directed mutagenesis of residue 
Cys2771 or Cys2773 in the CK domain prevented dimerization of VWF subunit, 
suggesting that residue Cys2771 or Cys2773 or both of them participate in the 
dimerisation of VWF [50]. Together with intermolecular disulphide bond formation in 
the D3 domain, dimerisation in the CK domain enables the VWF monomers 
efficiently form larger or ultra-large multimers in plasma.  
1.3.3 The functions of VWF 
VWF has two principal roles: 1) it mediates rapid adhesion of platelets at sites of 
vascular perturbation [16], as described in section 1.2; 2) it acts as a carrier protein for 
coagulation factor VIII to maintain normal circulating factor VIII levels. 
The coagulation factor, factor VIII becomes a cofactor in the coagulation cascade 
when activated to factor VIIIa. The factor VIIIa localises and amplifies thrombin 
generation. However, it is susceptible to cleavage inactivation when the protein C 
pathway is activated by thrombin. This generates activated protein C, one function of 
which is to inactivate factor VIIIa. Through binding to the factor VIII, VWF stabilizes 
it and protects it from degradation by activated protein C [51]. During its activation, 
thrombin cleaves FVIII after Arg1689, disrupting the VWF binding site [52-54].This 
results in the active form of factor VIII being released from VWF, allowing thrombin 
generation to be increased dramatically [54-56]. 
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1.3.4 Von Willebrand disease (VWD) 
The VWF gene is highly polymorphic, with mutations causing Von Willebrand 
disease (VWD) scattered over the various domains. VWD is the most common human 
congenital bleeding disorder which results from either a qualitative or quantitative 
deficiency in VWF, largely caused by mutations in the VWF gene. In terms of its 
phenotypic expression, three types of VWD (Table 1.1) have been identified: partial 
quantitative deficiency (type 1), qualitative deficiency (type 2) and complete 
deficiency (type 3) [57, 58]. The properties of the indicated types of VWD are well 
differentiated by the distribution of plasma VWF multimers in patients with 
corresponding VWD, as shown in Figure 1.5. The type 1 VWD plasma shows a 
normal VWF multimeric distribution but at a lower concentration, compared to 
normal plasma. The type 2A VWD plasma lacks high molecular weight multimers, 
the deficiency extent of which is more than that of the type 2B VWD plasma. The 
type 3 VWD plasma exhibits an almost compete deficiency of VWF. The type 2 
VWD is further divided into four subtypes, 2A, 2B, 2M and 2N. The most common 
subtype, type 2A, is associated with a loss of the high molecular weight multimers, 
which can be due to a single amino acid substitution within the repeated A1 and A2 
domains. Molecular modelling of the A2 domain demonstrates that these mutations 
may alter the conformation of VWF, thereby resulting in a particularly unravelled 
protein more susceptible to proteolysis by the VWF cleaving protease, ADAMTS13 
(section 1.4) [59, 60]. The type 2B VWD is characterised with an abnormally high 
affinity of VWF for platelet GpIb whereas the Type 2M is associated with defective 
GpIb binding sites. Type 2N patients have decreased FVIII binding which 
subsequently leads to low FVIII levels and enhanced clearance [61]. 
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Table 1.1   Classification of von Willebrand disease [57] 
 
 
 
Figure 1.5 Distribution of plasma VWF multimers in patients with VWD. Plasma 
samples were analyzed for VWF electrophoresed by agarose gel followed by Western blotting. 
Multimer patterns for normal plasma (NP) and patients with the indicated types of VWD are 
shown. This figure was taken from Sadler 1994[58] 
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1.4 The von Willebrand  Factor cleaving protease, ADAMTS13 
VWF multimeric size is in part controlled by a unique plasma protease, termed 
ADAMTS13 (A Disintergrin And Metalloproteinase with ThromboSpondin type 1 
motif, member 13) [62-64]. The importance of ADAMTS13 in regulating VWF 
function can be seen in clinical disorders in which an imbalance of activity is 
responsible for haemostatic dysfunction. Excessive cleavage of VWF by ADAMTS13 
results in VWD, and is observed as Type 2A VWD (see section 1.2.4), while 
inadequate cleavage of VWF in association with ADAMTS13 deficiency causes 
microvascular thrombosis in thrombotic thrombocytopenic purpura (TTP) (see section 
1.3.5). 
1.4.1 Synthesis and secretion of ADAMTS13 
The ADAMTS13 gene, which is located at the chromosome 9q34, contains 29 exons.  
It is approximately 37kb in length [63]. The ADAMTS13 cDNA translation product is 
a 1427 amino acids protein with a predicted molecular weight of 145kDa [65]. The 
molecular weight of plasma ADAMTS13 is approximately 190kDa, the increase 
being due to glycosylation [66]. Synthesised primarily in the hepatic stellate cells, 
endothelial cells and megakaryocytes, ADAMTS13 is secreted into plasma as an 
active enzyme, has a concentration of approximately 1µg/ml (~5nM) and an estimated 
half life of two to three days [67]. 
1.4.2 ADAMTS13, a multi-domain protease 
ADAMTS13 belongs to a family of related proteases with diverse functions. 
ADAMTS family members share a number of  domains: a signal peptide and 
propeptide, a metalloproteinase domain (MP), a disintegrin-like domain (Dis), a 
Thrombospondin type 1 repeat domain (TSR), a Cysteine-rich domain (Cys), a Spacer 
domain, and additional TSR(s) [68] (Figure 1.6). ADAMTS13 has two additional C-
terminal CUB domains after the eighth TSRs [64]. The crystal structures of the MP 
domain of ADAMTS1, 4 and 5 are available [69-71], which provide information 
about the structure of other ADAMTS members, including ADAMTS13. In this thesis, 
I have used a homology structural model of the ADAMTS13 MP domain to attempt to 
understand structure-function relationships. The crystal structure of the noncatalytic 
ADAMTS13 domains Dis-TSR-Cys-Spacer (residues 287-685) fragment has recently 
been solved [72] (Figure 1.7). The structural characteristics of each domain will be 
discussed in detail below. 
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Figure 1.6 Domain organisation of ADAMTS13. ADAMTS13 contains a metalloprotease 
domain (MP), a Disintegrin-like domain (Dis), a thrombospondin type-1 motif (TSR), a 
cysteine rich domain (Cys), a Spacer domain, seven thrombospondin type-1 repeats and two 
CUB domains. Adapted from [64] 
 
 
Figure 1.7 Structure of ADAMTS13 N-terminal domains (MDTCS).The structural 
homology modelling of the MP domain is based on the crystal structure of ADAMTS1, 4 and 
5 and prepared using the HHPred server (http://toolkit.tuebingen.mpg.de/hhpred) and Pymol 
(http://www.pymol.org). The original structural information of the crystal structure of Dis-
TSR-Cys-Spacer domains was taken from PDB file 3GHM [72]. Surface representation is 
shown. Functionally important residues in each domain are highlighted, which will be 
discussed in detail in following sections. 
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1.4.2.1 MP domain (Residues 75–289) 
The MP domain of ADAMTS family members consists of about 200 amino acids. 
The amino acid sequence motif HEXXHXXGXXH and a methionine constituting turn 
(Met-turn) are highly conserved in this domain of ADAMTS family members and 
form a Zn2+ binding environment. The bound Zn2+ and a nearby glutamate coordinate 
a water molecule, driving the peptide hydrolysis [73-75]. In ADAMTS13, Glu225 has 
this catalytic role. The Glu225 removes a proton (H+) from the Zn2+
The function of ADAMTS13 is also highly dependent on the Ca
-coordinated 
water molecule to form a hydroxyl ion that attacks the VWF Tyr1605 carbonyl group. 
This eventually leads to the hydrolysis of the VWF scissile bond (Tyr1605-Met1606).  
2+. Using site-directed 
mutagenesis, our lab has identified the residues Glu184, Asp187 and Glu212, close to 
the ADAMTS13 active site, as a high-affinity functional Ca2+ binding site in the 
ADAMTS13 MP domain [76] (Figure 1.8). These three Ca2+ binding residues are 
highlighted on the surface of the structural homology model of the ADAMTS13 MP 
domain, which is based on the crystal structure information of ADAMTS1, 4 and 5 
and prepared using the HHPred server (http://toolkit.tuebingen.mpg.de/hhpred) and 
Pymol (http://www.pymol.org). It was found the ADAMTS13 variants, E184A, 
D187A, and E212A dramatically increase the KD(app) for Ca2+ in ADAMTS13 
cleavage of small VWF fragment [76]. Under conditions of the cleavage reactions 
incubated with sufficient Ca2+
Apart from the Zn
, kinetic analysis of the ADAMTS13 D187A variant 
revealed a ~13-fold reduction in kcat/Km [76]. 
2+ and Ca2+ binding environment, some other residues in the MP 
domain can also be considered to be important for the high specificity and proteolytic 
efficiency of ADAMTS13 on its unique substrates VWF and the scissile bond. For 
instance, a S1 subsite (residues in MP domain interacting with Tyr1605) and a 
S1’subsite (residues in MP domain interacting with Met1606) must be important for 
cleavage of VWF. It can be noted that mutations of VWF Tyr1605 (P1) or Met1606 
(P1’) dramatically reduce its proteolysis by ADAMTS13 [77]. To describe the 
terminology [78, 79], residues and subsites including P1, P1’, S1 and S1’, I have 
prepared an illustrative diagram in Figure 1.9. Residues in the substrate, VWF, are 
termed Ps. The first residue N-terminal to the scissile bond is termed P1, and the 
residues before P1 are P2, P3… in turn. The first residue C-terminal to the scissile 
bond is termed P1’, and the next residue are P2’, P3’…in turn. The S1, S2, S3 and S1’, 
S2’, S3’ subsites are labelled according to which substrate P residue they 
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accommodate. The various S subsites in ADAMTS13 should accommodate the side 
chains of these P residues in VWF.  Recently, our lab has identified residues (D252-
P256) in the ADAMTS13 MP domain as comprising the S1’ subsite and these 
residues therefore contribute to scissile bond specificity [80]. However, very little is 
known on the ADAMTS S1 and other S subsites. This will be investigated in this 
thesis. 
 
Figure 1.8 Structural homology model of the ADAMTS13 MP domain. The structural 
homology model is based on the crystal structure of ADAMTS1, 4 and 5 and prepared using 
the HHPred server (http://toolkit.tuebingen.mpg.de/hhpred) and Pymol 
(http://www.pymol.org). The functionally important residues in the MP domain are 
highlighted. The catalytic Zn2+ (red), surrounding with three histidines (yellow), is located at 
the active centre of the MP domain. The catalytic Glu225 (magenta) is also involved in the 
hydrolysis process of VWF scissile bond. The Ca2+ (green) binding residues (Glu184, Asp187 
and Glu212) (blue) are also shown. 
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Figure 1.9 General nomenclature of residues and subsites around the VWF cleavage site 
and ADAMTS13 active site. Residues in VWF are termed Ps. The first residue N-terminal to 
the scissile bond is termed P1, and the residues before P1 are P2, P3… in turn. The first 
residue C-terminal to the scissile bond is termed P1’, and the next residue are P2’, P3’…in 
turn. S1, S2, S3 and S1’, S2’, S3’ are subsites, and are termed according to which substrate P 
residue they accommodate. The general nomenclature of cleavage site positions of the 
substrate was formulated by Schecter and Berger [78, 79] 
1.4.2.2 Disintegrin-like domain (Dis) 
The Dis domain follows the MP domain, between which there is a short linker 
sequence. The structure of this domain in ADAMTS family members ADAMTS1, 4 
and 5 has been solved and, more recently, the crystal structure of the ADAMTS13 Dis 
domain, as part of the Dis-TSR-Cys-Spacer structure, has also been solved [72], 
shown in Figure 1.8. The Dis domain (residues 290–385) of ADAMTS13 has one α-
helix, four ß-strands and four disulphide bonds to stabilise the loop regions.  
Using VWF115 (VWF residues 1554-1668) as a substrate, it was found that truncated 
ADAMTS13 MP-Dis variant proteolysed VWF115 slowly compared with full length 
ADAMTS13, but specific proteolytic products were still detected after long 
incubations (17 hours) [81]. By contrast, no specific proteolytic activity could be 
identified using a truncated ADAMTS13 MP variant under the same conditions [81]. 
These findings suggested the essential role of the Dis domain for both enzyme activity 
and specificity. Site-directed mutagenesis of non-conserved regions (among 
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ADAMTS family members) in the Dis domain identified ADAMTS13 variants 
R349A and L350G with reduced proteolytic activity. Kinetic analyses revealed a 5-20 
fold reduction in catalytic efficiency of VWF115 proteolysis by these variants. These 
residues (Arg349 and Leu350) form an exposed exosite on the surface of the Dis 
domain, located approximately 26 Angstroms from the active site. Kinetic analysis of 
VWF115 variant, D1614A, suggested that Arg349 in the ADAMTS13 Dis domain 
interacts directly with Asp1614 in the VWF A2 domain. In terms of the VWF 
sequence, Ala1612 was considered to be ideally positioned to form a hydrophobic 
interaction with Leu350 in the ADAMTS13 Dis domain. The functional importance 
of Leu350 was demonstrated by the marked reduction in activity of the combination 
ADAMTS13 variant, R349A/L350G, compared to individual ADAMTS13 variants, 
L350G or R349A [81]. These interactions may play a critical role in positioning the 
scissile bond over the active cleft of ADAMTS13 because they influenced cleavage 
parameters (kcat and Km) rather than binding affinity (KD) of ADAMTS13 for VWF 
[81].  
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Figure 1.10 The crystal structure of the ADAMTS13 Disintegrin-like domain. The Dis 
domain has one α-helix, four ß-strands and four disulphide bonds to stabilise the loop regions. 
The functionally important residues Arg345 and Leu350 in Dis domain are highlighted using 
Pymol. The original structural information was taken from PDB file 3GHN [72]. 
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1.4.2.3 Thrombospondin type-1 like repeats (TSR) 
Thrombospondin type 1-like repeats (TSR) are well conserved in ADAMTS proteases 
family members [82]. There are eight TSRs in total in ADAMTS13, one separating 
the Dis domain from the Cys domain and seven located between the spacer domain 
and the two C-terminal CUB domains. The crystal structure of TSR1 has an extended 
shape. It consists of three antiparallel strands and two ß-strands which are highlighted 
in Figure 1.11 [72]. 
The TSRs of ADAMTS13 contain a binding motif for CD36 which is a 
transmembrane protein present on the platelets and endothelial cells surface [83]. The 
residues that bind to CD36 are highly conserved among the eight TSRs. Through 
binding to CD36, ADAMTS13 is localized on the surface of on the platelets and 
endothelial cells, where it regulates the cleavage of VWF [83-85]. 
 
 
Figure 1.11 Crystal structure of the ADAMTS13 TSR. The crystal structure of TSR1 is 
shown in an extended shape and highlighted using Pymol. There are three antiparallel strands 
and two ß-strands (blue) in TSR. The CD36 binding sequence (Cys-Ser-Arg-Ser-Cys-Gly) is 
shown in green sticks. The original structural information was taken from PDB file 3GHN 
[72]. 
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1.4.2.4 Cysteine-rich domain (Cys) 
The Cys domain (Lys440-Cys555), which contains 10 cysteine residues, is well-
conserved among ADAMTS family members. The crystal structure of the Cys 
demonstrates that there are two α-helix, four ß-strands, three loops (U, V and P), and a 
hyper variable region (HVR) in this domain (Figure 1.12) [72].The HVR is predicted 
to contain protein specific binding sites (Figure 1.12). A critical role of this domain is 
suggested by the report that one polymorphism (P475S) contained within this domain, 
identified in the Japanese population, alters the ADAMTS13 activity but does not 
affect its secretion [86]. However, the precise mechanism of how the ADAMTS13 
Cys domain regulates VWF-cleaving activity of ADAMTS13 remains to be clarified. 
 
Figure 1.12 Crystal structure of the ADAMTS13 Cysteine-rich domain. The α-helix (red), 
ß-strands (yellow), disulphide bonds (orange), U-loop (green), V-loop (gray), P-loop (green) 
and the hyper variable region (HVR) (blue) are highlighted using Pymol. This figure was 
adapted from [72].  
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1.4.2.5 Spacer domain 
The ADAMTS13 Spacer domain ranges from residue Ser556 to Ala685. This domain 
is a cysteine-free region in all ADAMTS family members. The crystal structure of the 
Spacer domain demonstrates that there are ten ß-strands in this domain forming two 
antiparallel ß-sheets in a globular shape (Figure 1.13) [72].  
A deletion mutant of ADAMTS13 lacking the Spacer domain, is not able to 
efficiently proteolyse full-length VWF, suggesting an essential role of this domain for 
proteolysis of VWF by ADAMTS13 [87, 88]. Anti-ADAMTS13 autoantibodies, 
which are present in most adult patients with acquired thrombotic thrombocytopenic 
purpura (see section 1.4.4), have been shown to bind predominately to the Spacer 
domain [89, 90]. Site-directed mutagenesis and peptide inhibition assays have 
identified important roles for Spacer domain residues Arg659, Arg660, Tyr661 and 
Tyr665  in proteolytic cleavage of various substrates under static and fluid shear stress 
conditions (Figure 1.13)[91, 92]. These results demonstrated that residues within 
Tyr659-Tyr665 of the ADAMTS13 Spacer domain that are targeted by autoantibodies 
in TTP (see section 1.4) directly interact with a complementary exosite (Glu1660–
Arg1668) within the VWF A2 domain [92]. Remarkably, the ADAMTS13 
(R660K/F592Y/R568K/Y661F/Y665F) and ADAMTS13 
(R660K/F592Y/R568K/Y661F) variants exhibited increased proteolytic efficiency, by 
~10 and ~5 fold, towards a short fragment VWF 73 (Asp1596-Lys1668) and full-
length VWF, respectively [93]. The ADAMTS13 
(R660K/F592Y/R568K/Y661F/Y665F) and ADAMTS13 
(R660K/F592Y/R568K/Y661F) variants were also found to have reduced binding by 
anti-ADAMTS13 autoantibodies from TTP patients (see section 1.4.4) and therefore 
to be more resistant to inhibition [93]. 
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Figure 1.13 Crystal structure of the ADAMTS13 Spacer domain. The Spacer domain is a 
globular shape with 10 ß-strands which form two parallel antiparallel ß-sheets. Functionally 
important residues Arg659 (yellow), Arg660 (yellow), Tyr661 (blue) and Tyr665 (blue) 
which contribute to the interactions between the Spacer domain and VWF are also highlighted 
using Pymol. The original structural information was taken from PDB file 3GHN [72]. 
 
1.4.2.6 CUB domains 
Two CUB [complement C1r/C1s, Uegf (EGF-related sea urchin protein) and BMP-1 
(bone morphogenic protein-1)] domains, with ~110 amino acids in each, are located at 
the C-terminus of ADAMTS13. These two C-terminal CUB domains are only present 
in ADAMTS13 and not in any other ADAMTS family member. Molecular modelling 
shows a similar structure for the ADAMTS13 CUB1 and CUB2 domains, each with 
four ß-strands in this domain forming two antiparallel ß-sheets (Figure 1.14).  
There are five cysteine residues in the CUB1 domain and two in the CUB2 domain. 
Four cysteine residues (Cys1192, Cys1213, Cys1236 and Cys1254) in the CUB1 
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domain were found to be important for ADAMTS13 secretion and stability [94].The 
function of fifth cysteine the CUB1 domain remains unclear. Recent studies in our 
group suggested the CUB domains are required in the initial interaction between 
ADAMTS13 and VWF [29], while Feys et al. [95] found that TSR2-8 rather than the 
CUB domains affected its binding to globular VWF. Both plate binding assays and 
surface plasmon resonance (SPR) experiments suggested that the proximal carboxyl-
terminal domains of ADAMTS13 interact with the C-terminal region of VWF [29, 95]. 
Although the two CUB domains did not increase the proteolytic activity of wild type 
ADAMTS13 compared with ADAMTS13 truncation lacking these two domains, they 
did determine the substrate specificity of ADAMTS13 [96]. 
 
Figure 1.14 Molecular modelling structures of the ADAMTS13 CUB domains. The 
molecular models were made with the HHPRED server and based on the crystal structure of 
the CUB domain of complement C1s (PDB file 1NZI) [97]. Four ß-strands in each CUB 
domain form two antiparallel ß-sheets. The positions of disulphide bonds formed by the 
pairing of cysteine residues are highlighted in red using Pymol. A free cysteine residue 
(circled in red) is found on the surface of CUB1. 
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1.4.3 Mechanism of proteolysis of VWF by ADAMTS13    
In circulation, the functions of VWF are initially controlled by its adoption of a 
globular conformation [14]. This conformation results in interaction sites being 
hidden and inaccessible to their ligands. Consequently, VWF is able to patrol the 
intact vessel without unnecessarily binding to platelets or plasma proteins. At the site 
of the damaged vessel wall, however, the globular VWF recognises newly exposed 
collagen and leads to its specific recruitment. Under shear forces, VWF then 
undergoes a unique conformation change from its globular to an elongated 
conformation that presents previously hidden platelet binding sites, mediating the 
capture of circulating platelets to the site of vascular injury. These initial steps in the 
generation of the primary platelet plug highlight the importance of VWF 
conformation for its hemostatic function. With unfolding of VWF by shear forces, the 
cleavage site of VWF is exposed, and thereafter recognized and proteolysed by 
ADAMTS13. This proteolytic regulation by ADAMTS13 controls the multimeric size 
of VWF and therefore its hemostatic function [98]. Here (Figure 1.15), a model of 
interactions between ADAMTS13 and VWF, containing binding at multiple sites, 
eventually leading to scissile bond cleavage, is illustrated. It involves six critical steps:  
Step 1: VWF circulates in plasma in a globular conformation. The VWF A2 domain, 
in which the proteolytic site (Tyr1605-Met1606) is located, is buried by the VWF A1 
and A3 domains (Figure 1.15 A-C). However, a binding site for ADAMTS13 within 
the D4CK domains of VWF is constitutively exposed, and the proximal C-terminal 
domains (TSP5-CUB domains) of ADAMTS13 can reversibly bind to the globular 
protein (KD ~80nM) [29].  
Step 2:  Under increasing shear forces, the globular conformation of the VWF 
multimers unravels to a ‘string-like’ form [99]. As a consequence, additional exosite 
binding sites on VWF become accessible to complementary sites on ADAMTS13 [29, 
95] (Figure 1.15. D).  
Step 3:  After the vicinal Cys disulphide bond plug is extracted from the hydrophobic 
core of the VWF A2 domain [33], the exposed C-terminal residues Glu1660-Arg1668 
in the VWF A2 domain bind tightly to the residues Arg660/Tyr661/Tyr665 in the 
ADAMTS13 Spacer domain (Figure 1.15. E), dramatically increasing the affinity of 
ADAMTS13 for VWF (KD ~10nM) [92].  
Step 4:  Residue Arg349 in the ADAMTS13 Dis domain recognises a complementary 
residue Asp1614 in VWF [81] (Figure 1.15. F). This interaction is weak but critical, 
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as it contributes to the substrate specificity of ADAMTS13 rather than increasing 
binding affinity [81].  
Step 5:  Together, these interactions assist orientation of the VWF scissile bond 
(Tyr1605-Met1606) within the active site of ADAMTS13 (Figure 1.15. G).  
Step 6:  The final cleavage reaction occurs, followed by the dissociation of cleavage 
products allowing the protease to continue to work (Figure 1.15. G). 
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Figure 1.15 Proteolysis of VWF by ADAMTS13. (A) VWF multimers circulate in plasma 
in a globular conformation. (B) Each multimer is formed by disulphide linked VWF 
monomers. (C) The collagen binding site at the VWF A3 domain is still exposed even in its 
globular conformation. ADAMTS13 TSP (5-8) and CUB domains can bind to the C-terminal 
VWF D4CK domains, allowing VWF/ADAMTS13 complexes to form and circulate in 
plasma. (D) Under elevated shear forces, VWF unravels to expose a binding site at A1 
domain for platelet receptor GPIbα. The shear forces also extract the vicinal Cys disulphide 
bond plug in the A2 domain, causing A2 domain unfolding. (E) This unfolding reveals cryptic 
exosites and residues Arg660/Tyr661/Tyr665 in the ADAMTS13 Spacer domain are able to 
bind to the unfolded A2 domain (region Glu1660-Arg1668). (F) Thereafter, a critical 
interaction between Asp1614 in VWF and Arg349 in the ADAMTS13 Dis domain helps 
bring the Tyr1605-Met1606 scissile bond over the ADAMTS13 active site. (G) S1 and S1’ 
(residues Asp252-Pro256) subsites in the active site interact with Tyr1605 and Met1606, 
respectively. Together, these interactions eventually lead to scissile bond proteolysis. This 
figure was adapted from [100]. 
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1.4.4 Thrombotic Thrombocytopenic Purpura (TTP) 
The pathological importance of ADAMTS13 is highlighted by the clinical outcome 
due to its deficiency. Either congenital or acquired ADAMTS13 deficiency can result 
in a rare clinical syndrome, which is known as thrombotic thrombocytopenic purpura 
(TTP) [101-103]. Congenital TTP is a result of mutations in the ADAMTS13 gene 
and more than 70 ADAMTS13 mutations resulting in familial TTP have been 
reported [86, 90, 104-135]. As shown in Figure 1.16, single nucleotide 
polymorphisms appear in the Cys, and TSR domains,  nonsense mutations appear in 
the TSR, Cys and CUB domains, whereas missense mutations in each domain. The 
mutations leading to alternative splicing of ADAMTS13 mRNA or frame-shifts are 
also identified in almost all domains of ADAMTS13 (Figure 1.16). Acquired TTP is 
caused by patients’ autoantibodies against ADAMTS13 [101, 102]. TTP is a 
pathological condition characterised by microvascular thrombosis, consumptive 
thrombocytopenia, organ ischaemia and haemolytic uraemia. Without treatment it is 
almost uniformly fatal. Due to ADAMTS13 deficiency, uncleaved VWF ultra large 
multimers (Figure 1.17) [136] accumulate in the circulation and promote platelet rich 
microthrombi formation, occluding the microcirculation leading to the symptoms 
described above [137]. Currently, the most effective treatments for TTP are still 
plasma exchange and steroids, which have been validated by randomized clinical 
trials [138]. However, several novel therapeutic drugs and practice promise to further 
improve the prognosis of patients with TTP. Drugs under investigation in TTP include 
immunosuppressive drugs (eg. Rituximab[139-142] and Cyclosporine [143, 144]), 
recombinant VWF-cleaving protease (eg. rADAMTS13 [145]), inhibitors of VWF-
platelet interaction (eg. ARC1779 [146, 147] and ALX-0081 [148]) and reducing 
agent (eg. N-acetylcysteine [149]). A newly established mouse model in which some 
TTP-like symptoms can be triggered in ADAMTS13 knock-out mice is potentially 
useful for investigating the efficacy of new treatments for TTP [150]. 
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Figure 1.16 Polymorphisms and mutations of ADAMTS13 each domain found in 
thrombotic thrombocytopenic purpura (TTP) patients. The single nucleotide 
polymorphisms (green), nonsense mutations (red) and missense mutations (black) are listed 
above each domain structure of ADAMTS13. The mutations leading to alternative splicing of 
ADAMTS13 mRNA or frame-shifts are indicated under each domain. Abbreviations: MP 
stands for metalloprotease domian; Dis, disintegrin-like domain; 1, first thrombospondin type 
1 (TSP1) repeat; Cys-R, cysteine-rich domain; Spa, Spacer domain; 2-8, the second to the 
eighth TSP1 repeats; C1 and C2, two CUB domains (for complement C1r/C1s, Uegf, Bmp1 
domain). This figure was adapted from [135] 
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Figure 1.17 Ultra large (UL) VWF multimers in TTP. Supernatant from stimulated 
endothelial cells (EC), normal plasma (NPP) and TTP patient plasma were electrophoresed in 
a 1.2% agarose gel followed by Western blotting using anti-VWF-HRP antibody. The only 
difference between NPP and EC or TTP is that the ultra large VWF multimers are absent due 
to proteolysis by ADAMTS13. The Figure was adapted from Groot et al [136]. 
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1.5 VWF, ADAMTS13 and thrombotic diseases  
Although the incidence of both VWD and TTP are relatively low, around 100 per 
million and 4 per million respectively [61, 151], there is increasing epidemiological 
and clinical evidence indicating that the incidence of thrombotic diseases, including 
heart attack and stroke, highly correlates with VWF disorders [152, 153]. There are a 
number of reports demonstrating association between high plasma VWF levels and/or 
low plasma ADAMTS13 levels with an increase of the risk of thrombotic diseases 
[154-160]. However, evidence based on clinical trials has not made it clear whether 
VWF is a predisposing cause to the occurrence of arterial thrombosis or just a marker 
of endothelial damage, the latter being responsible for diseases.  
Using an ADAMTS13 gene knockout (ADAMTS13 (-/-)) mice model, it was found that 
ADAMTS13, by cleaving ultra-large VWF multimers, down-regulates platelet 
activation and enhances thrombus formation at the site of vascular lesions [161, 162]. 
Further studies have identified the C-terminal domains of ADAMTS13 as playing an 
important role in down-regulating thrombus growth [163]. Using an acute ischemic 
stroke model in ADAMTS13 (-/-) mice, it was also found that ADAMTS13 gene 
deletion makes the ischemic brain deteriorate [164]. By contrast, VWF deficiency in 
VWF (-/-) stroke mouse model reduced the infarct volumes ~2-fold [164]. 
Significantly, infusion of recombinant human ADAMTS13 into a wild-type stroke 
mouse model, the infarct volumes were also immediately reduced without cerebral 
haemorrhage [164]. Based on these findings, it is suggested that VWF would be a 
promising target in the prevention and/or treatment of thrombotic diseases and 
recombinant ADAMTS13 could be considered as a novel therapeutic agent for use 
against these thrombotic diseases. 
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1.6 Assays to evaluate ADAMTS13 activity  
The key function of ADAMTS13 is to proteolyse VWF. To evaluate the activity of 
ADAMTS13 is mainly to measure its VWF-cleaving ability. There are several ways 
that can be done.  
Firstly, the substrate, full length VWF or VWF fragments, should be unravelled by 
shear stress (such as flow chamber system) or chaotropic agents (such as urea or 
guanidine hydrochloride) to make the scissile bond accessible. Subsequently, the 
VWF should be incubated with ADAMTS13 containing necessary divalent cations 
(eg.Ca2+ and Zn2+
Proteolysis of VWF can then be established by different methods, including gel 
electrophoresis of VWF multimers, collagen binding assay, cleavage of short 
substrates and flow based assays, details of which are described in chapter 2. These 
four assays are currently the most widely used methods for evaluation ADAMTS13 
activity, although other assays are available. Generally, gel electrophoresis of VWF 
multimers is still the most important evidence to assess the function of ADAMTS13. 
However, this assay is complex and is difficult to standardise [165]. Cleavage of short 
VWF substrates is the most efficient way to screen functionally important amino acids 
in ADAMTS13 and to determine in a quantitative way which residues in VWF 
contribute to the proteolysis efficiency and specificity.  
).  
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1.7 Aims of my thesis 
1.7.1 Identification of novel VWF A2 domain residues contributing to 
ADAMTS13 substrate specificity 
The interaction of ADAMTS13 with VWF is complex, with multiple exosite 
interactions contributing to the approximation of the active site of ADAMTS13 with 
the VWF scissile bond, VWF Tyr1605-Met1606 [100, 166]. Although several 
interactions between VWF and ADAMTS13 have been identified, as shown in Figure 
1.15, remarkably little is known of the molecular interactions between the substrate 
and the MP domain of ADAMTS13. VWF is the only known substrate of 
ADAMTS13, which it cleaves at just a single bond. How such high substrate 
specificity is conferred remains unclear. In considering the binding and interaction 
between ADAMTS13 and VWF, there exist two obvious possibilities: only one side 
of cleavage site interacts with ADAMTS13, or both sides do. Recent findings have 
identified many of the residues involved in interactions VWF C-terminal to the 
scissile bond and the non-catalytic domains of ADAMTS13 [29, 80, 81, 87, 88, 95, 
166-169]. If there is only VWF C-terminal interaction with ADAMTS13, the affinity 
of the C-terminal cleavage products for ADAMTS13 will be equal to that of the 
uncleaved substrate. In addition, the C-terminal cleavage products will competitively 
inhibit the binding between ADAMTS13 and VWF. For this thesis, I hypothesised 
that VWF also contains a binding site N-terminal to the cleavage site to aid both in 
positioning of the scissile bond in the active site and enhancement of substrate 
specificity. If this is the case, the affinities of the individual cleavage products for the 
enzyme would be lower than that of the uncleaved substrate. Consequently, upon 
proteolysis overall binding affinity would be reduced, which favours disassociation of 
cleavage products.  
Previous studies have shown that VWF residues 1596DREQAPNLV1604, N-terminal to 
the cleavage site, are required for cleavage by ADAMTS13 [166, 170]. I aimed to 
identify the residues in this region that are important determinants for ADAMTS13 
proteolysis. A molecular model of ADAMTS13 MP and Dis domains is shown in 
Figure 1.18. This shows the active site cleft, and VWF A2 domain residues flanking 
the scissile bond Tyr1605-Met1606, are depicted as sticks. The residues Arg349 and 
Leu350 in the ADAMTS13 Dis domain interacting with residues Asp1614 and 
Ala1612 in VWF that are important for proteolysis are highlighted as C-terminal 
interactions [81]. The possible residues in the ADAMTS13 MP domain and 
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correspondingly interacting residues N-terminal to the cleavage site in VWF, which I 
hypothesise as potential N-terminal interactions, are also shown. The investigation of 
this hypothesis, that residues N-terminal to the scissile bond are crucial for interaction 
with VWF, will form most of the work of this thesis. 
1.7.2 Large scale expression of ADAMTS13 MP domain for crystallography 
Large scale production of ADAMTS13 MP domain for crystal structure trials was 
also attempted during the work of my thesis. If successful, the crystal structure 
determination of the ADAMTS13 MP domain will provide a more detailed structural 
map of the protease. The exact mechanism of how ADAMTS13 specifically 
recognizes and proteolyses its unique substrate VWF could be better understood based 
on the crystallography information. 
Although a modest yields of ADAMTS13 generated from a mammalian expression 
system has been established in our lab, production of increased amounts will be 
explored using several alternative approaches such as bacterial expression system 
(pET SUMO protein expression system) and insect cells expression system 
(Drosophila expression system). The second major aim of my work is therefore to 
optimise expression of the correctly folded ADAMTS13 MP domain, so that 
structural studies can be conducted.  
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Figure 1.18 Proposed molecular mechanism of VWF proteolysis by ADAMTS13. A 
molecular model of ADAMTS13 metalloprotease (MP – grey) and disintegrin-like (Dis - 
green) domains is shown with the active site Zn2+
 
 highlighted in blue. This shows a 
representation of the active site cleft, VWF A2 domain residues flanking the cleavage site 
Tyr1605-Met1606, depicted as sticks. The residues Arg349/Leu350 in the ADAMTS13 Dis 
domain interacting with Asp1614/Ala1612 in VWF that are important for proteolysis are 
highlighted as C-terminal interactions [81]. The residues N-terminal to the cleavage site in 
VWF and correspondingly interacting residues in the ADAMTS13 MP domain, which I 
hypothesised, are essential for proteolysis, are also shown.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Sequence alignment and molecular modelling 
2.1.1 ADAMTS13 MP domain 
Amino acid sequences of ADAMTS13 from different species retrieved from PubMed 
were aligned using AlignX software (Informax). Although the crystal structures of the 
ADAMTS13 MP domain has yet to be solved [72], those of ADAMTS1, 4 & 5 which 
share most residues with ADAMTS13 are available (ww.rcsb.org/pdb) [69-71]. Using 
the amino acid sequence of the ADAMTS13 MP as a query, the HHPRED server 
(http://toolkit.tuebingen.mpg.de/hhpred) automatically searches homologous amino 
acid sequences among ADAMTS1, 4 & 5. HHPRED server identified the sequences 
of ADAMTS5 to align best. In this was, the likely structure of ADAMTS13 MP 
domain was derived from the crystal structures of ADAMTS5 using the HHPRED 
server. The generated multiple sequence alignment, coordinating with the crystal 
structures of ADAMTS 5, was inputted into the software program Modeller [171]. 
The structure model of ADAMTS13 MP domain was then established. Based on this 
model, a software program Pymol (http://pymol.sourceforge.net/) (Delano Scientific 
LLC) was used for visualisation in order to predict the surface exposure, highlight 
specific residues, and estimate distances between residues.  
2.1.2 VWF  
The information on crystal structures of VWF A1, A2, and A3 domains are available 
in Protein Data Bank 
(http://www.pdb.org/pdb/results/results.do?qrid=8E9DA86D&tabtoshow=Current). 
The VWF A2 domain was visualised with Pymol (Delano Scientific LLC) based on 
the PDB information. Amino acid sequences of VWF from different species retrieved 
from PubMed were aligned using AlignX software (Informax). 
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2.2 Generation of recombinant ADAMTS13 and ADAMTS13 
variants 
2.2.1 Vectors 
(1) pcDNA3.1/myc-His vector 
Full-length human ADAMTS13 cDNA (4.3kb) was previously cloned in-frame into 
the mammalian expression vector pcDNA3.1/myc-His (5.5kb) (Invitrogen) (Figure 
2.1) in our lab by Dr. Crawley and Dr. de Groot [172]. pcDNA3.1 is a mammalian 
expression vector with multiple cloning sites preceding the C-terminal myc epitope 
and 6xHis tag, an ampicillin resistance marker and a cytomegalovirus (CMV) 
promoter to initiate gene expression. 
 
Figure 2.1 A diagram of the mammalian expression vector pcDNA3.1/myc-His (5.5kb) 
(Invitrogen) for subcloning of the ADAMTS13 truncations. Ampicillin= Ampicillin 
resistance gene; Pcmv= cytomegalovirous promoter which drives high level transcription in 
mammalian cells; Neomucin= Neomycin resistance gene; 6xHis= a 6 histidine tag which aids 
in efficient purification.  
(Invitrogen)
ADAMTS13 
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(2) pET SUMO vector 
The pET SUMO vector was purchased from Invitrogen (Figure 2.2). The pET SUMO 
expression system utilises a small ubiquitin-related modifier (SUMO) fusion to 
enhance the solubility of expressed fusion proteins. The SUMO plays an important 
role in the stabilization and localization of proteins in vivo. Addition of a single A to 
the 3´ ends of PCR products of the ADAMTS13 truncations makes them easily be 
inserted into the pET SUMO vector (Figure 2.3). After expression, the SUMO can be 
cleaved by the highly specific SUMO protease at the C-terminal, generating a native 
protein. 
 
Figure 2.2 Map of pET SUMO (Invitrogen). T7, T7 promoter; lacO, lac operator; RBS, 
Ribosome binding site; ATG, initiation ATG; HisG epitope, N-terminal 6xHis tag; SUMO, 
SUMO ORF; T, TA Cloning site (5’T-overhangs); T7 term, T7 terminator; Kanamycin, 
Kanamycin resistance gene; pBR322 ori, pBR322 origin of replication; rop, ROP ORF; lacI, 
lacI ORF. The TA Cloning site (5’ T-overhangs, the blank between the SUMO and the T7 
terminator), allows ligase-mediated cloning of Taq-amplified PCR products. 
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Figure 2.3 How TA cloning works. The pET SUMO vector supports a quick cloning 
strategy for the direct insertion of a PCR product into the vector. Taq polymerase, in a 
nontemplatedependent way, catalyses addition a single deoxyadenosine (A) to the 3’ ends of 
PCR products. The linearised pET SUMO vector has a single 3’deoxythymidine (T), allowing 
PCR inserts to ligate efficiently into the vector. 
(3) pMT-PURO vector 
The pMT-PURO vector contains a heterologous protein expression cassette driven by 
MT promoter. Together with a puromycin selection marker driven by the copia 
promoter, all are cloned in a single plasmid (Figure 2.2). In my present study, the 
empty pMT-PURO vector (double digested by restriction enzymes BglII and MluI) 
was kindly sent by Dr Jonas Emsley from University of Nottingham. To insert the 
MP-Dis coding cDNA fragment into this pMT-PURO vector, the targeting sequence 
was amplified from the template DNA (vector pcDNA3.1/myc-His containing MP-
Dis) by PCR (2.2.2). Specific primers flanking the MP-Dis coding sequence and with 
addition recognition site by restriction enzymes BglII and MluI were designed so that 
the PCR products after digestion were able to ligated with the pMT-PURO vector 
digested by the same double enzymes. Then, the digested PCR products and parent 
vector pMT-PURO were ligated by T4 ligase (see section 2.2.8) at room temperature 
for 2 hours, after which transformation (see section 2.2.3) and Miniprep (see section 
2.2.4) were performed. 
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Figure 2.4 Map of pMT-PUROPURO, puromycin N-acetyl-transferase; PCOPIA, copia 
promoter; PMT, metallothionein promoter; BiP, BiP signal sequence; MCS, multiple cloning 
site; V5, V5 peptide tag; His6, 6xHistidine tag; SV40 pA, SV40 late polyadenylation signal; 
pUCori, pUC origin;  Amp, ampicillin resistant gene. Adapted from [173, 174] 
2.2.2 Mutagenesis 
The pcDNA3.1/myc-His vector described in section 2.2.1 was used as a template for 
mutagenesis. Single-point or multiple-point mutants and truncated ADAMTS13 
mutants were generated using different inverse PCR strategies. Single-point or 
multiple-point mutations were introduced using primers that contained the desired 
mutation(s) and anneal to the corresponding sequence on opposite strands of the 
plasmid. Inverse PCR was then used to amplify circular plasmids containing the 
mutations. To express wild type ADAMTS13 MP domain and MP-Dis domains, full-
length ADAMTS13 cDNA was truncated to give rise to form the MP-Dis vector via 
inverse PCR-based methods. The MP-Dis vector ends after the Glycine385 but fuses 
with a 6xHis tag at the C- terminus. The MP vector ends after the Glutamine289 and 
also fuses with a 6xHis tag at its C- terminus.   
Primers were designed according to the guidelines in KOD Hot Start DNA 
Polymerase Protocol (Novagen), and manufactured, HPLC purified by Thermo 
Electron Company, Germany. The PCR reactions were performed with 1μl of 
polymerase (Stratagene), 5μl of 10x reaction buffer, 3μl of MgSO4(25mM), 5μl of 
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dNTPs (2mM each), 1.5μl of sense (5’) primer and 1.5μl of anti-sense (3’) primer 
(10μM each), 10ng of DNA template, and PCR water adding up to a final volume of 
50μl. The amplification conditions were as follows: denaturation (94°C, 2 minutes), 
25 cycles of denaturation (94°C, 15 seconds), annealing (57°C, 30 seconds) and 
extension (68°C, 1 minute per kb), and a final extension at 68°C for 7 minutes. The 
PCR products were treated with DpnI, which specifically digests the parental DNA 
template rather than the PCR products, at 37ºC for one hour.  
 2.2.3 Transformation 
The vectors generated by PCR or from Miniprep (see section 2.2.3) were transformed 
into XL10-Gold competent bacterial cells (Stratagene, USA). Briefly, 25μl cells were 
thawed slowly on ice and pre-incubated with 1μl of ß -Mercapto-ethanol (Stratagene, 
USA) for ~10mins to enhance cell membrane permeability. 1μl DpnI treated DNA 
was added to the mixture and incubated on ice for 30 minutes. Thereafter the cells 
were heat-shocked in a 42°C water bath for 30 seconds. Rapidly chilled for 2 minutes, 
the cells were incubated with 200μl pre-warmed S.O.C. medium (Invitrogen UK) in 
shaking incubator at 37ºC for one hour. The S.O.C. medium containing cells was then 
transferred to a Luria Bertani (LB) agar plate containing100μg/ml ampicillin (Sigma, 
UK) and kept in the 37ºC incubator overnight. 
2.2.4 Plasmid DNA purification (Miniprep) 
Plasmids DNA were extracted using a Miniprep kit (Qiagen, UK). Generally, several 
selections of transformed E. coli colonies were picked from the LB agar plate 
transformed from above step. These colonies were cultured in 5ml LB medium 
containing 100μg/ml ampicillin at 37°C/250rpm shaking incubator overnight. The 
culture was then centrifuged at 4000rpm for 20 minutes and the supernatant was 
decanted. The cell pellet was resuspended in 250μl resuspension buffer P1 containing 
RNase A. 250μl alkaline lysis buffer P2 was then added into the mixture to solubilise 
the bacterial cell membrane proteins and phospholipids and to denature 
chromosomal/plasmid DNA and proteins. After five minutes, 350μl neutralisation 
buffer, N3, was added to neutralise the alkali conditions, which resulted in a white 
precipitate being formed consisting of cell debris, denatured proteins, and 
chromosomal/plasmid DNA. After centrifugation at 13000rpm for 20 minutes, the 
supernatant was passed over a QIAprep spin column that contains a silica membrane 
for selective adsorption of plasmid DNA in high-salt buffer and centrifuged for 1 
minute. The flow-through was discarded and 750μl PE buffer containing ethanol was 
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used to wash the column through centrifugation at 13000rpm for 1 minute. The flow-
through was discarded and the residual PE buffer was removed by centrifugation for 
another 1 minute as before.  To elute the plasmid DNA from the column, 50μl low 
salt buffer EB was added to the column and left to stand for 1 minute before eluting 
the DNA by centrifugation for another 1 minute as before.  
2.2.5 DNA sequencing  
DNA was sequenced to verify whether the target mutation was introduced. To 
sequence the ADAMTS13 cDNA, specific sequence primers were applied (Appendix). 
500-600ng plasmid DNA was added to 3.2 pmol sequencing primer and the final 
reaction volume was made up to 10μl. DNA sequencing was performed at the 
Hammersmith Hospital MRC CSC Genomics Core Laboratory using an ABI 3700 
DNA analyser (Perkin-Elmer, UK), 
(http://www.csc.mrc.ac.uk/Research/Facilities/GenomicsLaboratory). Alignment and 
analysis of the sequencing results feed back from above laboratory were performed 
using BioEdit Sequence Alignment Editor Software (Tom Hall, Canada).  
2.2.6 Sub-cloning by restriction enzyme digestion  
Using PCR mutagenesis procedures for larger vectors (eg. full length ADAMTS13), 
unwanted mutations might be introduced into the rest of the vector. To avoid this, a 
sub-cloning strategy was considered. As all my investigated residues were located at 
the ADAMTS13 MP domain, I initially introduced mutations into a shorter vector 
fragment (pcDNA3.1ADAMTS13-MP-myc/His). Then the verified shorter vector 
fragment was sub-cloned into their parent vector (pcDNA3.1ADAMTS13-myc/His). 
Briefly, the verified MP vector with my target mutations was treated with restriction 
enzymes AscI and EcoRI (New England Biolabs). These digestions were performed 
using ~1.5μg DNA and 20U of the enzymes, diluted in the 10x NEB buffer 4, and 
incubated at 37°C for around 2 hours. The parent vector underwent the same 
treatment followed by removal of 5’and 3’ phosphates with 5U of calf intestinal 
alkaline phosphatase (Invitrogen, UK) for ~5 minutes to prevent self-ligation. 
Preventing self-ligation is important both in reducing the background of improperly 
self-ligated contaminant and in improving the yield of properly ligated product.  
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2.2.7 DNA agarose gel electrophoresis 
Agarose gel electrophoresis was used to visualise and separate DNA fragments 
according to their size. 0.8%(w/v) agarose (Biomed, UK) gels were prepared with 1x 
TBE (89mM boric acid, 89mM Tris-HCl and 2mM EDTA) buffer containing 
SYBR™ safe DNA gel stain (diluted 1:10000) (Invitrogen, UK). The PCR products 
samples or a 1kb DNA ladder (New England Biolabs, USA) were mixed with 4 x 
DNA loading buffer (New England Biolabs, USA), after which they were loaded and 
run on the agarose gel at 100V for half an hour. DNA bands were visualised using a 
Safe Imager™ blue light transilluminator (Invitrogen, UK). The desired DNA bands 
were then cut out for further gel extraction. 
2.2.8 DNA gel extraction  
The cut DNA bands containing fragments of interest were purified using the 
QIAquick gel extraction kit (QIAgen, UK). Gel slices containing DNA were 
resuspended in 3 volumes of solubilisation buffer QG to 1 volume gel (1 volume gel = 
100mg/100μl buffer QG) and incubated at 50°C for 10 minutes until the gel slices 
were completely dissolved. One gel volume of isopropanol was then added and mixed, 
after which the entire sample was centrifuged through a Quaquick spin column 
(QIAgen, UK) at 13000rpm for 1 minute and the flow-through was discarded. The 
column contains a silica membrane for selectively binding plasmid DNA in high-salt 
buffer. 500μl buffer QG was added to remove traces of agarose and centrifuged at 
13000rpm for 1 minute. The flow-through was discarded and the column was then 
washed with 750μl buffer PE containing ethanol. The flow-through was discarded and 
residual buffer PE was removed by centrifugation as before. DNA was then eluted 
with 50μl low salt buffer EB. 
2.2.9 DNA ligation  
Light absorbance reading at 260nm or direct visualisation on agarose gels was used to 
identify vector and insert fragments. Vector and insert DNA fragments were ligated in 
a reaction mixture containing a molar 1:3 ratio of vector DNA and insert DNA, 4μl 5x 
ligase buffer (Invitrogen, UK), and 1μl T4 DNA ligase (Invitrogen, UK) in a final 
reaction volume of 20μl, which was incubated at 14°C overnight.  
2.2.10 Large scale plasmid preparation (Maxiprep) 
As stable or transient transfection of mammalian cells needs sufficient quantity of 
DNA, large scale plasmid preparations were made with a Endo-free Plasmid 
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Maxiprep kit (Omega Bio-Tek, USA) according to the manufacturer’s instructions. 
For this, larger cultures (100ml) were grown. The vector with it correct sequence 
confirmed and containing the desired construct was transformed into One Shot® 
TOP10 cells (Invitrogen). An isolated colony was inoculated into 5ml LB containing 
100μg/ml ampicillin and incubated for 6 hours shaking at 250rpm at 37ºC. 500μl cells 
was then taken and placed into 100ml LB containing 100μg/ml ampicillin and 
incubated at 37ºC with shaking at 250rpm overnight. The culture was then centrifuged 
at 4000g for 10 minutes at 4ºC. The supernatant was decanted and the pellet was 
resuspended in 10ml Solution I buffer containing RNase A. The cells were then lysed 
with 10ml Solution II buffer and incubated at room temperature for 2 minutes. 5ml 
ice-cold N3 buffer was added to neutralize the alkaline conditions and mixed gently.  
This step precipitates genomic DNA and proteins while plasmid DNA remained in 
solution. The lysate was immediately poured into the barrel of the Lysate Clearance 
Filter Syringe over a fresh 50ml tube. After removing the end cap from the syringe tip 
and inserting the plunger into the barrel, the cleared lysate was expelled into the 50ml 
tube in which equal volume of ETR Binding Buffer (against volume of cleared lysate) 
was added. 3ml of Equilibration Buffer was added into an empty HiBind DNA Maxi 
Column and centrifuged at 4000g for 3 minutes. The flow-through liquid was 
discarded and the cleared lysate was added into the HiBind DNA Maxi Column and 
centrifuged at 4000g for 3 minutes. The flow-through liquid was discarded and 10ml 
ETR Wash Buffer was then added to the HiBind DNA Maxi Column and centrifuged 
at 4000g for 3 minutes followed by discarding the flow-through. 10ml EHB Buffer 
was then added to the HiBind DNA Maxi Column and centrifuged as before followed 
by discarding the flow-through. The HiBind DNA Maxi Column was then washed by 
15ml DNA Wash Buffer twice and centrifuged as before followed by discarding the 
flow-through. To make the HiBind DNA Maxi Column dry, the column was 
centrifuged at 4000g for another 10 minutes. The HiBind DNA Maxi Column was 
then placed into a clean 50ml centrifuge tube and 2ml Endo-Free Elution Buffer 
(10mM Tris, pH8.5) was added onto the centre of the column matrix and left to stand 
for 5 minutes before eluting the DNA by centrifugation for another 5 minutes as 
before. DNA concentrations were measured by NanoDrop (NanoDrop Technologies, 
Inc., USA). Plasmid DNA was then stored at -20 ºC. 
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2.3 Expression of ADAMTS13 and ADAMTS13 variants 
2.3.1 Mammalian cells culture 
2.3.1.1 General Tissue Culture 
All tissue culture was conducted in a class II flow cabinet (FASTER BHG 2004, 
JENCONS-PLS). To avoid contamination of cell lines, the surfaces and flasks used in 
the flow cabinet were thoroughly cleaned with 70% ethanol. Cells lines were grown at 
37ºC, 5% CO2 in humidified incubators (BIOHIT, Biological Instrumentation Service, 
Lancashire, UK). Frozen cells were stored in a liquid nitrogen container at around -
180ºC. Cultured cells were visualised using an inverted microscope CK2 (Olympus, 
Japan).  
2.3.1.2 Freezing cells 
Freezing medium was made up of complete medium Minimal Essential Medium 
(MEM) containing Pen/Strep/L-glutamine/10% FBS/non-essential amino acids and 
10% Dimethyl sulfoxide (DMSO) (Sigma). Cells were washed twice with autoclaved 
phosphate buffer saline (PBS) then detached from the flask surface with 0.5-1ml 
0.25% trypsin/EDTA (Sigma). The medium containing detached cells were then 
transferred to 50 ml tube and complete medium was added up to about 45ml to wash 
away the trypsin. The medium was spun at 4000rpm for 5-10 minutes and the 
supernatant decanted. Cell pellet was resuspended in complete medium by gently 
pipetting up and down, after which 1ml medium was taken for each vial to freeze. The 
cells were put into a box with isopropanol in the lower compartment and placed 
directly at -80ºC. It is important to transfer cells to the freezer as quickly as possible, 
to prevent damage to the cells by DMSO. The cells were kept at -80ºC overnight and 
the next day the vials were transferred to in liquid nitrogen. 
2.3.1.3 Cell revival 
Cells stored in 10% DMSO in liquid nitrogen were thawed at 37ºC, then placed in a 
T75 tissue culture flask (Nunc) with 4ml of warm growth media (MEM) (Sigma), 
supplemented with 10% Fetal Bovine Serum (FBS) (Biosera)/ Penicillin-
Streptomycin (Invitrogen)/L-Glutamine (Invitrogen)/non-essential amino acids 
(NEAA) (Sigma). Cells were allowed to attach for 2 hours, then the media was 
changed to get rid of residual DMSO and dead cells. 
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2.3.1.4 Cell passage 
Once cells had reached 80-100% confluency they could be passaged into larger 
culture flasks or splitted into more flasks. Cells were washed twice with autoclaved 
PBS then detached from the flask surface with 0.5-1ml 0.25% trypsin/EDTA (Sigma). 
Trypsin was inactivated by the addition of growth media and cells seeded 
appropriately. 
2.3.2 Drosophila Schneider 2 (S2) cell culture 
The S2 cell line was purchased from Invitrogen. Preparing cultured cells for 
transfection was performed according to the protocol of Drosophila Schneider 2 (S2) 
Cells from Invitrogen 
(http://tools.invitrogen.com/content/sfs/manuals/schneidercells_man.pdf.)  Initially 
T25 flasks were used with a total volume of 5 ml of Schneider Drosophila medium 
from Invitrogen. Before using the media, 10 % of FBS was added. The cultured cells 
for transfection by seeding 3x106 S2 cells (1x106cells/ml) in a T25 flask in 5ml 
complete Schneider Drosophila medium. The cells were growing 6-16 hours at 28ºC 
until they reached a density of 2~4x106
2.3.3 Expression of recombinant ADAMTS13  
cells/ml, which would be ready for transfection. 
Human Embyonic Kidney (HEK) 293 or HEK293T (transformed with SV40 large T 
antigen) cell line (American Type Culture collection, USA), which does not normally 
express ADAMTS13, was used for routine expression recombinant ADAMTS13, 
either stably or transiently respectively. HEK293T cells were cultured using complete 
Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, UK), which was 
supplemented with L-glutamine/ nonessential amino acids/10% FBS medium/ 
Penicillin Streptomycin before use. Once the cells grew to 70% confluence, the 
complete DMEM was removed, replacing with Opti-MEM reduced-serum medium 
(Invitrogen, UK). The cells were then transfected with DNA using 1mg/ml linear 
polyethylenimine (PEI, Polysciences, Inc). Transfection was performed at an 
optimum ratio of PEI 25kDa (µg): DNA (µg) of 2.25.  Both the DNA and the PEI 
were diluted using 150mM NaCl (sterile) solution. The PEI solution was drop-wise 
added to the DNA dilution, forming the transfection complex (DNA/PEI complex). 
The volume of the DNA/PEI complex that was added to the Opti-MEM was 1/10 
volume of the medium volume.  The medium was harvested and concentrated three 
days after transfection. Conditioned media containing ADAMTS13 variants were 
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concentrated using centrifugal filter devices (Amicon Ultra, milipore) while the 
truncated ADAMTS13 variants MP and MP-Dis were concentrated using a tangential 
flow filtration system (Labscale TFF, Millipore, UK). The MP and MP-Dis were 
dialysed in dialysis buffer (20mM Tris-HCl, 500mM NaCl, pH7.8) at 4 ºC overnight, 
after which purification of  MP and MP-Dis were carried out using metal ion affinity 
chromatography (section 2.5.1).  
2.3.4 Establishing stable cell line for ADAMTS13 MP-Dis expression 
As MP-Dis vectors encode neomycin, G418 was used for selection in transient 
tansfected HEK293 cells. For the stable cell line selection, cells were split and 
transfected with MP-Dis construct. The following day, the standard media was 
replaced with media containing G418. Over weeks, the cells that had stably 
incorporated the MP-Dis plasmid into their genomic DNA were selected. The amount 
of G418 required to kill cells not expressing the construct varied from cell line to cell 
line. For HEK293 cell line, 500μg/ml G418 in the media was used for stable clones 
selection. This selection took from one to two weeks. The media was changed gently 
in the dish every day, avoiding not to pipette directly onto the cells. Most of the cells 
would die and wash off the bottom of the dish, while colonies of stable cells would be 
left behind. 
2.3.5 Insect cells expression 
2.3.5.1 Preparing culture S2 cells for transfection 
Details have been described in section 2.3.2. 
2.3.5.2 Transient transfection of S2 cells 
The transfection mixture consists of solution A (36µl of 2M CaCl2, 20µg of pMT-
PURO vector and adding sterile water to a final volume of 300µl) and solution B 
(300µl of HEPES-Buffered Saline [50mM HEPES, 1.5mM Na2HPO4, 280mM NaCl, 
pH7.0]). The solution A was slowly added dropwise to solution B with vortexing and 
mixing. The resulting solution was incubated at room temperature for 30-40 minutes. 
After ~30 minutes, a fine precipitate should form. The solution was mixed and added 
dropwise to the cells. Each drop was swirled to mix in and incubated 24-48 hours at 
28ºC, after which the medium was transfered into a tube and centrifuge at 1000g for 2 
min. Then the supernatant was removed and the cells were washed with fresh warm 
complete medium (Schneider 2 medium containing 10% FBS). The cells were 
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continued to incubate at 28ºC for two to three days before inducing with 0.5mM 
CuSO4. 50-100μl of the medium was taken out from the T25 flask (induced) from day 
1, 2, 3 and 5 to check if proteins were being expressed and secreted into the medium. 
The 50-100μl of the medium was centrifuged at 1000g for 2-3 minutes and the 
supernatant was transferred into a new and clean microcentrifuge tube for Western 
blotting. The pellet was also kept. 
2.3.5.3 Stable cell line construction  
Initial steps for preparation of stable cell lines were similar to those of transient 
transfection. However, after the calcium phosphate step, 10µg of puromycin was 
added every 3 days for a month. Then the cells were induced with 0.5mM CuSO4 and 
expression could be checked. For large scale expression, it could be scaled up by 
moving cells from T25 to T75 to T175 then into 2 L flask. When conducting large 
scale expression, the stable S2 cells have to be adapted to 1x Express-five medium 
(without FBS) (Invitrogen, UK) in the T175 flasks. To achieve this, the 10% FBS was 
removed gradually, rather than at once.  
2.4 Expression of recombinant full length VWF and VWF 
variants 
The expression vectors of recombinant full length VWF variants were generated as 
the similar way of ADAMTS13 (section 2.2). Full length VWF plasmids were 
transiently transfected into the HEK293T cells, similarly to that of ADAMTS13 
transfection (section 2.3.3). Three or four days after transfection, the conditioned 
medium containing the recombinant full length VWF or VWF variants were harvested. 
To ensure the VWF multimers not be damaged by centrifugation, the medium was not 
concentrated and directly used for further analysis. 
2.5 Purification of ADAMTS13 constructs 
2.5.1 Metal ion affinity chromatography  
A Fast Protein Liquid Chromatography (FPLC) (GE Healthcare) system was used for 
purification, the principle of which is to measure of light absorbance of the samples 
flowing through at 280nM and collect of peak fractions. As both the ADAMTS13 MP 
and MP-Dis constructs had a  metal ion binding 6xHis-tag on the C-terminal ends, 
they could be purified with affinity chromatography using a Ni2+ column. Nickel 
sulphate hexahydrate was passed over a Ni2+ chelating HiTrap column (GE 
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Healthcare). The column was then equilibrated with binding buffer (20mM Tris-HCl, 
500mM NaCl, 20mM Imidazole, pH7.8) The conditioned medium containing MP or 
MP-Dis, which was dialysed (20mM Tris-HCl, 500mM NaCl) overnight before 
purification, was injected and flowed through the column.  The column was then 
washed with binding buffer (20mM Tris-HCl, 500mM NaCl, 20mM Imidazole buffer), 
after which, the MP and MP-Dis were eluted with elution buffer (20mM Tris-HCl, 
500mM NaCl, 500mM Imidazole). The peak fractions were collected and dialysed in 
lower salt buffer (20mM Tris-HCl, 150mM NaCl, pH7.8). The obtained MP and MP-
Dis might be only partially pure, which was demonstrated by silver staining (section 
2.5.5). Therefore, further purification by gel filtration was required (section 2.5.2). 
2.5.2 Gel filtration chromatography  
The principle of gel filtration is that smaller molecules pass through the column more 
slowly due to diffusing into the pores of the beads, while larger molecules pass 
through the column more quickly due to less entering the pores of the beads. The MP 
and MP-Dis samples were concentrated from 4ml to 1ml by centrifugation (2500x g) 
at 3 minute intervals several times using Amicon Ultra Centrifugal Filter Devices 
(Milipore). Using the FPLC system (GE Healthcare), a 120mL HiLoad 16/60 
Superdex 75pg column (GE Healthcare) was equilibrated with buffer (20mM Tris-
HCl, 500mM NaCl, pH7.8) overnight. Dialysed (20mM Tris-HCl, 500mM NaCl, 
pH7.8) and concentrated MP and MP-Dis samples were flowed through the column 
and peak fractions were collected. Analysis of the peak fractions were performed by 
SDS-PAGE together with silver staining (section 2.5.2) 
2.5.3 Hydrophobic interaction chromatography 
Separation of proteins on interaction chromatography (HIC) media is based on several 
factors involving in the interplay between the hydrophobicity of the medium, the 
property and composition of the sample, the distribution and prevalence of 
hydrophobic amino acid residues exposed on the surface, and the concentration of 
involved salt in the binding buffer. The HIC column is made of polypropylene, which 
is biocompatible and noninteractive with biomolecules. The separation can be easily 
achieved using a chromatography system such as FPLC. To purify the MP-Dis 
construct using HIC, there are generally four main steps to carry out. Firstly, start 
buffer (20mM Tris-HCl, 2M NaCl, pH7.0) and elution buffer (20mM Tris-HCl) were 
prepared. Before use, these buffers, especially the high salt concentration start buffer 
were filtered through 0.45µm filter to avoid UV baseline drift. Secondly, since 
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adsorption is carried out at high salt concentration, the sample was adjusted to the pH 
and ionic strength of the start buffer (high salt buffer) for consistent and reproducible 
results. Therefore, the sample initially purified though Ni2+
2.5.4 Heparin column purification  
 column was diluted 1in 10 
into a suitable volume of start buffer. Thirdly, start buffer was used to wash the 1ml 
HiTrap Phenyl HP column (GE Healthcare) until the column equilibration achieved. 
The diluted sample was then injected, followed by continually wash with the start 
buffer. Finally, elution buffer was pumped in a linear increase of concentration in 
order that the MP-Dis construct would be eluted with a linear decrease of the salt 
concentration in the HIC column. 
A 5ml HiTrap Phenyl HP column (GE Healthcare) was used in heparin column 
purification for my expressed recombinant MP-Dis proteins. Immobilised heparin in 
the column has two main modes of interaction with proteins. It can operate as an 
affinity ligand, for example, in its interaction with coagulation factors. Heparin also 
functions as a high capacity cation exchanger, due to its anionic sulphate groups. In 
both cases, gradient elution with salt is most commonly used. To purify MP-Dis, the 
heparin column was equilibrated with at least 10 column volumes of loading buffer 
(25mM NaCl, 50mM MES-NaOH, pH6.6) before loading samples. The samples were 
then injected slowly to allow the protein has more chance to bind. After loading the 
samples, 1.5 column volumes of loading buffer (25mM NaCl, 50mM MES-NaOH, 
pH6.6) were used to wash the column. To avoid the target protein being lost in the 
flow through and/or the washing step, all the fractions were collected and kept. In 
flow through and wash steps, the collection tubes were frequently changed and not 
subsequently combined to avoid dilution. To elute the protein, a gradient starting with 
100% loading buffer (25mM NaCl, 50mM MES-NaOH, pH6.6) and ending with 
100% elution buffer (1M NaCl, 50mM MES-NaOH, pH6.6) was conducted. Small 
fractions of ~2ml per tube were used to collect in this step. 
2.6 Analysis of ADAMTS13 and VWF 
2.6.1 SDS-PAGE  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins based on their molecular weight. SDS is an anionic detergent, which 
unfolds proteins. In most proteins, the binding of SDS to the polypeptide chain 
confers an even distribution of negative charge per unit mass, thereby resulting in a 
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fractionation by approximate size during electrophoresis. Protein samples were 
diluted in 4x SDS-PAGE loading buffer (Invitrogen) and heated at 95°C for 15 
minutes to denature the proteins. If necessary, 6% v/v β-mercaptoethanol was loaded 
to the 4x loading buffer to reduce disulphide bonds. The mixture of protein samples 
with loading buffer were loaded to NuPAGE Bis-Tris pre-cast 4-12% polyacrylamide 
gels (Invitrogen) and electrophoresed at 200V for ~35 minutes. The gel was then used 
for either Coomassie staining with Imperial Protein Stain (Thermo Scientific) or 
Western blotting analysis. 
2.6.2 Coomassie staining 
For Coomassie staining, the SDS-PAGE (section 2.6.1) gel was rinsed three times 
with 100ml ddH2O for 5 minutes before adding Imperial Protein Stain (Thermo 
Scientific) for one hour. The gel was then distained by washing with 100ml ddH2O for 
1.5-2 hours followed by drying with Model583 gel dryer (BioRAd, USA). 
2.6.3 Silver staining 
Silver staining is another way to detect proteins after electrophoretic separation on 
polyacrylamide gels, which is more sensitive to identify the purity of samples than 
Coomassie staining. To establish the target fractions containing pure MP or MP-Dis 
from Ni2+
2.6.4 BCA total protein assay 
 column purification or gel filtration (section 2.5.2), peak fractions were 
analysed by SDS-PAGE (2.6.1) and followed by silver staining. The SDS-PAGE gels 
were fixed, stained and developed according to the following procedure. All related 
solutions were prepared freshly and shortly before use. SDS-PAGE gels were firstly 
treated with fixing solution (20ml 95% ethanol, 5ml acetic acid, 25ml ddH2O) for 30 
minutes, and then incubated with incubation solution (15ml 95% ethanol, 3.4g Na-
actetate·3H2O, 0.1g Na2S2O3·5H2O, 35ml ddH2O) with 25% glutaraldehyde (added 
just before use) for 30 minutes. Following by washing with ddH2O 3 x 20 minutes, 
the gels were then stained with silver solution (0.05g AgNO3, 50ml ddH2O) containing 
10µl formaldehyde (added just before use) for 40 minutes, after which the gels were 
washed with ddH2O 3 x 1 minute to remove the unbound AgNO3. The gels were then 
developed with developing solution (1.25g Na2CO3, 50ml ddH2O) containing 5µl 
formaldehyde (added just before use) about 15 minutes until bands were visible. The 
chemical reactions were terminated with stop solution (0.73Gedta, 50ml ddH2O).  
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A bicinchoninic acid (BCA) total protein assay kit (Thermo Scientific) was used to 
test the total protein concentration of purified proteins (MP, MP-Dis and VWF 115), 
according to the manufacturer’s instructions. The principle of BCA total protein assay 
is based on the formation of a Cu2+ /protein complex under alkaline conditions, 
followed by reduction of the Cu2+ to Cu1+. The amount of reduction is proportional to 
the protein concentration in sample. It has been found that cysteine, tyrosine, 
trytophan and the peptide bond are able to reduce Cu2+ to Cu1+. In alkaline solutions, 
BCA forms a purple blue complex with Cu1+. This provides a basis to monitor the 
reduction of alkaline Cu2+
 2.6.5 Western blotting  
 by proteins and thus test the protein concentration in 
sample. Serial dilutions of bovine serum albumin (BSA), ranging from 2mg/ml to 
25μg/ml, were used as a standard and different dilutions of sample were prepared. 
25µl of each standard and unknown diluted samples were applied in duplicate to the 
wells of a microtitre plate. BCA Reagent A was mixed with Reagent B at a ratio of 
50:1, forming the mixture of working reagent. 200µl of this mixture was loaded into 
each well containing the standard or samples. The plate was covered and incubated at 
37°C on a plate shaker for 30 minutes. The absorbance was measured at 560nM using 
a spectrophotometer (uQuant, Biotek).  
To evaluate the expression levels, secretion, and intracellular retention of 
ADAMTS13 and its variants, Western blotting was applied to analyse the conditioned 
medium and the cell pellets from tissue cultures. The conditioned medium samples 
were mixed with 4x SDS-PAGE loading buffer (Invitrogen) containing 6% v/v β-
mercaptoethanol which reduced disulfide bonds to separate proteolysed protein 
fragments. The samples were heated at 95°C for 15 minutes, after which they were 
centrifuged and loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide gels 
(Invitrogen). A SeeBlue Plus2 Pre-stained standard (Invitrogen) was also loaded in a 
separated lane of the gels. The electrophoresis was performed at 200V for ~35 
minutes. The proteins were transfered to a sheet of special blotting paper called 
nitrocellulose membrane (0.2µm) (Amersham Biosciences) at 35V for one hour. The 
membranes were blocked in 2.5% blocking reagent (Amersham) in PBS-0.1%Tween 
for ~one hour with shaking, after which the membranes were incubated with primary 
antibody in blocking buffer at 4°C overnight. Rabbit anti-ADAMTS13 polyclonal 
antibody was used in dilution of 1:5000 for the full length ADAMTS13 variants while 
monoclonal anti-His tag antibody (Invitrogen) diluted 1:1000 was applied for the MP 
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and MP-Dis truncations. After membranes were washed five times with PBS-
0.1%Tween, they were incubated with secondary antibody at room temperature with 
shaking for one hour. For the full length ADAMTS13 variants, anti-rabbit IgG-HRP 
(Dako) (1/5000) was used as the secondary antibody while goat anti-mouse IgG-HRP 
(Dako) (1/5000) was applied for the MP and MP-Dis variants. The membranes were 
then washed five times PBS-0.1%Tween and detected with ECL chemiluminescent 
substrate (Immobilon, Milipore), according to the manufacturer’s instructions. The 
membranes were then exposed to film.  
2.6.6 Enzyme-linked immunosorbent assay (ELISA) 
The concentrations of full length ADAMTS13 and VWF and their variants was 
assessed by ELISAs. Normal human control plasma (Technoclone, Austria) was used 
to generate a standard curve. For Full length ADAMTS13, a polyclonal anti-
ADAMTS13 antibody was used to capture ADAMTS13 to the plate. A biotinylated 
anti-TSP-1 (2-4) antibody was used as detection antibody. A 96-well plate was coated 
with rabbit polyclonal anti-ADAMTS13 antibody in coating buffer (50mM sodium 
carbonate, pH9.6) at 4°C overnight. The plate was washed with PBS-0.1%Tween 
following each incubation step. After blocking (PBS-2%BSA) for one hour, serial 
dilutions of control plasma and conditioned medium samples were added into each 
well and incubated at room temperature for two hours. The ADAMTS13 bound to the 
polyclonal anti-ADAMTS13 antibody was detected by biotinylated anti-TSP1 (2-4) 
antibody (0.2μg/ml in PBS-1%BSA), which itself was detected by HRP-conjugated 
streptavidin (Amersham Pharmacia). After one hour, plates were washed and 
incubated with the HRP substrate (ortho-phenylene-diamine) (Sigma, UK) for colour 
development which was stopped with 50μl H2SO4 (2.5mol/L). The light absorption 
was measured at 492nm using a spectrophotometer (uQuant, Biotek).  
For full length VWF, polyclonal rabbit anti-human VWF antibody (Dako) was used as 
the coating antibody and HRP-conjugated polyclonal rabbit anti-human VWF 
antibody (Dako) as detected antibody. 
2.6.7 VWF multimer analysis 
SDS-PAGE gel analysis is not suitable to examine the multimeric distribution pattern 
analysis of VWF multimers due to the higher molecular weight VWF multimers not 
being separated properly by this gel. The VWF multimeric pattern was therefore 
visualised by analysis in agarose gels under non-reducing conditions. A method 
optimised by Dr. McKinnon in our lab was used to perform VWF multimer analysis. 
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1.2% agarose gels (1.5mm diameter) were prepared by dissolving 1.2g high gelling 
temperature agarose (Seakem) in 100ml of gel buffer (200mM Tris-HCl, 100mM 
Glycine, 0.1% SDS, pH9.0) and cast using a Bio-Rad mini-gel casting system. 
Samples were diluted with sample buffer (10mM Tris-HCl, 1mM EDTA, 2% SDS, 
8M urea, 0.01% bromophenol blue, pH8.0) and incubated at 60°C for 30 minutes. 
Gels were assembled in a Bio-Rad mini-gel electrophoresis tank filled with chilled 
running buffer (100mM Tris-HCl, 150mM Glycine, 0.1% SDS, pH8.4) and placed in 
an ice box. 10μl of each sample was loaded and the electrophoresis was run first at 
60V for 20 minutes and then at 35V for ~ 4 hours until the tracking dye had reached 
the bottom of the gel. After electrophoresis, Western blotting and immuno-staining 
with polyclonal rabbit anti-human VWF-HRP antibody (Dako) was performed 
(section 2.6.5). 
2.7 Preparation of purified VWF 115, VWF 76 and variants 
2.7.1 Expression of VWF 115, VWF 76 and variants 
VWF 115, which spans residues Glu1554-Arg1668, is a short VWF A2 domain 
fragment. VWF 76, which spans residues Glu1593-Arg1668, lacks the 40 N-terminal 
amino acids of VWF 115. Both substrates have previously been cloned into the 
bacterial expression vector pET100 (Invitrogen), which is fused with an Xpress 
epitope and a 6xHis tag to the N-terminus of the vector [163]. The VWF 115, VWF 
76 and their variants were expressed at a high level in Rosetta DE3 E.coli cells 
(Novagen). The Rosetta DE3 cells are genetically modified to ensure encoding of 
eukaryotic tRNA species that are rare in prokaryotic cells to enhance the synthesis of 
eukaryotic proteins. 1ng plasmid DNA of the vector was transformed into ~10μl of 
the competent Rosetta DE3 cells as described in section 2.2.2. A bacterial colony was 
selected to inoculate 12ml of LB broth (see Appendix) containing 100µg/ml 
ampicillin and incubated at 37°C with shaking (~250 rpm) for 4~6 hours. Then the 
culture media was spined to collect bacterial pellets. The pellets were resuspended in 
~5ml fresh medium and to inoculate 1L 2x YT broth (see Appendix) cultures for each 
construct. Expression of the recombinant protein was induced by adding 1mM 
Isopropyl ß-D-1-thiogalactopyranoside (IPTG) (Sigma) and cultured at 37°C with 
shaking (~250 rpm) for 16 hours. Bacterial cells were harvested by centrifugation at 
5000 x g for 30 minutes at 4°C. The supernatant was removed completely and the cell 
pellets were stored at -80°C until cell lysis and inclusion body preparation. 
2.7.2 Purification of VWF 115, VWF 76 and variants 
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In the Rosetta DE3 E.coli cells expression system, the high level expression of VWF 
115, VWF 76 and variants results in insoluble proteins aggregating as inclusion 
bodies. To harvest the inclusion bodies, the bacterial cell pellets were resuspended in 
room temperature using 1x BugBuster reagent (Novagen) (5ml reagent/g wet cell 
paste) by pipetting or gentle vortexing. The resuspended mixtures were transferred 
into 50ml tubes. 1μl (25 units) Benzonase® Nuclease (Novagen) per 1ml of 
BugBuster reagent was added to the mixtures, followed by addition of rLysozyme 
Solution (30KU/μl) (Novagen) up to a final concentration of 1KU/ml. The cell 
suspensions were incubated on a shaking platform or rotating mixer at a slow setting 
at room temperature for 30mins. As benzonase was added, the extract should not be 
viscous. The insoluble cell debris were pelleted by centrifugation at 5,000xg at 4°C 
for 30minutes. The supernatants were removed and frozen for later analysis of soluble 
fraction proteins. The inclusion body pellets were resuspended using 5ml BugBuster 
Reagent/g wet cell paste, with pipetting up and down and vortexing to obtain an even 
suspension.  The rLysozyme Solution (30KU/μl) (Novagen) was added up to a final 
concentration of 1KU/ml, follwed by vortexing gently to mix. The mixtures were then 
incubated at room temperature for 5–10 minutes. 6 volumes of 1:10 diluted BugBuster 
reagent (in deionized water) was added to the suspensions, with vortexing for 1 
minute. The suspensions were centrifuged at 5,000xg for 15minute at 4°C to collect 
the inclusion bodies. The supernatants were removed. The inclusion bodies were 
resuspended in 6 volumes of 1:10 diluted BugBuster, mixed by vortexing, and 
centrifuged as before. This step was repeated if necessary. The pellets were 
resuspended in 2ml 1:10 diluted reagent, and the samples were transfered to 2ml tubes 
and centrifuged at 16,000xg for 15min at 4°C and the supernatants were removed 
completely. To purify the proteins, the inclusion bodies were firstly solubilised in a 
buffer containing 20mM Tris-HCl (pH7.8), 500mM NaCl, 20mM Imidazole and 8M 
urea. They were then purified with a nickel HiTrap column on an FPLC system (Äkta, 
Amersham Pharmacia Biotech) (section 2.5.1). A linear gradient wash (8M-0M urea 
linear gradient in ~30 minutes) was performed to remove the urea and refold the 
proteins. The proteins were eluted from the nickel column with 500mM Imidazole.  
They were then dialysed using a 3-6kDa cut-off membrane (Thermo Scientific) in 
lower salt buffer (20mM Tris-HCl, 150mM NaCl, pH7.8) at 4°C overnight. The purity 
of the proteins was analysed by SDS-PAGE followed by Coomassie staining (section 
2.6.1 and 2.6.2). Protein concentrations were quantified with a BCA total protein 
assay (Thermo Scientific) (section 2.6.4). 
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2.8 ADAMTS13 activity assays  
2.8.1 Proteolysis of VWF 115 
I used the VWF 115 substrate to evaluate the proteolytic activities of ADAMTS13 
and its variants. The proteolysis of VWF 115 can be qualitatively visualized by SDS-
PAGE/Coomassie staining (section 2.6.1 and 2.6.2) or accurately quantified by HPLC 
(section 2.8.3). Use of VWF 115 as substrate does not require shear stress or 
chaotropic agents (such as urea) to unfold VWF. This is in contrast to the assays 
containing full length multimeric VWF as substrate. The concentrations of wild type 
ADAMTS13 and ADAMTS13 variants in conditioned medium which were assessed 
by ELISA (section 2.6.3) were adjusted to equal concentrations in the proteolysis 
reactions. The conditioned medium containing ADAMTS13 or ADAMTS13 variants 
(0.5-5nM) were pre-incubated with CaCl2 (5mM CaCl2, 20mM Tris-HCl, 150mM 
NaCl, pH7.8) for one hour. The purified VWF 115 (0.5-20µM) substrates were then 
added into the ADAMTS13 mixtures.  Aliquots of samples (15µl for SDS-PAGE or 
65µl for HPLC analysis) were removed at various time points and reactions stopped 
with 5µl 0.5M EDTA which can chelate Zn2+ and Ca2+
2.8.2 SDS-PAGE analysis of VWF 115 proteolysis  
 from the ADAMTS13 MP 
domain. The aliquots of samples were stored at -80°C until analysis by SDS-
PAGE/Coomassie staining or HPLC. 
The aliquots of samples from the proteolysis reaction were loaded on SDS-PAGE gels 
and electrophoresed as described in section 2.6.1. The gels were then stained with 
Coomassie stainning (Imperial protein stain, Pierce) (section 2.6.2), allowing 
visualisation of the C-terminal cleavage products (10kDa),   the N-terminal cleavage 
products (7kDa), and the uncleaved VWF 115 (17kDa). 
2.8.3 HPLC analysis of VWF 115 cleavage products  
High pressure liquid chromatography (HPLC) analysis of the cleavage products was 
used to quantify the proteolysis of VWF 115 by ADAMTS13. An ACE 5 C4-300 
(Ace) column (Hichrom) was used on an Akta HPLC system (GE Healthcare). Both 
HPLC grade acetonitrile and water were supplemented with 0.1% trifluoroacetic acid 
before use. The column was equilibrated with 20% acetonitrile. The samples were 
loaded on the column with 20% acetonitrile and eluted with a 20-50% acetonitrile 
gradient, during which light absorbance at 205nM was measured. This allowed 
separate elution of the two cleavage products and the uncleaved VWF 115. Cleavage 
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products and uncleaved VWF 115 were quantified by measurement of the areas under 
the light absorbance peak using Unicorn analysis software (GE Healthcare). For time-
course analysis, percentage proteolysis was plotted against time using GraphPad 
Prism 4 software (GraphPad Software). The kcat/Km was determined from time-course 
analysis and the data was fitted to the equation:  
. 
[AP] is VWF 115 cleavage product peak area at time t, [APf] is the peak area after 
complete VWF 115 cleavage, e is ADAMTS13 concentration, and t is reaction time. 
For individual determination of the Km, Vmax, and kcat, the initial rate of proteolysis of 
VWF 115 (after 5-10 minutes) was measured at increasing substrate concentrations 
(0.25-25µM). Data were transformed into Michaelis-Menten and Lineweaver-Burk 
plots, and the kinetic constants were derived using Prism 4 software (GraphPad, San 
Diego, CA), by which the Km and kcat will be determined after fitting the data to 
equation below: 
Y=Vmax*X/(Km+X) 
X is the VWF 115 concentration (nM) and Y the initial rate (nM cleaved per sec). 
From the Michaelis Menten plot the Km and kcat could be determined. 
2.8.4 Static VWF multimer proteolysis assay 
The proteolysis of full length VWF multimers by ADAMTS13 and ADAMTS13 
variants was analysed under static conditions using a chaotropic agent (urea or 
guanidine-HCl) to unfold VWF and make the scissile bond susceptible to cleavage by 
ADAMTS13. The VWF multimers used in these assays were purified from a 
commercial VWF/FVIII concentrate by Dr Tom McKinnon. The purification was 
performed by gel filtration chromatography and heparin-Sepharose affinity 
chromatography, described in section 2.5.2 and 2.5.4. The VWF multimers were 
incubated with 1.5M guanidine-HCl at 37°C for 30 minutes. The denatured VWF was 
then diluted 10-fold to a final concentration of 10μg/ml into reaction buffer (20mM 
Tris-HCl, 150mM NaCl, 0.5% BSA, 5mM CaCl2, pH7.8), in which 1-5nM 
ADAMTS13 had been pre-incubated for 60 minutes in advance. The reaction was 
incubated at 37°C for 1 to 2 hours before terminating with loading buffer (10mM 
Tris-HCl, 2% SDS, 8M urea, 1mM EDTA, pH8.0). The proteolysis of the VWF 
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multimers was analyzed by 1.2% agarose gel electrophoresis and Western blotting 
(sections 2.6.5 and 2.6.7). 
2.9 Peptide inhibitory assay 
Purified peptide (wild type and mutant, 1mM) (Alta Bioscience) was incubated with 
3.5nM ADAMTS13 and CaCl2 (5mM CaCl2, 20mM Tris-HCl, 150mM NaCl, pH7.8) 
at 37°C for 30 minutes, and 6μM VWF 115 was then added. The reaction was stopped 
at different time points (0, 15, 30 and 60 minutes) with EDTA and analysed on a 12% 
SDS-PAGE Bis-Tris gel, followed by Coomassie staining (section 2.6.1 and 2.6.2). 
To quantify the effect of peptides on VWF 115 proteolysis by ADAMTS13, various 
concentrations (0-1.5mM) of the peptides were individually incubated with 1nM 
ADAMTS13 and CaCl2 (5mM CaCl2, 20mM Tris-HCl, 150mM NaCl, pH7.8) at 37°C 
for 30 minutes, and 2.5μM VWF 115 was then added. After 15 minutes, the reaction 
was stopped at different time points with EDTA (40mM). Subsamples were analyzed 
by HPLC (section 2.8.3) and the initial rate of cleavage was determined. 
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CHAPTER 3: IDENTIFICATION OF POTENTIAL 
CHARGED RESIDUE INTERACTIONS BETWEEN 
SHORT SUBSTRATE VWF (VWF 76 AND VWF 115) AND 
THE ADAMTS13 MP DOMAIN 
3.1 Introduction  
Recent studies have shown that a C-terminal interaction between ADAMTS13 
(TSR(2-8)) and  VWF (D4CK) forms an initial step of a multi-step interaction of 
ADAMTS13 with VWF. However, the most important interactions of ADAMTS13 
are with the VWF A2 domain [62, 77, 92, 168]. The ADAMTS13 Spacer domain 
binds tightly to the C-terminus of the VWF A2 domain (residues 1659-1668) while 
the Disintegrin-like domain interacts with residues (e.g. Asp1614) close to the 
cleavage site [81, 88, 92, 168].  
Each of the above interactions involves VWF residues C-terminal to the Tyr1605-
Met1606 bond. However, residues N-terminal to the cleavage site (His1472-Tyr1605) 
may also be proposed to interact with ADAMTS13. If both sides of the scissile bond 
interact with ADAMTS13, the overall binding affinity would be reduced upon 
proteolysis, which would aid dissociation of cleavage products. It has been shown that 
VWF 73 (Asp1596-Lys1668) (Fig 3.1) is the minimal substrate for ADAMTS13 
[170]. Deletion of 8 residues (from Arg1597 to Val1604) N-terminal to the scissile 
bond abolishes cleavage [166], which further suggests that important interaction sites 
may lie within several residues close to Tyr1605. Considering the short distance 
between Asp1596 and Tyr1605, these residues may interact within the ADAMTS13 
MP domain. Because of these considerations, I decided to investigate the role of 
residues N-terminal to the cleavage site in the cleavage reaction. I will first describe a 
preliminary investigation in which I attempted to prepare the fragments of VWF 
corresponding to N-terminal cleavage fragment of VWF 115 (Glu1554-Lys1668) and 
VWF 76 (Ser1593-Lys1668). Then, I will describe attempts I made to identify a role 
of charged residues in the N-terminal region of the VWF A2 domain that might 
interact with ADAMTS13. Ultimately, these preliminary attempts to define critical 
interaction sequences or residues proved unsuccessful. However, I present these 
results because on the basis my findings I was able to eliminate the possibility of a 
charged interaction being important in proteolysis of these short fragments. This 
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enabled me to consider whether a hydrophobic interaction might be more important, 
something that will be considered in section 4.  
 
Figure 3.1 The amino acid sequences of VWF 73, VWF 76 and VWF 115.   VWF 73 
(Asp1596-Lys1668), VWF 76 (Ser1593-Lys1668) and VWF 115 (Glu1554-Lys1668) share 9 
residues N-terminal to the cleavage site. There are only 3 charged residues among them, 
Asp1596, Arg1597 and Glu1598, which are highlighted in blue.  
3.2 Effect of N-terminal cleavage fragments of VWF 76 and 
VWF 115 on their proteolysis  
VWF and its shorter fragments VWF 115 (Glu1554-Lys1668), VWF76 (Ser1593-
Lys1668) and VWF73 (Asp1596-Lys1668) are all specifically proteolysed by 
ADAMTS13 at the site of the Tyr1605-Met1606 bond, generating N-terminal and C-
terminal of the cleavage products.  As shown in Figure 3.1, VWF 115, VWF 76 and 
VWF 73 share the same residues C-terminal to the cleavage site. It has been reported 
that the residues Val1607-Lys1668 (which is 1 amino acid shorter than the C-terminal 
cleavage product of VWF 115) exhibited a strong inhibitory effect on the proteolysis 
of the shorter VWF fragment Leu1591-Lys1668 [169], suggesting that product 
inhibition might be an essential feature of the regulation of ADAMTS13 activity. 
Consistent with strong product inhibition, the cleavage of VWF multimers by 
ADAMTS13 is promoted by the presence of denaturants but hardly approaches 
completion despite prolonged incubation. Therefore, along with shear-induced 
exposure of the cleavage site, cleavage product inhibition may modulate the 
proteolysis and the distribution of plasma VWF multimer.  
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However, it remains unknown whether the N-terminal fragment from the cleavage 
reaction might have a similar inhibitory effect on proteolysis. To study this, a Stop 
codon was introduced, replacing the M1606 codon of the VWF 115 and VWF 76 
vectors individually, using site-directed mutagenesis (Section 2.2.1), generating VWF 
Glu1554-Tyr1605 and VWF Ser1593-Tyr1605, respectively. As it was not sure 
whether the N-terminal cleavage product would aggregate as inclusion bodies in 
Rosetta DE3 cells, the inclusion bodies were harvested using BugBuster reagent 
(Novagen), while supernatants were also kept. FPLC (Section 2.5) was then used to 
purify the fragments by Ni2+
 
 column. It was found that most VWF Glu1554-Tyr1605 
appeared in the supernatant fraction (Figure 3.2B&D) rather than in the inclusion 
bodies (Figure 3.2A&C). FPLC confirmed that VWF Ser1593-Tyr1605 was also 
present in the supernatant fraction (Figure 3.3A). To assess the purity of FPLC 
purified target protein in the elution peak fraction, SDS-PAGE followed by 
Coomassie staining (Figure 3.2C and Figure 3.3B) and Western blotting (anti-X-
press-HRP antibody) (Figure 3.2D and Figure 3.3C) were performed. Unfortunately, 
the obtained fragments representing the cleavage product of VWF 115 and VWF 76 
were not pure enough and protein precipitation occurred, which prevented 
determination of their concentration for further investigation. Because of these 
difficulties, I decided not to continue attempting to prepare and investigate the use of 
these recombinant fragments. In section 4.4, I will describe an alternative approach in 
which I use a synthetic peptide (DREQAPNLVY), representing the N-terminal of the 
cleavage product of VWF 73, to competitively inhibit proteolysis of VWF 115 by 
ADAMTS13. 
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Figure 3.2 Purification of recombinant N-terminal fragment (VWF Glu1554-Tyr1605) 
corresponding to the cleavage product of VWF 115. (A) Chromatogram of purification of 
recombinant N-terminal cleavage product of VWF 115 (inclusion bodies fraction) by Ni2+
 
 
affinity chromatography. Protein elution was achieved with the use of high concentrations of 
Imidazole (250mM). (B) Chromatogram of the purification of the supernatant fraction by 
nickel affinity chromatography. Protein elution was achieved with the use of 250mM 
Imidazole. The eluted fraction (A2) is highlighted by an arrow. (C) Analysis of the 
supernatant fraction by SDS-PAGE. Non-reducing SDS-PAGE on a 5-12 % NuPAGE MES 
gel followed by Coomassie staining: affinity column flow through X1 (lane 1), elution with 
500mM Imidazole fraction A2 (lane 2). The molecular weight of recombinant VWF Glu1554-
Tyr1605 is 10kDa. Lad: ladder of protein molecular weight marker. (D) Analysis of the 
supernatant fraction by Western blotting. Reducing SDS-PAGE on a 5-12 % NuPAGE MES 
gel analysed by western blotting, using anti-X-press epitope antibody: elution with 250mM 
Imidazole fraction A2 (lane 1).  
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Figure 3.3 Purification of recombinant N-terminal fragment (VWF Ser1593-Tyr1605) 
corresponding to the cleavage product of VWF 76. (A) Chromatogram of nickel affinity 
chromatography purification of the VWF Ser1593-Tyr1605 (supernatant fraction). This 
fragment was expressed in Rosetta DE3 cells, and supernatant fraction was separated from the 
inclusion bodies using BugBuster reagent (Novagen). Protein elution was achieved with the 
use of high concentrations of Imidazole (250mM). The eluted fraction (A2) is highlighted by 
an arrow. (B) Non-reducing SDS-PAGE on a 5-12 % NuPAGE MES gel followed by 
Coomassie staining: affinity column flow through X1 (lane 1), elution with 250mM Imidazole 
fraction A2 (lane 2). The molecular weight of VWF Ser1593-Tyr1605 is 5.5kDa. Lad: ladder 
of protein molecular weight marker. (C) Reducing SDS-PAGE on a 5-12% NuPAGE MES 
gel analysed by Western blotting, using anti-X-press epitope antibody: elution with 250mM 
Imidazole fraction A2 (lane 1).  
3.3 A potential charged interaction between VWF residues 
Asp1596/Glu1598 and the ADAMTS MP domain 
Previous results in our lab have indicated that VWF 115 with 3 charged residues that 
are substituted, VWF 115 (DRE1596/7/8AGA), is proteolysed inefficiently, which 
suggests that residues Asp1596-Arg1597-Glu1598 (Figure 3.4) may contribute to the 
interaction between the VWF region N-terminal of the scissile bond and ADAMTS13 
MP domain. As Asp1596 and Glu1598 are both negatively charged residues, the 
correspondingly interacting residues in ADAMTS13 MP domain would probably be 
of positive charge. In a homology model of the ADAMTS13 MP domain structure 
(section 2.1.1), I have identified two positively charged, surface exposed patches 
consisting of Arg267/Arg268 and Arg278/Arg280 (Figure 3.5). I hypothesized that 
either of these patches could potentially form ionic bonds with negatively charged 
residues Asp1596 or/and Glu1598 (Figure 3.5). It was reported that a TTP patient 
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with the mutation ADAMTS13 R268P had no detectable ADAMTS13 activity, which 
appeared to support the possibility that ADAMTS13 Arg268 is in a charged 
interaction with VWF. However, investigation of recombinant ADAMTS13 
containing R268P demonstrated that it was not secreted from HeLa cells [86].  
 
Figure 3.4 Cartoon view of the crystal structure of the VWF A2 domain. Charged 
residues Asp1596, Arg1597 and Glu1598 are highlighted in red at the bottom of the model. 
The scissile bond Tyr1605-Met1606 is buried in the middle of the model. At the top of the 
model, the location of another important residue, Asp1614, is also highlighted in yellow.  The 
original structural information was taken from PDB file 3GXB [32]. 
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Figure 3.5 Model of the ADAMTS13 Metalloprotease (MP) and Disintegrin-like (Dis) 
domains. It has been established [81] that Arg349 (red) in the ADAMTS13 Dis domain 
interacts with VWF Asp1614. Zn2+
3.4 Functional analysis of the importance of VWF residues 
Asp1596/Glu1598 and ADAMTS13 residues Arg278/ Arg280 
and Arg267/Arg268 
 and 3xHis (blue) form part of the active site and are 
located in the middle of the ADAMTS13 MP domain. On the left hand side, two patches of 
positively charged residues (Arg278/Arg280 and Arg267/Arg268) highlighted in yellow are 
hypothesized to interact with VWF Asp1596/Glu1598. 
To establish the importance of the two negative residues Asp1596 and Glu1598 in the 
VWF A2 domain, they were mutated to Asn and Gln, respectively, using site-directed 
mutagenesis (Section 2.2.1). Similarly, to identify the importance of the patches of 
Arg278/Arg280 in the ADAMTS13 MP domain, these two charged residues were 
mutated into Ala.  
3.4.1 Expression of ADAMTS13 R267A/R268A and R278A/R280A variants 
ADAMTS13 R278A/R280A mutants were transiently expressed in HEK293T cells. 
Conditioned media was analyzed by SDS-PAGE on a 5-12% NuPAGE MES gel, 
 84 
followed by Western blotting using rabbit anti-ADAMTS13 polyclonal antibody. This 
demonstrated that ADAMTS13 R278A/R280A variant was expressed and secreted 
similarly to WT ADAMTS13 (Figure 3.6), suggesting that the mutations did not by 
themselves induce any gross structural changes that influenced enzyme secretion. The 
concentrated media was filtered, concentrated and the concentration of the 
ADAMTS13 variants was established by ELISA. Because of the poor secretion of 
Arg267/Arg268 mutants, I decided not to further investigate these residues change. 
 
Figure 3.6 SDS-PAGE and Western blotting of ADAMTS13 R278A/R280A variants.   
SDS-PAGE on a 5-12 % NuPAGE MES gel analysed by Western blotting, using rabbit anti-
ADAMTS13 polyclonal antibody: Non-reduced conditioned medium of WT ADAMTS13 
(lane 1), reduced and 10 times concentrated medium of WT ADAMTS13 (lane 2), Non-
reduced conditioned medium of ADAMTS13 R278A/R280A (lane 3), reduced and 10 times 
concentrated medium of ADAMTS13 R278A/R280A (lane 4).   
3.4.2 Expression and purification of VWF 115 variants D1596N/E1598Q 
An expression vector for the fragment of the VWF A2 domain, VWF 115 (spanning 
VWF residues 1554–1668), its mutagenesis, and expression have been previously 
described (18), see section 2.7.1. VWF 115 (D1596N/E1598Q) was introduced 
(section 2.2.2) expressed in Rosetta DE3 cells and then purified by FPLC (section 
2.3.1). A column-based refolding method was attempted (Figure 3.7A), allowing the 
protein to gradually recover its native conformation. The inclusion bodies were 
solubilised in 8M urea and then passed over a Ni2+ column. A linear gradient wash 
(8M-0M urea linear gradient in ~30 minutes) was performed to remove the urea and 
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slowly refold the proteins immobilised on the column. After refolding, the proteins 
were eluted with a 250mM Imidazole, the elution peak of which is shown in Figure 
3.7A. The purity of the proteins was assessed by SDS-PAGE followed by Coomassie 
staining. It showed that a single band was present at the 17kDa position (Figure. 3.7B), 
consistent with the predicted molecular weight of VWF 115. 
 
Figure 3.7 Purification of recombinant VWF 115 (D1596N/E1598Q). (A) A 
chromatogram of the purification of the recombinant VWF 115 (D1596N/E1598Q) by nickel 
affinity chromatography. A linear gradient wash (8M-0M urea linear gradient in ~30 minutes) 
was performed to remove the urea and slowly refold the proteins. Protein elution was 
achieved with the use of high concentrations of Imidazole (250mM). The eluted fraction (A2) 
is indicated by an arrow. (B) Non-reducing SDS-PAGE on a 5-12% NuPAGE MES gel 
followed by Coomassie staining: affinity column flow through X1(lane 1), elution with 
250mM Imidazole fraction A2 (lane 2). The predicted molecular weight of recombinant VWF 
115 (D1596N/E1598Q) is approximately 17kDa.  
3.4.3 Functional analysis of the ADAMTS13 R278A/R280A mutant 
Activity assays containing 0.5nM WT ADAMTS13, or the ADAMTS13 
R278A/R280A mutant, and 6μM VWF 115 were incubated at 37°C. At the times 
indicated, reactions were stopped with EDTA. Proteolysis of VWF 115 by the 
ADAMTS13 R278A/R280A mutant was initially assessed qualitatively by SDS-
PAGE followed by Coomassie staining (Figure 3.8). Proteolysis was assessed by the 
generation of the 10kDa and 7kDa VWF 115 cleavage products. Compared to WT 
ADAMTS13, the R278A/R280A mutant proteolysed VWF 115 normally, indicating 
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that these positively charged residues do not have a major role in the interaction with 
VWF 115. 
 
Figure 3.8 Proteolysis of WT VWF 115 by WT ADAMTS13 and the ADAMTS13 
(R278A/R280A) variant.  For activity assays, 0.5nM WT or variant ADAMTS13 and 6μM 
VWF 115 were incubated at 37°C. At the times indicated, reactions were stopped with EDTA 
and analysed by SDS-PAGE followed by Coomassie staining. Proteolysis was assessed by the 
generation of the 10kDa and 7kDa VWF 115 cleavage products.  
3.4.4 VWF 115(D1596N/E1598Q) proteolysis by WT ADAMTS13 
Although previous results in our lab had suggested that VWF 115 (DRE1596/7/8AGA) 
is proteolysed inefficiently, the quality of the SDS-PAGE gel supporting the 
importance of Asp1596-Arg1597-Glu1598 was not high (these results are not 
presented here). Nonspecific bands appeared between the 10kDa band and 7kDa band. 
The VWF 115 (DRE1596/7/8AGA) protein samples available were also found to be 
precipitated. I decided to use VWF 115 (D1596N/E1598Q), the target of which was 
mutated to polar residues to prevent precipitation,   instead of (DRE1596/7/8AGA), 
for functional analysis of Asp1596 and Glu1598. I thought it unlikely that Arg1597 
would be as important as its two adjacent negatively charged residues. Activity assays 
containing 3.5nM WT ADAMTS13 and 6μM WT VWF 115 or VWF 115 
(D1596N/E1598Q) were incubated at 37°C. At the times indicated, reactions were 
stopped with EDTA. Proteolysis of VWF 115 (D1596N/E1598Q) by the WT 
ADAMTS13 was initially assessed qualitatively by SDS-PAGE followed by 
Coomassie staining (Figure 3.9). Surprisingly, compared to WT VWF 115, there is no 
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difference in appearance rate of the cleavage products, at 10kDa and 7kDa position. It 
appears, therefore, that substitution of Asp1596 and Glu1598 did not appreciably 
influence VWF 115 proteolysis (Figure 3.9). This suggests that these two negative 
charged residues are unlikely to contribute to the interaction between VWF and 
ADAMTS13. 
 
 
Figure 3.9 Proteolysis of VWF 115(D1596N/E1598Q) by WT ADAMTS13. Activity 
assays containing 3.5nM WT ADAMTS13 and 6μM WT VWF 115 or VWF 115 
(D1596N/E1598Q) were incubated at 37°C. At the times indicated, reactions were stopped 
with EDTA and analysed by SDS-PAGE followed by Coomassie staining. Proteolysis was 
assessed by the generation of the 10kDa and 7kDa VWF 115 cleavage products.  
3.5 Discussion  
To investigate the potential interaction between charged residues N-terminal to the 
cleavage site and the ADAMTS13 MP domain, I initially focused on VWF residues 
Asp1596/Glu1598 and ADAMTS13 residues Arg267/Arg268 and Arg278/Arg280. I 
hypothesized that one or both of these patches (Arg267/Arg268 and Arg278/Arg280) 
in ADAMTS13, could potentially form ionic bonds with negatively charged VWF 
residues Asp1596 or/and Glu1598 influencing cleavage (Figure 3.5). However, my 
results demonstrated that neither the VWF residues Asp1596/Glu1598 nor the 
ADAMTS13 residues Arg278/Arg280 are of functional importance,  as substitutions 
of these residues did not affect proteolysis of  VWF 115 (Figure 3.8 and 3.9). 
Recently, two research groups [175-177] identified a novel Ca2+-binding site in the 
VWF A2 domain, which regulates VWF cleavage by ADAMTS13. The Ca2+ is 
coordinated by VWF residues at Asp1498, Asp1596, Arg1597, Ala1600, Asn1602, 
and a water molecule (see Figure 3.10). Both groups found that mutations at the Ca2+-
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binding site impaired the protective effect of Ca2+
 
 on VWF A2 domain cleavage. 
However, the WT VWF73 and VWF 73 (D1596A) mutant were cleaved at similar 
rates, indicating that the calcium-binding side chain of Asp1596 does not directly 
contribute to recognition of an unstructured substrate. This finding is consistent with 
my results for VWF 115 D1596N as described above.  
 
Figure 3.10 A Ca2+-binding site within the VWF A2 domain. The Ca2+
 
 is coordinated by 
Asp1498, the α3β4-loop (involved in Asp1596, Arg1597, Ala1600, Asn1602), and a water 
molecule (red sphere). This figure was adapted from [171]. 
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CHAPTER 4: IDENTIFICATION OF RESIDUES N-
TERMINAL TO THE VWF CLEAVAGE SITE 
CONTRIBUTING TO ADAMTS13 SUBSTRATE 
SPECIFICITY 
4.1 Introduction 
To investigate further the VWF residues important for cleavage by ADAMTS13, I 
considered again the activities of previously reported short VWF A2 domain 
fragments that span the cleavage site. One, VWF 64 (1605-1668), could not be 
cleaved by ADAMTS13 [170], while others, such as VWF 73 (1596-1668), VWF76 
(1593-1668) and VWF 115 (1554-1668) are proteolysed, as mentioned in section 3.1, 
efficiently [167, 168, 170] (Figure 4.1). Moreover, there is no appreciable difference 
in cleavage efficiency between VWF 73, VWF 76 and VWF 115. The values of 
kcat/Km for these three shorter VWF fragments are all approximately 7.0 x105 M-1s-
4.2 Preparation and comparison of different VWF 115 variants 
with substitutions between Asp1596 and Tyr1605 
1(Table 4.1). Because the difference between the substrates that are and those that are 
not cleaved reside in sequences N-terminal to the scissile bond, I conjectured that the 
VWF1596-1604 N-terminal sequence must contain a structural determinant that is 
essential for proteolysis, despite the negative results I described in the preceding 
chapter. Accordingly, in the present study I have investigated the role of residues N-
terminal to the VWF cleavage site, initially by systematic substitution. 
I introduced a panel of single and multiple amino acid substitutions into the short 
VWF A2 domain substrate (Figure 4.1), VWF 115, which spans residues Glu1554-
Arg1668 (Figure. 4.1). The VWF sequence Asp1596-Tyr1605 is shown (Figure. 4.2).  
VWF 115 and its variants were expressed, purified, and quantified as previously 
described in section 2.7, before functional analyses. In a preliminary activity assay, 
3.5nM of ADAMTS13 was incubated with 6μM of each substrate at 37°C. The 
reaction was stopped at different time points (0, 20 and 60 minutes) with EDTA and 
analysed on a 12% SDS-PAGE gel with Coomassie staining. Cleavage of WT VWF 
115 by ADAMTS13 was rapid when examined by SDS-PAGE to visualize the 
cleavage products. The SDS-PAGE gel of VWF 115 cleavage products (Figure 4.3) 
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Figure 4.1 Sequences and cleavage efficiencies of different A2 domain fragments. The A2 
domain binding sites are buried by A1 and A3. Shear forces unravel the VWF A1A2A3 
domains to unfold the A2 domain. Comparison of the sequences and cleavage efficiencies of 
the unravelled A2 domain in the form of short fragments, VWF 115, VWF 76, VWF 73, and 
VWF 64 by ADAMTS13 suggests that VWF residues 1596-1604 must contain critical amino 
acids necessary for ADAMTS13 proteolysis. 
Table 4.1 Kinetic analysis of VWF 115, VWF 76 and VWF 73  
 
 
 
 
 
1596DREQAPNLV1605Y-M1606 
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shows that after a 20 minute incubation of ADAMTS13 with WT VWF 115, the 
10kDa and 7kDa cleavage products appear. In accordance with results in section 3.3.4, 
the substitution of VWF residues 1596-9DREQ to four serines did not affect the 
proteolysis of VWF 115 when compared to WT. However, the proteolysis of VWF 
115 (Y1605A) was appreciably reduced, while the cleavage of VWF 115 (N1602A) 
was not reduced and VWF 115 (V1604S) was only slightly reduced. Interestingly, the 
mutation of Leu1603 (the P3 residue) to serine abolished its proteolysis (Figure 4.2 
and Figure 4.3). I then performed kinetic analysis of these samples using HPLC to 
quantitatively determine cleavage, as described in section 2.8.3. In time course 
investigations, VWF 115 (Y1605A), VWF 115 (L1603A) and (L1603S) all had 
greatly reduced cleavage (Figure 4.4). I used the time course experiments to calculate 
the specificity constant, kcat/Km, for cleavage of each VWF variant. The values of 
kcat/Km are shown in Table 4.2. The reductions in kcat/Km of VWF 115 (DREQ/SSSS 
and N1602A) variants were around 2 fold, while that of VWF 115 (V1604S) variant 
was 5 fold. The greatest reduction in kcat/Km of VWF 115 variants with substitutions 
between Asp1596 and Tyr1605 was over 400 fold, which appeared in VWF 115 
(L1603S). In addition, reduction in VWF 115 (L1603A) (~ 100 reduction in kcat/Km) 
was appreciably larger even than the 38-fold reduction of the VWF 115 Y1605A. 
 
Figure 4.2 Partial amino acid sequence of the ADAMTS13 substrate VWF 115. VWF 
amino acids are shown as single letter, the ADAMTS13 cleavage site is indicated, and 
substitutions/deletions referred to in the text are annotated below the sequence. VWF 115 
spans residues 1554Glu-1668Arg, but residues shown are only for VWF73, 
spanning1596Asp-1668Arg. 
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Figure 4.3 Qualitative analysis of VWF 115 cleavage by ADAMTS13. 3.5nM of 
ADAMTS13 was incubated with 6μM of each substrate at 37°C; the reaction was stopped at 
different time points (0, 20 and 60 minutes) with EDTA and analysed on a 12% SDS-PAGE 
gel with Coomassie staining.  
 
 
 
Figure 4.4 Percentages of VWF 115 cleavage over time. 2.5μM VWF 115 and its variants 
were incubated with 0.5nM ADAMTS13. HPLC was used to calculate % substrate cleavage 
by determination of the peak area of cleavage products.  
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Table 4.2 Kinetic analysis of VWF 115 and its variants. The time course experiments in 
Figure 4.4 were used to calculate kcat/Km. Values of the kcat/Km were obtained using Enzfitter 
software and the equation described in section 2.8.3.  For the P1 mutant (Y1605A), the 
experiment was performed using higher concentrations (5nM) of ADAMTS13 than the other   
VWF 115 variants, which were studied using 0.5nM of ADAMTS13. *[80]; **[81]; ***[167]. 
4.3    Further comparison of P3 with P1 residue substitutions in 
VWF 115 
VWF Leu1603 is the third residue N-terminal to the cleavage site, which is why it 
termed the P3 residue and correspondingly Tyr1605 is termed P1 [78, 79]. As showed 
in Figure 4.4, the difference between VWF 115 (L1603A) and VWF (Y1605A) 
variants cleaved by ADAMTS13 seemed small when analysed by HPLC. Both VWF 
variants were proteolysed minimally when low ADAMTS13 concentrations (0.5-
1.0nM) were used (Figure 4.4). On increasing ADAMTS13 concentrations (~10 fold), 
a difference between these variants could be observed clearly (Figure 4.5). 
Additionally, the proteolysis of the VWF 115 (L1603S) variant was greatly reduced 
(>400 fold reduction in catalytic efficiency) compared to WT VWF 115. Although 
this reduction in kcat/Km was appreciably larger even than the 38-fold reduction of the 
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VWF 115 (Y1605A) variant with the substituted P1 residue, the P1 residue 
substitution to Ser in a VWF 115 (Y1605S) variant also had barely detectable 
cleavage when examined by SDS-PAGE (Figure. 4.6). This was the case whether 
1nM (Figure 4.6A) or 10nM (Figure 4.6B) ADAMTS13 was used. 
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Figure 4.5 Time course of cleavage of VWF 115 P1 and P3 variants. The VWF 115 
variants (2.5μM) were cleaved by ADAMTS13 (5nM). Samples were taken at different time 
points, and the reaction quenched with 5μl 0.5M EDTA before analysis using HPLC (section 
2.4.3) to determine percentage of VWF 115 cleavage.  
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Figure 4.6 Cleavage of WT VWF 115, VWF 115 L1603S, and VWF 115 Y1605S by 
ADAMTS13. Cleavage of 6μM WT VWF 115 and variants was performed with 1nM (A) and 
10nM (B) WT ADAMTS13. The reactions were stopped at different time points (0, 20 and 60 
minutes) with EDTA and visualized on a 12% SDS-PAGE gel with Coomassie staining.   
4.4 Systematic investigation of the VWF P3 residue, Leu1603 
4.4.1 Investigation of additional VWF P3 residue substitutions on proteolysis by 
ADAMTS13 
A panel of amino acid substitutions at the P3 position was introduced into the VWF 
115 substrate (Figure. 4.7). The importance of the P3 residue (Leu1603) was further 
confirmed when it was mutated to asparagine, alanine, or lysine. All of these variants 
had severely reduced (L1603A) or undetectable (L1603N and L1603K) cleavage 
(Figure 4.8A).  In contrast, substitution of VWF Leu1603 with large hydrophobic 
residues Met and Phe had minimal influence on cleavage (Figure 4.8B). 
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Figure 4.7 Partial amino acid sequence of VWF 115 with the substitutions introduced 
into the P3 position.   
 
 
 
Figure 4.8 Cleavage of VWF 115 and its P3 variants by ADAMTS13. 3.5nM of 
ADAMTS13 was incubated at 37°C with 6μM of each variant with a P3 substitution. The 
reaction was stopped at different time points (0, 20 and 60 minutes) with EDTA and analysed 
on a 12% SDS-PAGE gel with Coomassie staining.  The upper panel, A, shows cleavage of 
VWF 115 L1603A, L1603N and L1603K, while the lower panel, B, shows cleavage of VWF 
115 L1603M and L1603F.  
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Time-course experiments with 1nM ADAMTS13 indicated that even the conservative 
residue change, L1603A, produced∼100-fold reduction in cleavage efficiency (Figure 
4.4); however, quantitation of such low level of proteolysis was imprecise. Using 
higher concentrations (10 nM) of ADAMTS13 to induce sufficient cleavage of the 
VWF 115 L1603A variant, substrate titration of the initial rate of proteolysis of the 
variant was performed, see section 2.8.3. This demonstrated a reduced kcat of 0.11 ± 
0.07s−1, compared with WT ADAMTS13, 0.33 ± 0.18s−1
 
, and an increased Km of 6.8 
± 3.6μM, compared with WT ADAMTS13, 0.91 ± 0.51μM (Figure 4.9).  
 
Figure 4.9 Determination of kcat and Km for WT VWF 115 and for the VWF 115 L1603A 
variant. High concentrations of ADAMTS13 (10nM, rather than 1nM) were used to induce 
proteolysis of VWF L1603A, the initial rates of which were determined by HPLC, corrected 
for protease concentration and plotted as a function of substrate concentration. The values of 
kcat and Km are shown in the inset table (n=3). 
4.4.2 The L1603A substitution inhibits proteolysis of full length multimeric VWF 
by ADAMTS13 
To verify the findings of the importance of the P3 residue in VWF proteolysis by 
ADAMTS13, I introduced both the L1603A and L1603S substitutions into a more 
physiological substrate, full-length recombinant VWF. The full-length WT VWF and 
VWF L1603A and L1603S were analysed by 1.2% agarose gel electrophoresis 
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followed by Western blotting using anti-VWF-HRP antibody, see section 2.6.3. These 
variants were expressed normally and had normal multimer distribution (Figure 4.10).  
 
Figure 4.10 Multimer distribution of full length VWF and its variants. Recombinant WT 
VWF and VWF L1603A and L1603S were examined for their multimer composition by 1.2% 
agarose gel electrophoresis followed by Western blotting using anti-VWF-HRP.  
To examine the effect of the L1603A, P3 mutation on the proteolysis of full-length 
recombinant VWF, 6nM of ADAMTS13 was incubated with 2.2nM of full length 
multimeric VWF and 1.5M urea at 37°C, see section 2.8.4. The reaction was stopped 
with EDTA at different time points (0, 40, 80 and 150 minutes) and analysed on 1.2% 
agarose gel electrophoresis with Western blotting. When the L1603A mutation was 
introduced into full-length VWF, it was clear that the proteolysis was greatly reduced 
or even abolished, as seen by the lack of disappearance of the larger multimers 
(Figure 4.11).  
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Figure 4.11 L1603A substitution in full length multimeric VWF inhibits proteolysis by 
ADAMTS13. 6nM of ADAMTS13 was incubated with 2.2nM of full length multimeric VWF 
and 1.5M urea at 37°C. The reaction was stopped at different time points (0, 40, 80 and 150 
minutes) with EDTA and analysed on a 1.2% agarose gel electrophoresis with Western 
blotting for VWF. HMW= high molecular weight; LMW= low molecular weight. 
Western blotting analysis under reducing conditions of proteolytic products of full-
length WT VWF, VWF L1603A and L1603S by WT ADAMTS13 was also 
conducted. The reactions were performed exactly the same as described above. The 
only difference was that samples were taken at progressive time points and quenched 
with 5µl 0.5M EDTA with 2-Mercaptoethanol (10%). For Western blotting, the 
membrane was treated with stripping buffer (50mM Glycine and 1mM EDTA, pH2.3) 
before blocking. It was shown that full-length WT VWF was rapidly and effectively 
cleaved by ADAMTS13, with the appearance of characteristic cleavage products at 
176kDa and 140kDa positions. By contrast, minimal cleavage of the VWF L1603A 
and L1603S variants was observed (Figure. 4.12).  
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Figure 4.12 Proteolysis of recombinant full-length WT VWF, VWF L1603A and L1603S 
by ADAMTS13. 20nM of ADAMTS13 was incubated with 1μg/ml of full length multimeric 
VWF and 1.5M urea at 37°C. The reaction was stopped at different time points (0, 30 and 90 
minutes) with EDTA. Changes in VWF were examined by SDS-PAGE under reducing 
conditions with Western blotting for VWF.  
4.4.3 Inhibition assay using NTP 
Further evidence for an important docking site within VWF Asp1596-Tyr1605 was 
obtained using a synthetic N-terminal peptide (NTP), Asp1596-Tyr1605 (Figure 4.13) 
containing this sequence (1596DREQAPNLVY1605
 
) to inhibit ADAMTS13 cleavage of 
VWF 115. This peptide was purchased from AltaBioscience. Addition of 1 mM WT 
NTP clearly reduced cleavage of VWF 115 by ADAMTS13 when visualized by SDS-
PAGE (Figure 4.13). In contrast, a synthetic NTP variant containing the L1603A 
substitution was without apparent effect upon cleavage, suggesting again an important 
role for Leu1603. The influence of the NTP upon the initial rate of VWF 115 
proteolysis by ADAMTS13 was quantified by HPLC (Figure 4.13). Although WT 
NTP produced a large concentration dependent reduction in cleavage rate, the effect 
of NTP L1603A was very modest.  
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Figure 4.13 Inhibition of VWF 115 proteolysis by ADAMTS13 by the NTP and its 
variant. NTP (WT and mutant, 1mM) was incubated with 3.5nM ADAMTS13 and CaCl2 at 
37°C for 30 minutes, and 6μM VWF 115 was then added. The reaction was stopped at 
different time points (0, 15, 30 and 60 minutes) with EDTA and analysed on a 12% SDS-
PAGE gel with Coomassie staining.  
 
Figure 4.14 Inhibition of initial rates of cleavage of VWF 115 by the NTP and its 
variants. 0-1mM NTP or NTP (L1603A) was incubated with 1nM ADAMTS13, CaCl2 at 
37°C for 30 minutes, and 2.5μM VWF 115 was then added. After 15 minutes, the reaction 
was stopped with EDTA. Thereafter, the initial rate of VWF 115 proteolysis was quantified 
using HPLC. 
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4.5 Identification of functional subsites on ADAMTS13 that 
interact with the VWF P3 and P1 residues 
4.5.1 Model of ADAMTS13 MP domain with potential residues forming the S3 
subsite 
Using a peptide model, the distance between VWF Leu1603 and the scissile bond was 
estimated to be about 10 Angstroms (Figure 4.15). Because VWF Leu1603 is so close 
to the scissile bond (Y1605-Met1606), it will likely directly interact with the 
ADAMTS13 MP domain. VWF Leu1603 is the third residue N-terminal to the 
cleavage site, which is why it termed the P3 residue (Tyr1605 is termed P1). The 
corresponding interacting ADAMTS13 subsites with P3 and P1 are named the S3 and 
S1 subsites, respectively [78, 79]. On the structural model of the MP domain, I have 
identified 11 residues that are on the surface and might form interacting residues with 
the P3 and P1 residues of the substrate. These residues are Leu151, Leu152, Leu185, 
Val195, Thr196, Gln197, Leu198, Trp206, Leu232, Leu273 and Leu274 (Figure 4.16). 
As well as their surface locations, the distances between these residues and the active 
site are estimated to be around 10-11 angstroms. Most of these 11 residues are 
hydrophobic, which could be compatible with a hydrophobic interaction with 
Leu1603. 
 
Figure 4.15 Peptide model of VWF cleavage site. Using Pepbuild software, the distance 
between Leu1603 and the scissile bond (Tyr1605-Met1606) was measured to be ~10 
Angstroms. 
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Figure 4.16 Location of 11 candidate residues that may interact with the substrate P3 
and P1 residues on the structural model of ADAMTS13 MP domain. The model was 
generated using the HHPRED server from the crystal structures of ADAMTS1, 4& 5, and 
related residues were highlighted using Pymol. The active centre (light blue, with Zn2+
 
 shown 
in yellow) and residues flanking the S1’ pocket (purple) are highlighted [81]. The 11 
candidate residues that may interact with VWF Leu1603 or VWF Tyr1605 are labelled in 
colour on the surface of the model. The ADAMTS13 substitution mutations that I have made 
of these residues, see section 4.5.3, are listed on the left of the model.  
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4.5.2 Alignment of ADAMTS family MP domains spanning the locations of 
potential S3 subsites  
A partial ADAMTS family MP domain alignment is shown in Figure 4.17. Residues 
Leu152, Leu198 and Trp206 in ADAMTS13 are not conserved among ADAMTS 
family members, suggesting that they may be involved in enzyme specific functions 
rather than being necessary for the structural frame of the protease domain. 
Interestingly, residue 206 in the ADAMTS family is mostly arginine. This implies 
that it could be well tolerated in ADAMTS13. For this reason, I mutated Trp206 to 
arginine. Leu 198 is generally hydrophobic in other ADAMTS family members, I, 
therefore, mutated Leu 198 to serine.  Leu152 is not conserved but is frequently 
charged in other family members. Therefore, I mutated Leu152 to arginine.  
 
Figure 4.17 Sequence alignment of ADAMTS family member MP domain. The amino 
acid sequences N-terminal to the active site cleft of ADAMTS family members are aligned, 
see section 2.1.1. Red letters in yellow boxes show conserved sequence identity, black letters 
in grey boxes are blocks of similar residues. Black letters with white background are non-
conserved amino acids. Trp206 in ADAMTS13 family is Arg in nearly every other ADAMTS 
family member. There are mainly charged residues (Arg, Glu, or Asp) in the Leu152 site of 
other ADAMTS family members, while mainly Val is located in the Leu198 position.  
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4.5.3 Preliminary functional analysis of ADAMTS13 variants 
Substitutions of the 11 candidate residues that may interact with Leu1603 or Tyr1605 
were individually introduced into the ADAMTS13 vector using site-directed 
mutagenesis, see section 2.2.2. All these ADAMTS13 variants were transiently 
expressed in HEK293T cells. Western blotting analysis of conditioned media (see 
section 2.6.3) demonstrated some differences in expression and secretion of these 
mutants. The ADAMTS13 variants V195S/A, L198S/E, L273N, L152R, W206R, 
L185A, T196A and Q197A were secreted similarly to WT ADAMTS13. In contrast, 
the ADAMTS13 variants L151S, L232S/N, L273S and L274S were poorly secreted, 
suggesting that the mutations might induce gross structural changes. The concentrated 
media was filtered, concentrated and the concentration of the ADAMTS13 variants 
was established by ELISA, which confirmed the variation of their expression and 
secretion. As shown in Table 4.3, the concentrations of the ADAMTS13 variants 
V195S/A, L198S/E, L273N, L152R, W206R, L185A, T196A and Q197A in 
conditioned medium from transiently expressed HEK293T cells were similarly to that 
of WT ADAMTS13. Based on the concentrations determined by ELISA, as described 
in section 2.6.6,  the reduction in expressed level of the ADAMTS13 variants L151S, 
L232S/N, L273S and L274N was ~10 fold, that of the ADAMTS13 variants L198E 
and L274S was ~5 fold, and L273N ~2 fold.  
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ADAMTS13 Concentration (nM) Secretion 
WT  54 Normal 
L151S 1.5 ↓↓↓ 
L185A 43 Normal 
V195S 32 Normal 
V195A 51 Normal 
L198S 35 Normal 
L198E 8 ↓↓ 
L232S 1.3 ↓↓↓ 
L232N 1.8 ↓↓↓ 
L273S 4.8 ↓↓↓ 
L273N 21 ↓ 
L274S 9 ↓↓ 
L274N 4.6 ↓↓↓ 
L152R 45 Normal 
W206R 38 Normal 
Table 4.3 Expression and secretion of the 11 candidate ADAMTS13 residues that may 
interact with VWF Leu1603. The ADAMTS13 candidate S variants were transiently 
expressed in HEK293T cells. Western blotting (see section 2.6.3) analysis of the conditioned 
media was used to initially assess the expression and secretion of these variants. The 
concentrated media was filtered, concentrated and the concentration of the ADAMTS13 
variants was established by ELISA (see section 2.6.4). ↓= moderately reduced; ↓↓= severely 
reduced; ↓↓↓= no secretion/activity or barely detected.  
 107 
4.5.4 Functional analysis of the ADAMTS13 variants containing candidate S3 
subsite substitutions using substrate VWF 115 
All the potential ADAMTS13 S3 candidate residues are shown in a structural model 
which was modelled on the crystal structures of ADAMTS1, 4 & 5 (see section 2.1.1). 
Based on the location of each candidate reside in the model of MP domain (Figure 
4.16), it was initially predicted that ADAMTS13 Leu152 or Trp206, or the cluster of 
Leu198/Leu232/Leu273/Leu274 may form the S3 subsite. Because the distance 
between these six hydrophobic residues (Leu152, Trp206, Leu198, Leu232, Leu273 
and Leu274) on the surface of the model and the active Zn2+ are all around 10 
Angstroms, which is similar to the distance between Leu1603 and the scissile bond 
(Tyr1605-Met1606). 
 
Figure 4.18 Location of potential ADAMTS13 residues interacting with VWF Leu1603. 
The structure was modelled on the crystal structures of ADAMTS1, 4 & 5. The active centre 
(light blue, with Zn2+ shown in black) and residues flanking the S1’ pocket (white) are 
highlighted [81]. The 10 candidate residues that may interact with Leu1603 or Tyr1605 are in 
black on the surface of the model. The cluster Leu198/Leu232/Leu273/Leu274, which is 
highlighted by a yellow circle, is predicted to form S3. Below the active site cleft, the VWF 
cleavage site residues, Leu1603-Met1606 are shown. The distance between Leu1603 and the 
scissile bond (Tyr1605-Met1606) is about 10 Angstroms, which is similar to that of the 
distance between cluster residues and the active Zn2+. 
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In order to assess the effect of the S3 candidate residue mutations on the activity of 
ADAMTS13, the activities of ADAMTS13 variants L152R, W206R, L198S, L232N, 
L273N and L274S were studied using proteolysis of VWF 115 and SDS-PAGE to 
monitor cleavage. 1nM WT ADAMTS13 or ADAMTS13 variants in concentrated 
dialysed conditioned medium were pre-incubated in buffer of 20mM Tris-HCl, 
150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37 ºC before the addition of 6µM 
VWF115. 15µl Samples were taken at time points (0, 20mins and 60mins) and the 
reaction quenched with 5µl 0.5M EDTA before analysis using SDS-PAGE gel 
followed by Coomassie staining. It was found that ADAMTS13 variants L198S, 
L232N and L274S exhibited reduced ability to cleave VWF 115, while ADAMTS13 
variants L152R and W206R variants cleaved VWF 115 normally (Figure 4.19).  
To examine quantitatively the activities of ADAMTS13 variants L198S, L274S and 
L232N, 1nM WT ADAMTS13 and these variants were pre-incubated with 20mM 
Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC before the addition 
of 2μM VWF 115 at 37°C. The reaction was stopped at various time points with 
EDTA and then analysed on HPLC to assess the percentage cleavage of VWF 115, 
from which the catalytic efficiency, kcat/Km, was determined using Prism 4 software 
(GraphPad USA) (Figure 4.20). This revealed a 4.6 fold reduction in kcat/Km for 
ADAMTS13 L198S when compared to WT ADAMTS13 and a 15.8 fold, reduction in 
kcat/Km for ADAMTS13 variant L274S (Table 4.4). No proteolytic cleavage fragments 
could be detected for the ADAMTS13 L232N, a variant which also had severely 
reduced secretion.  
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Figure 4.19 SDS-PAGE analysis on potential ADAMTS13 S3 variants. 1nM WT 
ADAMTS13 and ADAMTS13 variants L152R, L198S, W206R, L232N, L273N and L274S 
pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC 
before the addition of 6µM VWF115. The reaction was stopped at different time points with 
EDTA and analysed on a 12% SDS-PAGE gel with Coomassie staining. For each experiment 
a single band can be seen at time zero, corresponding to the intact VWF substrate. The 
intensity of this band decreases as the reaction proceeds and smaller bands can be seen which 
correspond to the two cleavage products. 
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Figure 4.20 Quantitative and functional analysis of ADAMTS13 variants L198S, L274S 
and L232N by HPLC.  1nM WT ADAMTS13 and ADAMTS13 variants L198S, L274S and 
L232N were pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 
hour at 37 ºC before the addition of 2μM VWF115 at 37°C. The reaction was stopped at 
various time points with EDTA and was studied quantitatively by HPLC (n=3). 
 
 
Table 4.4 kcat/Km values of HPLC analysis of ADAMTS13 variants. The proteolytic 
activity of ADAMTS13 (variants) was determined using HPLC under conditions in which the 
catalytic efficiency, kcat/Km, was determined using Prism 4 software (GraphPad USA) (n=3).  
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4.5.5 Proteolysis of full-length VWF by ADAMTS13 candidate S3 mutants  
Cleavage of full-length WT VWF was performed as described in section 2.4.4.  In this 
reaction, 0.55µg/ml purified plasma derived VWF (purified from plasma concentrates, 
as described in section 2.8.4, was incubated in the presence of 1.5M denaturant 
(guanidine hydrochloride) at 37°C. For the analysis of the ADAMTS13 L198S and 
L274S variants, 5nM enzyme was used. They were pre-incubated for 30 minutes in 
20mM Tris-HCl, 0.5% bovine serum albumin, 5mM CaCl2. Subsamples were 
removed at various time points (0-90 minutes), and the reaction was stopped with 
EDTA (40mM). Changes in VWF multimeric composition resulting from 
ADAMTS13 proteolysis were analysed by agarose gel electrophoresis and Western 
blotting for VWF, see section 2.6.5 [14]. All functional assays were repeated a 
minimum of three times and with different preparations of VWF and ADAMTS13. 
Western blotting for VWF demonstrated that the proteolytic ability of the 
ADAMTS13 L198S variant was reduced, as seen by the reduced disappearance of the 
larger multimers (Figure 4.21). Western blotting analysis under reducing conditions of 
proteolytic products of full-length VWF by WT ADAMTS13 and ADAMTS13 
L198S and L274S variants was also performed. The reaction was performed exactly 
the same as described above. The only difference was that samples were taken at 
progressive time points and quenched with 5µl 0.5M EDTA with β-mercaptoethanol 
(10%). It was shown that reduced cleavage was observed when full-length VWF 
multimers were proteolysed by ADAMTS13 L198S variant and minimal cleavage by 
L274S variant (Figure. 4.22).  
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Figure 4.21 Multimer gel analysis of full-length VWF proteolysis by ADAMTS13 S3 
candidate residue mutants.  Western blotting for proteolytic products of full-length VWF 
multimers by WT ADAMTS13 and ADAMTS13 L198S variant was performed. 5nM WT 
ADAMTS13 and mutant L198S in dialysed conditioned medium were pre-incubated with 
20mM Tris-HCl, 150mM NaCl, pH7.8, and 5mM CaCl2 for 1 hour at 37ºC before the addition 
of pre-denatured VWF at a final concentration of 0.55µg/ml. Samples were taken at 
progressive time points and quenched with 5µl 0.5M EDTA before VWF multimer gel 
analysis (see section 2.2.11).   
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Figure 4.22 SDS-PAGE analysis under reducing conditions of full-length VWF 
proteolysis by ADAMTS13 S3 candidate residue mutants. Western blotting under 
reducing conditions of proteolytic products of full-length WT VWF by WT ADAMTS13 and 
ADAMTS13 L198S and L274S variants was performed. 5nM WT ADAMTS13 and mutant 
L198S in dialysed conditioned medium were pre-incubated with 20mM Tris-HCl, 150mM 
NaCl, pH7.8, and 5mM CaCl2 for 1 hour at 37ºC before the addition of pre-denatured VWF at 
a final concentration of 0.55µg/ml. The samples were taken at progressive time points and 
quenched with 5µl 0.5M EDTA with 2-Mercaptoethanol (10%) before VWF gel analysis.  
4.5.6  Investigation of the S1 subsite in ADAMTS13 
As explained earlier, the first residue N-terminal of the scissile bond is termed P1. 
Correspondingly, residues in the ADAMTS13 MP domain directly interacting with P1 
are part of what is termed the S1 subsite. It has been reported that mutagenesis of the 
VWF Tyr1605 (P1) and/or Met 1606 (P1’) residues to Ala greatly reduces their 
proteolytic efficiency by ADAMTS13 [77]. The reduced proteolysis of VWF 115 
Y1605A suggests the S1 subsite of ADAMTS13 plays an important role in efficient 
VWF proteolysis. Pruss et al [77] have shown that VWF 115 Y1605N, without an 
aromatic ring in the P1 position, is also proteolysed inefficiently, but Y1605F, 
containing an aromatic ring, is cleaved normally. VWF 115 Y1605H, with a 
Imidazole ring, is cleaved only slightly slower, suggesting that the ADAMTS13 S1 
subsite may preferentially accommodate aromatic side chains (Figure 4.23).  
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In an alignment of the MP domain structures of the different ADAMTS family 
members (Figure 4.24), candidate residues potentially forming the S1 subsite might 
include Val195, Tyr196 and Gln197, considering their location and distance from the 
active site in the ADAMTS13 structural model, shown in Figure 4.18. The amino acid 
sequence alignment of ADAMTS family members shows that residues Val195, 
Tyr196 and Gln197 are non-conserved (Figure 4.24) and could therefore contribute to 
an enzyme specific subsite. An ADAMTS13 mutant V195M/T196A/Q197D, which 
contains residues that are present in ADAMTS1, 4 & 5 (Fig 4.24), was made to 
investigate the possible nature of the S1 subsite of ADAMTS13. Moreover, it has 
been demonstrated that Glutamate (E) is a natural P1 residue in the ADAMTS1 
substrate [178, 179]. If ADAMTS13 tolerates aromatic rings within the cleavage site 
of VWF, VWF 115 Y1605E should not be tolerated. VWF 115 Y1605E was therefore 
made as a possible substrate to further explore the S1 subsite of ADAMTS13. In what 
follows, I expected that WT ADAMTS13 would efficiently proteolyse WT VWF 115, 
but inefficiently proteolyse VWF 115 Y1605E, while the ADAMTS13 variant 
V195M/T196A/Q197D would efficiently proteolyse VWF 115 Y1605E, but 
inefficiently proteolyse WT VWF 115. 
In order to explore this hypothesis that ADAMTS13 residues Val195, Tyr196 and 
Gln197 form the S1 subsite, ADAMTS13 V195M/T196A/Q197D variant was 
expressed in HEK 293T cells and quantified by ELISA (section 2.5) and  VWF 115 
Y1605E  was expressed in Rosetta DE3 cells, purified by FPLC, and quantified by 
BCA. 3.5nM WT ADAMTS13 and ADAMTS13 V195M/T196A/Q197D variant were 
pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour 
at 37ºC before the addition of 6µM VWF115 or VWF 115 Y1605E. The reaction was 
stopped at different time points with EDTA and analysed on a 12% SDS-PAGE Bis-
Tris gel with Coomassie staining.  The SDS-PAGE gel in Figure 4.25 showed that 
WT ADAMTS13 variant inefficiently proteolysed VWF 115 Y1605E. It was also 
found that ADAMTS13 V195M/T196A/Q197D variant inefficiently cleaved WT 
VWF 115, with no cleavage products detected. However, ADAMTS13 
V195M/T196A/Q197D mutant could not efficiently cleave VWF 115 Y1605E either.  
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Figure 4.23 Efficiency of cleavage of VWF 115 P1 (Tyr 1605) variants by ADAMTS13 
considered in terms of the P1 side chain. The original data of the cleavage efficiency of 
VWF 115 P1 variants Y1605F, Y1605H and Y1605N was reported in [77], and that of VWF 
115 Y1605A is reported here in table 4.2. The structures of the amino acids were taken 
from http://www.molecularstation.com/molecular-biology-images/data/510/AminoAcids.gif  
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Figure 4.24 Amino acid sequence alignment of ADAMTS family members.  Amino acid 
sequence alignment of ADAMTS13 MP domain (residues 171-263) with that of other 
ADAMTS family members. The active site HEXHXXXXXH sequence is labelled. Conserved 
(dark yellow) and homologous (light yellow) regions are highlighted. Residues number 195, 
196 and 197 in ADAMTS13 are Val, Thr and Gln while in ADAMTS1 the matching residues 
are Met, Ala and Asp, as shown by the black box. 
These findings suggest that introducing triple mutations to ADAMTS13 may impair 
the activity of the enzyme, rather than removal of interaction with VWF P1 residue 
Tyr1605. Because the ADAMTS13 residues, Val195, Thr196, and Gln197 are so 
close to the active Zn2+
 
, any slight change of the side chain of these three residues 
may influence the positioning of the scissile bond in the active centre. Especially, 
mutation of Val195 to Met is a bigger substitution in side chain (compared to Ala), 
which may lead to potentially allosteric effect on ADAMTS13. 
ADAMTS13     195VTQ197 
ADAMTS  1         MAD 
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Figure 4.25 Studies with VWF 115 Y1605E and ADAMTS13 V195M/T196A/Q197D. 
3.5nM WT ADAMTS13 and ADAMTS13 V195M/T196A/Q197D variant were pre-incubated 
with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37 ºC before the 
addition of 6µM VWF115 or VWF 115 Y1605E. The reaction was stopped at different time 
points with EDTA and analysed on a 12% SDS-PAGE gel with Coomassie staining.  
4.5.7 Preliminary analysis of ADAMTS13 S1 subsite variants  
Based on the location of each candidate residue in the structural model of the MP 
domain (Figure 4.26), it was initially predicted that ADAMTS13 Leu151 and Val195 
may form the S1 subsite.  
In order to assess the effect of the S1 candidate residue mutations on the activity of 
ADAMTS13, the ADAMTS13 variants L151S and V195S were studied using 
proteolysis of VWF 115 with SDS-PAGE to monitor cleavage. 1nM WT ADAMTS13 
or ADAMTS13 variants in concentrated dialysed conditioned medium were pre-
incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 
37ºC before the addition of 6µM VWF115. 15µl Samples were taken at time points (0, 
20 and 60 minutes) and the reaction quenched with 5µl 0.5M EDTA before analysis 
using SDS-PAGE gel followed by Coomassie staining. It was found that the 
ADAMTS13 V195S variant had severely reduced activity, while no proteolytic 
cleavage fragments could be detected for the ADAMTS13 L151S variant (Figure 
4.27).  
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Figure 4.26 Location of potential ADAMTS13 residues interacting with VWF Tyr1605. 
The active centre (light blue, with Zn2+
To examine quantitatively the activities of ADAMTS13 variants L151S and V195S, 
1nM WT ADAMTS13 and these variants were pre-incubated with 20mM Tris-HCl, 
150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37 ºC before the addition of 2µM 
VWF115 at 37°C. The reaction was stopped at various time points with EDTA and 
was then analysed on HPLC to assess the percentage cleavage of VWF 115. The 
catalytic efficiency, kcat/Km, was determined using Prism 4 software (Figure 4.28). 
This revealed a 12.3 reduction (Table 4.5) in catalytic efficiency for the ADAMTS13 
variant V195S when compared to WT ADAMTS13. No proteolytic cleavage 
fragments could be detected for the ADAMTS13 L151S.  
 shown in black) and residues flanking the S1’ pocket 
(white). The 10 candidate residues that may interact with Leu1603 or Tyr1605 are labelled in 
black on the surface of the model. The cluster Leu151/Val195, which is highlighted by a 
yellow circle, is predicted to form the S1 subsite.  
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Figure 4.27 SDS-PAGE activity analysis of potential ADAMTS13 residues interacting 
with VWF Tyr1605. 1nM WT ADAMTS13 and ADAMTS13 variants L151S and V195S 
pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC 
before the addition of 6µM VWF115. The reaction was stopped at different time points with 
EDTA and analysed on a 12% SDS-PAGE gel with Coomassie staining. For each experiment 
a single band can be seen at time zero, corresponding to the intact VWF substrate. The 
intensity of this band decreases as the reaction proceeds and smaller bands can be seen which 
correspond to the two cleavage products (10kDa and 7kDa). 
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Figure 4.28 Quantitative analysis of ADAMTS13 variants L151S and V195S by HPLC. 
1nM WT ADAMTS13 and ADAMTS13 variants L151S and V195S were pre-incubated with 
20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37 ºC before the addition 
of 2μM VWF115 at 37°C. The reaction was stopped at various time points with EDTA and 
then was studied quantitatively by HPLC under conditions in which the catalytic efficiency, 
kcat/Km, was determined using Prism 4 software (n=3). 
 
 
Table 4.5 kcat/Km values (n=3) derived from the time course curves shown in the Figure 4.26.  
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4.5.8 Analysis of ADAMTS13 S1 subsite variants using full-length VWF  
Cleavage of full-length WT VWF was performed as described in section 2.4.4. In this 
reaction, 0.55 µg/ml purified plasma derived VWF (purified from plasma concentrates, 
as described in section 2.6.5) was incubated in the presence of 1.5M denaturant (urea 
or guanidine hydrochloride) at 37°C. For the analysis of the ADAMTS13 V195S 
variants, 5nM enzyme was used. They were pre-incubated for 30 minutes in 20mM 
Tris-HCl, 0.5% bovine serum albumin, 5mM CaCl2. Subsamples were removed at 
various time points (0-90 minutes), and the reaction was stopped with 5µl 0.5M 
EDTA with β-mercaptoethanol (10%). Changes in VWF multimeric composition 
resulting from ADAMTS13 proteolysis were analysed by SDS-PAGE and Western 
blotting for VWF, see sections 2.6.5 and 2.6.7. For Western blotting, the only 
difference with agarose gel electrophoresis was that samples were reduced and the 
membrane was treated with stripping buffer (50mM Glycine and 1mM EDTA, pH2.3) 
before blocking step. It was showed that minimal cleavage was observed for 
proteolysis by ADAMTS13 V195S variant, in contrast to that of WT ADAMTS13 
(Figure 4.29).  
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Figure 4.29 Western blotting analysis of full-length VWF proteolysis by ADAMTS13 S1 
candidate residue variants.  Western blotting for reduced proteolysis products of full-length 
WT VWF multimers by WT ADAMTS13 and ADAMTS13 V195S variant as described in 
section 2.2.11. 5nM WT ADAMTS13 and ADAMTS13 V195S variant in dialysed 
conditioned medium were pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8, and 
5mM CaCl2 for 1 hour at 37ºC before the addition of pre-denatured VWF at a final 
concentration of 0.55 µg/ml. Samples were taken at progressive time points and quenched 
with 5µl 0.5M EDTA with β-mercaptoethanol (10%) before VWF multimer gel analysis. 
Compared with normal Western blotting, the only difference was that the transferred 
membrane was treated with stripping buffer (50mM Glycine and 1mM EDTA, pH2.3) before 
the blocking step. 
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4.5.9 Further activity assays on ADAMTS13 candidate S3 subsite variants  
As shown in Table 4.4, the kcat/Km for proteolysis of VWF 115 by the ADAMTS13 
L198S variant is ~5-fold reduced, which is very similar to that for the cleavage of 
VWF 115 V1604S by WT ADAMTS13. This raised the possibility that the candidate 
S3 subsite residue, ADAMTS13 Leu198, might interact with VWF Val1604 (P2 
residue) rather than VWF Leu1603 (P3 residue). To exclude this contention, further 
experiments were performed. If ADAMTS13 Leu198 directly interacted with VWF 
V1604S, I hypothesized that there would be no difference in efficiency of proteolysis 
between WT VWF 115 and VWF 115 V1604S when cleaved by the ADAMTS13 
L198S variant. To clarify this, 1nM WT ADAMTS13 and ADAMTS13 variants 
L198S were pre-incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM 
CaCl2 for 1 hour at 37ºC before the addition of 6µM VWF115 or VWF 115 V1604S. 
The reaction was stopped at different time points with EDTA and analysed on a 12% 
SDS-PAGE Bis-Tris gel with Coomassie staining. It was found that the reduction in 
proteolysis of VWF 115 V1604S by WT ADAMTS13 was similar to that of WT 
VWF 115 by ADAMTS13 L198S, but less than that of VWF 115 V1604S by 
ADAMTS13 L198S (Figure 4.30).  These results clearly suggest that the effects of 
both of these substitutions were independent of each other, making the interaction 
between the residues unlikely.  
In a similar manner, I next examined whether the ADAMTS13 variants L198S, 
V195S (although Val195 was predicted to be the potential S1 subsite), and L274S 
induce cleavage of the VWF 115 L1603S variant, of a decreased magnitude compared 
to that of WT ADAMTS13. For these experiments, it was necessary to use high 
concentrations (30nM) of the ADAMTS13 variants, as the usual catalytic 
concentrations (1-3nM) failed to induce proteolysis of VWF 115 L1603S. For the 
ADAMTS13 L198S variant, similar, minimal cleavage of the VWF 115 L1603S 
occurred to that observed for WT ADAMTS13 (Figure 4.31). For the ADAMTS13 
V195S and Leu274S variants, there was a suggestion of less cleavage of the VWF 115 
L1603S variant. 
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Figure 4.30 Studies with VWF 115 V1604S, the P2 residue, and ADAMTS13 L198S. 
1nM WT ADAMTS13 and ADAMTS13 variants L198S were pre-incubated with 20mM Tris-
HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC before the addition of 6µM 
VWF115 or VWF 115 V1604S. The reaction was stopped at different time points with EDTA 
and analysed on a 12% SDS-PAGE gel with Coomassie staining. For each experiment a 
single band can be seen at time zero, corresponding to the intact VWF substrate. The intensity 
of this band decreases as the reaction proceeds and smaller bands can be seen which 
correspond to the two cleavage products. 
 
Figure 4.31 Cleavage of VWF 115 L1603S by ADAMTS13 V195S, L198S and L274S. 
30nM WT ADAMTS13 and ADAMTS13 variants V195S, L198S and L274S were pre-
incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC 
before the addition of 6µM VWF 115 L1603S. The reaction was stopped at different time 
points with EDTA and analysed on a 12% SDS-PAGE Bis-Tris gel with Coomassie staining. 
For each experiment a single band can be seen at time zero, corresponding to the intact VWF 
substrate. The intensity of this band decreases as the reaction proceeds and smaller bands can 
be seen which correspond to the two cleavage products (10kDa and 7kDa). 
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4.6   Discussion 
Because of the findings, described previously in references [166, 167, 169 and 170], I 
hypothesised that the 9 residues N-terminal to the cleavage site are critical for the 
proteolysis reaction of ADAMTS13 on VWF. I attempted to delineate the 
contribution of these 9 residues to proteolysis. To study this, I introduced a number of 
mutations of these 9 amino acids into a VWF 115 expression vector, after which the 
VWF 115 mutants were expressed and purified. Their proteolysis by ADAMTS13 
was then analysed. I found that Leu1603 (P3), the third residue N-terminal of the 
VWF cleavage site Y1605 (P1), played an important role in VWF 115 proteolysis. 
The significance of Leu1603 was comprehensively confirmed through various 
experiments, including comparison of proteolysis of VWF 115 N-terminal mutants, 
comparison of different P3 mutants, investigation of full-length VWF with P3 mutants, 
and use of the specific synthetic peptide 1596DREQAPNLVY1605
These experiments all pointed to a critical role of VWF Leu1603 in cleavage by 
ADAMTS13. If this residue is very important, then it is likely to have been conserved 
throughout evolution. I therefore investigated this by alignment of known VWF 
sequence results around the ADAMTS13 cleavage site. Interestingly, this 
demonstrated that Leu1603 is perfectly conserved in VWF of all investigated 
mammals (Figure 4.32), which further strengthens the possible functional importance 
of Leu1603 in VWF proteolysis. 
 in an inhibitory assay.  
As Leu1603 is quite close to the scissile bond (Y1605-M1606), it would likely 
directly interact with the ADAMTS13 MP domain. Therefore, 11 candidate residues 
(Leu151, Leu152, Leu185, Val195, Thr196, Gln197, Leu198, Trp206, Leu232, 
Leu273 and Leu274), located on the surface of structural model of the ADAMTS13 
MP domain and at a suitable predicted distance to the active site, were subsequently 
investigated. Eventually, a cluster consisting of Leu198/Leu232/Leu274 residues in 
the ADAMTS13 MP domain were considered as a potential S3 subsite pocket, which 
may directly interact with VWF Leu1603 (P3). Although ADAMTS13 (L198S) only 
exhibited ~5 fold reduced proteolytic activity of VWF 115, ADAMTS13 (Leu274S) 
exhibited ~16 fold and ADAMTS13 (Leu232N) more than 20 fold reduction.  
I also identified that another hydrophobic cluster Leu151/Val195 in the ADAMTS13 
MP domain. Based upon its proximity to the active site, I hypothesize that this may 
form part of a S1 subsite, interacting with the VWF P1 residue. To explore the 
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possible importance of these residues, I have performed a sequence alignment of 
ADAMTS13. This shows that Leu151 and Val195 are also conserved in different 
species (Figure 4.33). 
There is another possibility that cluster Leu151/Val195 forms the S3 subsite while the 
Leu198/Leu232/Leu274 cluster forms the S1 subsite. However, this possibility was 
considered unlikely. Based on the location and distance of these two clusters to the 
active site in the ADAMTS13 structural model, the cluster Leu151/Val195 could not 
concurrently form the S3 subsite to dock the P3 residue if the cluster 
Leu198/Leu232/Leu274 formed the S1 subsite.  
 
Figure 4.32 Amino acids sequence alignment of VWF around the cleavage site. The 
amino acids sequences of 20 species were retrieved from Pubmed 
(http://www.ncbi.nlm.nih.gov/protein?term=vwf). They were aligned using AlighX software 
(Informax). It is clear that Leu1603 in VWF is perfectly conserved in mammals. This figure 
was adapted and modified from [180]. 
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Figure 4.33 Amino acids sequence alignment of ADAMTS13 around the active site in 
different species. The amino acids sequences of 7 species were retrieved from Pubmed 
(http://www.ncbi.nlm.nih.gov/protein?term=ADAMTS13). They were aligned using AlighX 
software (Informax). The hydrophobic residues Leu151, Val195, Leu198, Leu232, and 
Leu274, along with the active site, conserved Ca2+
 
 binding site and charged residue Arg349 
are highlighted. This figure was adapted and modified from [180]. 
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CHAPTER 5: IDENTIFICATION OF RESIDUES C-
TERMINAL TO THE VWF CLEAVAGE SITE THAT 
MIGHT CONTRIBUTE TO ADAMTS13 SUBSTRATE 
SPECIFICITY 
5.1 Introduction 
Previous studies [166] found that deletions of several residues on either side of the 
Tyr1605-Met1606 bond, Val1604 (P2)-Arg1597 (P9) or the Gly1609 (P4’)-Gln1624 
(P18’), abolished cleavage, indicating that the MP domain might interact with some of 
the residues included. In previous chapters, I have established that it is Leu1603 (P3) 
that plays an essential role in VWF A2 domain interacting with ADAMTS13 MP 
domain. Dr Rens de Groot in our lab has recently studied residues C-terminal to the 
cleavage site and has identified an important residue, Asp1614, within the sequence 
Gly1609 (P4’)-Gln1624 (P18’) that interacts with ADAMTS13 Dis domain [81]. I 
was interested in whether additional residues, or the distance between Met 1606(P1’) 
and 1614(P9’), was also important for ADAMTS13 proteolysis and substrate 
specificity. To study this, I introduced 2 groups of mutations into this region of VWF 
115. I inserted 2 glycines after Gly1609 in VWF 115 (Glyin) and I deleted 2 residues, 
Gly1609-Asn1610, from VWF 115 (Glyout) (Figure 5.1).  
Furthermore, any role for the P3’ or P2’ residue, has remained unclear. To investigate 
this, I mutated V1607/T1608, individually and together to alanine, in VWF 115 in 
order to clarify any role.  
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Figure 5.1 VWF 115 variants with insertions and deletions of two residues between 
VWF Asp1614 and VWF scissile bond (Tyr1605-Met1606). The distance between VWF 
Asp1614 and VWF scissile bond (Tyr1605-Met1606) was measured to be ~26 Angstroms 
using the ADAMTS13 structural homology model. Glyin represents that VWF 115 with 2 
Glycines inserted between VWF Gly1609 and VWF Asn1610. Glyout represents that VWF 
115 with deletion of VWF Gly1609 and VWF Asn1610. Both Glyin and Glyout variants will 
change the distance between VWF Asp1614 and VWF scissile bond, which further may affect 
its proteolysis by ADAMTS13. 
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5.2 Functional analysis of VWF 115 variants 
5.2.1 Expression and purification of VWF 115 variants  
The mutagenesis and expression of VWF 115 was prepared as described in section 
2.7.1. VWF 115 (Glyin), VWF 115 (VT1607/8AA), VWF 115 (V1607A), VWF 115 
(T1608A) were expressed in Rosetta DE3 cells and then purified by FPLC (section 
2.7.2). The purity of these variants were then analysed by SDS-PAGE followed by 
Coomassie staining and their concentrations were determined by BCA (section 2.6.1). 
All these VWF 115 variants were shown to have a good level of expression (Figure 
5.2) and essentially pure proteins were obtained. 
 
 
Figure 5.2 Purification of recombinant VWF 115 Glyin, P3’ and P2’ variants.  
Chromatogram of the purification of the recombinant VWF 115 variants (inclusion bodies 
fraction) by nickel affinity chromatography. Protein elution was performed using of high 
concentrations of Imidazole (250mM). The eluted fraction (A2) is highlighted by an arrow (A) 
VWF 115(Glyin); (B) VWF 115(VT1607/8AA); (C) VWF 115(T1608A);  (D) VWF 
115(V1607A). 
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5.2.2 VWF 115 variants proteolysed by ADAMTS13 
To investigate the effect of inserting 2 glycines after Gly1609 in VWF 115 on its 
proteolysis, 2.5nM WT ADAMTS13 was pre-incubated with 20mM Tris-HCl, 
150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 37ºC before the addition of 5µM 
VWF 115 or VWF 115 Glyin. The reaction was stopped at different time points with 
EDTA and analysed on a 12% SDS-PAGE Bis-Tris gel with Coomassie staining. As 
was shown in SDS-PAGE gel in Figure 5.3, inserting 2 glycines after Gly1609 in 
VWF 115 (Glyin) resulted in somewhat slower proteolysis than that of wild type 
VWF 115 by ADAMTS13. This suggests that the distance between Met 1606 (P1') 
and 1614 (P9') is important. 
 
 
Figure 5.3 Proteolysis of VWF 115 (Glyin) by wild type ADAMTS13. Activity assays 
were performed with 2.5nM wild type ADAMTS13 and 5µM VWF 115, which were 
incubated at 37°C. At the times indicated, reactions were stopped with EDTA and analysed by 
SDS-PAGE. Proteolysis was assessed by the generation of the 10kDa and 7kDa VWF 115 
cleavage products. VWF 115 (Glyin) is proteolysed inefficiently by ADAMTS13 compared to 
that of wild type VWF 115.  
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To investigate VWF 115 (P2'-P3') variants, 3.5nM WT ADAMTS13 was pre-
incubated with 20mM Tris-HCl, 150mM NaCl, pH7.8 and 5mM CaCl2 for 1 hour at 
37ºC before the addition of 6µM VWF115 or VWF 115 variants including 
VT1607/8AA, V1607A and T1608A. The reaction was stopped at different time 
points with EDTA and analysed on a 12% SDS-PAGE Bis-Tris gel with Coomassie 
staining. A shown in Figure 5.4, the VWF 115 variants, VT1607/8AA and V1607A, 
were proteolysed inefficiently by ADAMTS13, while that of T1608A behaved 
similarly to wild type VWF 115. This suggest that it was P2' (Val1607) rather than P3' 
(Thr1608) mutation that reduced VWF 115 proteolysis by ADAMTS13, although the 
reduction was rather modest.  
 
Figure 5.4 Proteolysis of VWF 115 P2’ and P3’ variants by wild type ADAMTS13. 
Activity assays containing 3.5nM wild type ADAMTS13 and 6µM VWF 115 were incubated 
at 37°C. At the times indicated, reactions were stopped with EDTA and analysed by SDS-
PAGE followed by Coomassie staining. Proteolysis was assessed by the generation of 
cleavage products.  
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5.3 Discussion 
Previous studies have reported that the VWF P1’ residue Met1606 and P9’ residue 
Asp1614 directly interact with ADAMTS13 and contribute to VWF proteolysis [80, 
81]. I hypothesised that the distance between Met 1606(P1’) and 1614(P9’) might also 
be important for the interaction involved above residues between ADAMTS13 and 
VWF. As predicted, inserting 2 glycines after Gly1609 (Glyin)  in VWF 115 resulted 
in its slower proteolysis by ADAMTS13 compared to that of wild type VWF 115, 
indicating that the distance between Met 1606 (P1’) and Asp1614 (P9’) is indeed 
important. This also suggests that the 9 residues P1’ -P9’ may form structure rather 
than being a loop. There is another possibility that the position of the side chain of 
Met 1606 (P1’) or/and 1614 (P9’) may rotate after inserting 2 glycines in the P1’ -P9’ 
sequence. This made it impossible for P1’-S’ and P9’-S9’ interactions to occur 
simultaneously and therefore impaired the proteolysis of VWF 115 by ADAMTS13.  
Due to the rather modest reduction in proteolysis of VWF 115 P2’ variant compared 
to that of wild type VWF 115 by ADAMTS13 and no difference in proteolysis 
between  VWF 115 P3’ variant and wild type, P2’ (Val1607) may not directly interact 
with specific subsites, S2’, in ADAMTS13. Therefore, I did not introduce the P2’ 
mutation Val1607A to full length VWF and to investigate the effect of on the 
proteolysis of VWF multimers by ADAMTS13. In fact, another VWF P2’ variant 
V1607D has been reported to be associated with type 2A VWD [181]. Using COS-7 
cells expression system, Lyons et al. [181] demonstrated that the P2’ variant V1607D 
impaired the transport of VWF multimers from the endoplasmic reticulum to the 
Golgi complex. In addition, the V1607D mutation had more profound effects on the 
secretion of higher molecular weight multimers than lower molecular weight forms.  
Among the 9 residues from Met 1606 (P1’) to Asp1614 (P9’), P4’ mutation (G1609R) 
and P8’ mutation (S1613P) have also been reported contributing to type 2A VWD 
[182, 183]. It has been shown Ala1612 (P7’) interacts with Leu350 in the 
ADAMTS13 Dis domain.ADAMTS13 readily cleaves the substrate FRETS-VWF73 
despite the presence of 2, 4-dinitrophenyl substituent at position Asn1610 (P5’) [184]. 
In conclusion, only P1’, P7’ and P9’ may be direct involved in the interaction of VWF 
with ADAMTS13 contributing to the proteolysis of VWF. 
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CHAPTER 6: EXPRESSION AND PURIFICATION OF 
ADAMTS13 MP-DIS 
6.1 Background: comparison of different expression systems  
The crystal structure of the noncatalytic ADAMTS13 Dis-TSR-Cys-Spacer domains 
has recently been determined [72]. However, the structure of the active site domain, 
the MP domain of ADAMTS13, has yet to be solved. All my results (comprising the 
S3, S1 and S2’ subsites) in previous chapters, along with the identified functionally 
important residues (such as Ca2+
For this purpose, I need an expression system capable of producing over 10mg 
amount of protein. In this chapter, I explored several alternative approaches such as 
bacterial expression (pET SUMO protein expression) and insect cells expression 
systems to increase expression yields above that of the mammalian expression system 
for ADAMTS13 that is routinely used in our lab. Various purification strategies and 
methods involving in Ni
 binding site, S1’ subsite, etc.), are based on a 
homology structural model of the ADAMTS13 MP domain. I expect that this 
structure can be determined and if so, could confirm these findings and assist to 
identify more functional residues, which would further transform our understanding of 
the interactions between the MP domain of ADAMTS13 with VWF. The successful 
crystallisation of MP-Dis domains homologues, such as ADAMTS1 [69], ADAMTS4 
[70], and ADAMTS5 [71] suggests that it may be possible to crystallise the 
ADAMTS13 MP domain. Therefore, I am interested in obtaining crystals of the MP-
Dis domains of ADAMTS13, which could be used for structural determinations.  
2+
6.2 HEK293T cells expression of MP-Dis 
 column, heparin column, gel filtration, and hydrophobic 
interaction chromatography were carried out to purify and refold the recombinant 
ADAMTS13 MP-Dis domain. 
6.2.1 Analysis of MP and MP-Dis expression  
I will first consider use of the mammalian expression system with HEK293T cells for 
producing the MP and MP-Dis. To assess the expression and secretion of the MP and 
MP-Dis variants, Western blotting (section 2.6.5) was performed on the harvested 
conditioned media obtained from the transfection of HEK293T cells with full length 
ADAMTS13, MP and MP-Dis expression vectors (section 2.3.3) (Figure 2.1). As 
shown in Figure 6.1, secretion of the ADAMTS13 truncated variants was good. 
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Moreover, the ADAMTS13 variants, MP and MP-Dis, were expressed much better 
than that of the full length ADAMTS13. The ADAMTS13 variants were identified 
based on their molecular weights. Using an anti-MP domain monoclonal antibody, a 
band of molecular weight around 190kDa for wild type full length ADAMTS13 was 
detected, consistent with its known molecular weight (Figure 6.1). The detected bands 
for MP and MP-Dis truncations appeared at the estimated molecular weight of 
approximately 30kDa and 40kDa, respectively (Figure 6.1), consistent with the 
predicted molecular weights of these ADAMTS13 truncated variants. 
 
Figure 6.1 Western blotting analysis of secreted ADAMTS13 and its truncated variants, 
MP and MP-Dis in HEK293T cells. Conditioned medium was concentrated before analysis. 
Western blotting was performed on the conditioned media under non-reducing conditions. 
The intensity of the bands indicates approximately the amount of protein present in the 
conditioned medium. FL: full length ADAMTS13; MP-Dis: ADAMTS13 Metalloprotease 
and Disintegrin-like domains; MP: ADAMTS13 Metalloprotease domain. 
It is possible that the ADAMTS13 truncated variants may have been proteolysed by 
native enzymes present in the HEK293T cells. So it is difficult to identify whether or 
not or how much cleaved ADAMTS13 MP and MP-Dis variants under non-reducing 
conditions analysis, as the structure of the ADAMTS13 variants can be held together 
by numerous intramolecular disulphide bonds within each of the molecular even if 
they are proteolysed. Therefore, another Western blotting was performed on the 
conditioned media under both reducing and non-reducing conditions (Figure 6.2). It 
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was found that there was only a slight difference in molecular weight between the 
proteins in the reduced and non-reduced samples for both the MP and MP-Dis 
variants (Figure 6.2). The disruption of intramolecular disulphide bonds caused by 
reducing agent (β-mercaptoethanol) resulted in the conformational change of the 
reduced proteins from their original globular form into a linear form. This can explain 
why the proteins present in the reduced samples migrate at a slightly lower rate than 
those in the non-reduced samples. There were no detected fragmented proteins in the 
reduced samples, indicating that the MP and MP-Dis variants have not been 
proteolysed. 
 
Figure 6.2 Western blotting analysis of conditioned medium from HEK293T cells 
containing ADAMTS13 truncated variants, MP and MP-Dis. Conditioned medium was 
concentrated before analysis. Western blotting was performed on the conditioned media under 
both reducing and non-reducing conditions. Reducing conditions were prepared by adding 6% 
v/v β-mercaptoethanol into the samples loading buffer. The intensity of the bands indicates 
approximately the amount of protein present in the conditioned medium. MP: ADAMTS13 
Metalloprotease domain. MP-Dis: ADAMTS13 Metalloprotease and Disintegrin-like domains. 
6.2.2 Activity assay for ADAMTS13 and its variants using VWF 115 
The activity of the expressed ADAMTS13 variants was assessed by VWF 115 
cleavage assay. 2nM full length ADAMTS13 or its truncations and 5µM VWF 115 
were incubated at 37°C. At the times indicated, reactions were stopped with EDTA 
and analysed by SDS-PAGE followed by Coomassie staining. As expected, full-
length ADAMTS13 proteolysed VWF 115 very efficiently. After 1 hour reaction, 
most of the VWF 115 was cleaved. By contrast, for MP-Dis variant, the 10kDa 
cleavage products were detected after 16 hours incubation (Figure 6.3). The MP 
variant displayed no appreciable VWF 115 cleavage ability, even after 16 hours 
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reaction. These results suggest that the MP-Dis retains an ability to proteolyse VWF 
115 and is likely to be more suitable for crystal structure investigation than the MP. 
 
Figure 6.3 Proteolysis of WT VWF 115 by full length ADAMTS13 and its MP-Dis and 
MP truncations. ADAMTS13 mediated VWF 115 cleavage assays containing 2nM full 
length ADAMTS13 or its truncations and 5µM VWF 115 were incubated at 37°C. At the 
times indicated, reactions were stopped with EDTA and analysed by SDS-PAGE and 
Coomassie staining. Proteolysis was assessed by the generation of the 10kDa and 7kDa VWF 
115 cleavage products. FL: full length; MP-Dis: ADAMTS13 Metalloprotease and 
Disintegrin-like domains; MP: ADAMTS13 Metalloprotease domain. 
6.2.3 Ni2+ column purification of MP-Dis 
As described in previous sections that the MP-Dis was expressed and could cleave 
VWF 115, a larger scale protein expression and purification was then performed. A 
HEK293 stable cell line prepared for large scale expression of the MP-Dis has been 
described in section 2.3.4 and this was used. Initial purification was conducted by 
Ni2+ affinity chromatography (section 2.5.1). The 6xHis tag fused to the MP-Dis 
truncation is able to bind to the Ni2+-coated beads within the column. The MP-Dis 
was then eluted with increasing concentrations of Imidazole, which is a Ni2+ ligand 
which competes with the 6xHis tag for binding to the Ni2+-coated beads. The 
chromatogram of this purification procedure is shown in Figure 6.4A. The proteins 
passed through the column were detected according to the changes in UV absorbance. 
The flow through fraction contained proteins that lacked a 6xHis tag and therefore 
were unable to bind to the Ni2+ column. 35mM (wash peak 1) and 50mM (wash peak 
2) Imidazole were used as initial washing to get rid of proteins bound non-specifically 
to the column. The MP-Dis tightly bound to the column was eventually eluted by 
250mM Imidazole and collected as elution fraction. The elution fraction was analysed 
by SDS-PAGE and Coomassie staining, shown in Figure 6.4B. It demonstrated that 
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the MP-Dis obtained was still impure, as a series of bands appear above the 40kDa 
position. 
 
 
 
Figure 6.4 Ni2+ column purification of recombinant MP-Dis. (A): Chromatogram of the 
initial purification of the MP-Dis by Ni2+ affinity chromatography. Wash peak 1 was used 
35mM Imidazole. Wash peak 2 was used 50mM Imidazole. Elution peak was performed with 
250mM Imidazole. (B): Non-reduced (NR) and reduced (R) elution fraction were analysed by 
SDS-PAGE on a 5-12% NuPAGE MES gel followed by Coomassie staining. The molecular 
weight of recombinant MP-Dis was predicted to be approximately 40kDa.  
6.2.4 Gel filtration chromatography 
Gel filtration chromatography (section 2.5.2) was used to purify the MP-Dis fraction 
which had been partially purified above in section 6.2.3. Using the FPLC system, 5ml 
dialysed (20mM Tris-HCl, 500mM NaCl, pH7.8) and concentrated MP-Dis samples 
were flowed through a 120mL HiLoad 16/60 Superdex 75pg column and the peak 
fractions were collected. The chromatogram representing the MP-Dis is shown in 
Figure 6.5, a large peak appear covering the fractions of A1, A2, A3, and A4.  
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Figure 6.5 Gel filtration purification of the MP-Dis. Using the FPLC system (GE 
Healthcare), a 120mL HiLoad 16/60 Superdex 75pg column (GE Healthcare) was equilibrated 
with buffer (20mM Tris-HCl, 500mM NaCl, pH7.8) overnight. Dialysed (20mM Tris-HCl, 
500mM NaCl, pH7.8) and concentrated MP-Dis samples were flowed through the column. 
The A1, A2, A3 and A4 fractions were collected.  
Silver nitrate staining analysis of the elution fractions is also represented (Figure 6.6). 
The band intensity on the silver nitrate stain gives an indication of the quantity and 
purity of protein available in each fraction. It was shown that unwanted bands, 
suggestive of that aggregated MP-Dis variant, or of contaminated proteins, were 
eluted in the early fractions (fraction A1 and A2).  To clarify the nature of these bands, 
further experiments using Western blotting were performed, described in section 6.2.5. 
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Figure 6.6 Silver nitrate staining of the peak fractions collected from gel filtration.  The 
A1, A2, A3, A4 collected from the peak covered fractions were analysed on the silver nitrate 
staining (section 2.6.3). The MP-Dis variant was identified by the red box is indicated based 
upon its expected molecular weight of 40kDa.  
6.2.5 Hydrophobic interaction chromatography 
The principle and methods of using hydrophobic interaction chromatography (HIC) to 
purify proteins are described in section 2.5.3. Generally, the initially purified MP-Dis 
samples through Ni2+ column was firstly diluted 1 in 10 into a final volume of 10ml 
high salt buffer (20mM Tris-HCl, 2M NaCl, pH7.0). Using the FPLC system, the 
diluted samples were flowed through a 1mL HiTrap Phenyl HP column and the peak 
fractions were collected. The chromatogram representing the MP-Dis construct is 
shown in Figure 6.7. Peak fractions A6, A7, A8 and A9 were selected for further 
analysis. SDS-PAGE and Coomassie staining analysis of the peak fractions was 
shown in Figure 6.8A. As second bands appeared in the early eluted fractions (A6 and 
A7), Western blotting of these fractions was carried out (Figure 6.8B). The Western 
blotting result was consistent with that of the Coomassie staining, suggesting that 
there was some protein aggregation of the MP-Dis. However, additional bands were 
found using silver nitrate staining analysis of the elution fractions (Figure 6.8C). 
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These results suggest that the MP-Dis variant obtained could be purified to a 
reasonable degree, but the method could possibly be improved.  
 
 
Figure 6.7 Hydrophobic interaction chromatography of the ADAMTS13 MP-Dis variant. 
1ml HiTrap Phenyl HP column (GE Healthcare) was equilibrated with start buffer (20mM 
Tris-HCl, 2M NaCl, pH7.0). The Ni2+ purified samples were diluted and adjusted to the pH 
and ionic strength of the start buffer before injected into the column. With a linear increase of 
concentration of elution buffer (20mM Tris-HCl), the MP-Dis construct was eluted from the 
column.  
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Figure 6.8 Coomassie staining, Western blotting and silver nitrate staining analysis of 
the peak fractions collected from HIC purification of MP-Dis. (A) The fractions A6, A7, 
A8, A9 collected from the peak illustrated in Figure 6.7 were analysed on SDS-PAGE 
followed by Coomassie staining; (B) Western blotting with anti-His-HRP antibody; (C) Silver 
nitrate staining. The MP-Dis variant has a predicted molecular weight of 40kDa, indicated by 
the arrows. 
6.2.6 Quantification of the expressed and purified MP-Dis 
It was not possible to evaluate the yields of the MP-Dis, using the BCA total protein 
assay, as the samples obtained by purification were not pure enough. Alternatively, 
using plasma ADAMTS13 as standard, a modified ELISA assay were performed, 
polyclonal anti-human ADAMTS13 antibody was used as the coating antibody and 
HRP-conjugated anti-C-terminal-His-tag antibody as detected antibody. Although a 
good yield of ADAMTS13 has been established in our lab, using HEK293 cells that 
stably express ADAMTS13 MP-Dis variant I just obtained less than 0.5mg protein 
from more than 5 liters. Although promising, these results suggest that this approach 
will not provide sufficient MP-Dis for structural studies. 
6.2.7 pET SUMO protein expression system 
Recently, I have tried to use pET SUMO protein expression system on ADAMTS13 
MP-Dis expression. There are several reasons why I tried using this system. First, the 
SUMO vector (Figure 6.9 and 6.10) allows generation of native protein using SUMO 
protease to cleave the expressed SUMO moiety. Secondly, it is easy to remove the 
SUMO fusion protein and SUMO protease after cleavage by affinity chromatography 
on a nickel-chelating resin. Thirdly, the N-terminal polyhistidine (6xHis) tag on the 
SUMO fusion protein enables it detected and purified. Finally, N-terminal SUMO 
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fusion protein will increase expression and solubility of recombinant fusion proteins. 
My results demonstrated that, compared with HEK 293T cells expression system, this 
system indeed increased expression of recombinant ADAMTS13 MP-Dis variant and 
also increased solubility of recombinant fusion proteins. However, the purity of 
obtained proteins hardly met the requirement for crystallography and further assay 
identified that these proteins exhibited much less ability to cleave VWF 115 than that 
of the protein expressed and purified from HEK293T cells (these results has not been 
included here). Therefore, I gave up these attempts using the bacterial expression 
system to large scale express and purify ADAMTS13 MP-Dis, and explored other 
ways. 
6.2.8 Discussion 
As a secreted protein, ADAMTS13 possesses many disulphide bridges and contains 
10 putative N-glycosylation sites in or near its MP domain, Spacer domain, TSR4, 
and CUB domains [185]. In addition, the presence of the MP domain may present the 
ADAMTS13 truncations (MP and MP-Dis) with the capacity to inter-molecular 
proteolyse or process themselves. Producing the ADAMTS13 MP and MP-Dis 
truncations therefore is considerable challenge. 
In my thesis, I tried various purification strategies and methods involving in Ni2+ 
column, heparin column, gel filtration, and hydrophobic interaction chromatography. 
It was considered that the more steps for purification, the more chance to lose target 
protein during flow through. Therefore, this led to lower yields of recombinant 
ADAMTS13 MP-Dis. But another reason is that the yields of HEK 293T cells 
expression system for producing the ADAMTS13 MP-Dis did not meet the 
requirement for crystallography. I hypothesised that the two N-Glycans of the 
ADAMTS13 MP may influence the secretion and purification of the the ADAMTS13 
MP-Dis. I later found the secretion of a variant ADAMTS13 MP-Dis (N142Q/N146Q) 
was barely detected (these results have not been included here). Therefore, the 
strategy of expression variant ADAMTS13 MP-Dis to improve purification is 
unpractical.  
A Japanese group [72] has successfully crystallized the non-catalytic domains 
(DTCS), but failed in their attempts to do the same for the MP domain. They used 
CHO cells to express ADAMTS13 truncations including MP domain fragment, 
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indicated that this system may not suitable for the expression and purification of the 
problematic protein (the MP-Dis domains of ADAMTS13).  
6.3 MP-Dis expressed using insect cells 
6.3.1 Introduction 
Recently, the crystal structure of only 3 members, ADAMTS1, 4 and 5, among 19 
members in ADAMTS family have been determined [69-71]. I realised that all these 
three proteins were successfully expressed and purified in an insect cells expression 
system. I therefore decided to investigate use of these cells for high level expression 
of the MP-Dis domains of ADAMTS13. 
Among insect cell expression systems, Drosophila expression system (DES) 
consisting of Drosophila melanogaster Schneider 2 (S2) cells has been widely used in 
high yield expression of recombinant proteins. The S2 cells grow rather rapidly in 
culture at room temperature without the need for CO2. Recently, Iwaki et al. [173] 
generated a plasmid, pMT-PURO, for selection of transfected S2 cells using 
puromycin, which allows appreciable acceleration of the selection time. The pMT-
PURO vector, containing a heterologous protein expression cassette driven by MT 
promoter and a puromycin selection marker driven by the copia promoter in a single 
plasmid is shown in Figure 2.2.  
Using the pMT-PURO vector and S2 cells expression system, Iwaki et al. [173] have 
expressed several haemostasis-related proteins, such as plasminogen, urokinase-type 
plasminogen activator (u-PA), coagulation factor XII, prekallikrein (PK) and high 
molecular weight kininogen (HMWK). I expected a higher level expression of the 
MP-Dis domains of ADAMTS13 to be achieved using this expression system. 
6.3.2 Prepartion of the pMT-PURO containing MP-Dis Vector  
The construction of expression vector (pMT-PURO containing MP-Dis Vector) was 
described in section 2.2.1. The new vector was double digested by restriction enzymes 
BglII and MluI, after which DNA gel electrophoresis was performed. As was shown 
in Figure 6.11, the first lane is pMT-PURO vector after ligation with MP-Dis, which 
is approximately 6kb. The second lane is the sample produced by the restriction 
enzyme digest of the pMT-PURO vector after ligation with MP-Dis. As predicted, 2 
bands (5kb and 1kb) appeared in the second lane, indicating that the MP-Dis fragment 
was successfully introduced into the expression vector. The Plasmid DNA believed to 
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contain the new constructed vector (Figure 2.2) was sequenced to verify that the 
correct sequence was introduced.  
 
Figure 6.11 Electrophoresis of expression vector used in insect cells. The first lane is the 
pMT-PURO vector after ligation with the ADAMTS13 MP-Dis, which is approximately 6kb. 
The second lane is the sample produced by the restriction enzyme digest of the pMT-PURO 
vector after ligation with MP-Dis. As predicted, 2 bands (5kb and 1kb) appears in the second 
lane indicating that the MP-Dis fragment was successfully introduced into the expression 
vector.  
6.3.3 Analysis of expression of ADAMTS13 MP-Dis domain in S2 cells expression 
system 
The methods of transient transfection of the pMT-PURO vector containing the 
ADAMTS13 MP-Dis into S2 cells has been described in section 2.3.5.2. Preliminary 
analysis of the transient transfection conditioned medium using Western blotting 
showed that the ADAMTS13 MP-Dis variant was well secreted (Figure 6.13). 
Therefore, S2 stable cell line was constructed as described in section 2.3.5.3. To 
assess the expression and secretion of the MP-Dis variant in S2 stable cell line 
compared to that in the HEK293 stable cell line, Western blotting was performed on 
the harvested conditioned medium obtained from transient and stable line of S2 cells 
and the HEK293 stable cell line, under both reducing and non-reducing conditions. As 
shown in Figure 6.12, there was a good level of secretion of the ADAMTS13 MP-Dis 
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variant in the S2 cells. Moreover, the ADAMTS13 MP-Dis variant was expressed in 
S2 stable line much better than that in the HEK293 stable cell line. It was found there 
was only a slight difference in molecular weight between the proteins in the non-
reducing and reducing samples, which was consistent with the findings in section 
6.2.1 and Figure 6.2. Based on these results, I am performing large-scale expression 
of the ADAMTS13 MP-Dis variant using this S2 stable cell line. 
 
Figure 6.12 Western blotting analysis of conditioned medium containing ADAMTS13 
truncated variant, MP-Dis. The ADAMTS13 MP-Dis variant, were expressed in S2 cells 
and HEK293 cells. Western blotting was performed on the conditioned medium under both 
reducing and non-reducing conditions. Reducing conditions were prepared by adding 6% v/v 
β-mercaptoethanol into the samples loading buffer. The intensity of the bands indicates the 
amount of protein present in the conditioned medium. The predicted molecular weight of the 
ADAMTS13 MP-Dis variant is 40kDa.The cell lines, where the conditioned media taken 
from, were indicated at the bottom. HEK293: HEK293 stable cell line; S2(T): transient 
transfected S2 cells; S2(S): S2 cell stable line.  
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CHAPTER 7: DISCUSSION AND CONCLUSION 
In my thesis, I aimed to characterise the ADAMTS13 MP domain, so as to decipher 
how ADAMTS13 controls the size of VWF, a multidomain adhesive protein, essential 
for normal haemostasis and for thrombosis. To study this, I used combination of 
biochemical and genetic approaches to map the binding sites between ADAMTS13 
and VWF and to understand the molecular mechanism of the scissile bond cleavage of 
VWF by ADAMTS13. I used protein molecular modelling and amino acid sequence 
alignment (among species and family members) to predict the candidate residues 
potentially contributing to protein-protein interaction. With site-directed mutagenesis 
and inverse PCR, recombinant proteins with target mutation or deletion were 
expressed in bacterial cells or mammalian cells. To evaluate the effect of introduced 
mutations, enzyme activity assays were performed. SDS-PAGE and Western blotting 
were used for qualitative analysis and ELISA/HPLC were used for further 
quantification. With these methods and techniques, I identified that the hydrophobic 
interaction between VWF residue Leu1603 (P3) and ADAMTS13 residues 
Leu198/Leu232/Leu274 (S3 subsite) is an essential determinant of the high substrate 
specificity and proteolysis efficiency of the enzyme ADAMTS13. This can be 
visualised in a model of this interaction (Figure 7.1).  
My results suggest that VWF P3 interaction with the S3 subsite of the ADAMTS13 
MP is absolutely essential for proteolysis to occur. The interactions of ADAMTS 
family members with their corresponding substrates are generally not well known and 
the detailed understanding of how VWF is positioned and scissile bond cleaved by 
ADAMTS13 may generalise to other family member and provide a useful general 
model for this multidomain metalloprotease family. 
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Figure 7.1 Model of the ADAMTS13 active centre aligned with VWF. The ADAMTS13 
active site and functional important residues in the ADAMTS13 metalloprotease (MP, light 
blue) and Disintegrin-like (Dis, gray) domains are highlighted using Pymol. The box enlarged 
is to show specific positioning of the scissile bond over the ADAMTS13 active site cleft. 
ADAMTS13 residues contributed to VWF proteolysis are highlighted: Leu198, Leu232, and 
Leu274 are in dark blue; Val195 and Leu151 in dark brown; Arg349 in green; active centre in 
light blue with Zn2+ in brown and catalytic Glu225 in light yellow; and residues flanking the 
S1’ pocket in purple. The S1 pocket is predicted to lie around the Val195/Leu151 cluster that 
accommodates the P1 residue Tyr1605. The cluster of Leu198/Leu232/Leu274, I propose, 
provides the S3 subsite for the P3 residue Leu1603. The bottom figure shows the VWF1603-
1614 polypeptide, with identified interacting residues (P3, P1, P1’, and P9’) highlighted. This 
figure was taken from [180]. 
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7.1 A general framework for understanding the ADAMTS 
family substrate interactions 
The ADAMTS family has been found in mammals and invertebrates, and is classified 
into the subfamily of the M12 family as they are functionally related to the snake 
venom toxin reprolysin [186]. They are involved in normal protein processing and 
various pathological conditions: e.g. arthritis [187, 188], cancer [189], TTP [63] the 
Ehlers–Danlos [190] and Weill–Marchesani syndrome [191]. The ADAMTS family is 
also closely related to the ADAM (a disintegrin and metalloproteinase) family and to 
MMPs (matrix metalloproteinases). These three families belong to a superfamily of 
metzincins because they share a conserved residue methionine downstream of a 
conserved sequence HEXXHXXGXXH as active site. A recent review has compared 
the domain structure organisation of ADAMTS, ADAM and MMP [192]. 
As one of the 19 members of the ADAMTS family, ADAMTS13 shares similarity of 
domain structure with other members [68]. All the ADAMTS family members are 
synthesized initially in an inactive form as pre-proenzymes. From the N- to the C-
terminus, each member comprises: (a) a signal peptide; (b) a pro-domain; (c) a 
metalloprotease domain; (d) a disintegrin-like domain, (e) a central thrombospondin 
type I like repeat (TSR); (f) a cysteine-rich domain; (g) a Spacer domain of variable 
length; and (h) a variable number of C-terminal TSR (non in the ADAMTS4). Some 
of the ADAMTS members have no known function while others are divided into three 
distinct functional classifications: (a) ADAMTS2, ADAMTS3 and ADAMT14 are 
procollagen N-peptidases; (b) ADAMTS13 is well-known as a VWF-cleaving 
protease; and (c) ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMT9 and 
ADAMT15 are potential aggrecanases. ADAMTS1, initially cloned as an 
inflammation-related gene [193] has recently been found to be involved in tissue 
remodelling [194], angiogenesis [195] and wound healing [196]. ADAMTS4 is 
responsible for the degradation of aggrecan (a major proteoglycan of cartilage) and 
brevican (a brain-specific extracellular matrix protein) [197, 198]. ADAMTS5 also 
functions as an aggrecanase, cleaving aggrecan [187, 188]. Amino acid sequence 
alignment of the ADAMTS family shows that the sequences of ADAMTS1, 
ADAMTS4 and ADAMTS5 align with ADAMTS13 better than other members, 
particularly the metalloproteinase domain (see Chapter 2). Therefore, it is reasonable 
to predict that ADAMTS1, 4, 5 and 13 may share similarity of functional aspects, 
especially mechanisms of substrate recognition. In fact, our lab has recently identified 
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the S1’ pocket of ADAMTS13 [81] based on the determined crystal structure and S1’ 
pocket information of ADAMTS1 [69]. The S1’ pocket of ADAMTS5 has also been 
determined recently [199]. It will be interesting to further study the mechanisms of the 
cleavage of the substrate scissile bond by ADAMTS family. Previous studies have 
demonstrated that the process of ADAMTS13 cleaving its substrate VWF is a 
multidomain, conformation-driven proteolysis reaction [100]. I, here for the first time, 
identified that the interaction of ADAMTS13 S3 with VWF P3 is a critical 
determinant of VWF proteolysis. Although ADAMTS family members recognise 
various substrates and cleavage sites, for example, ADAMTS1 specifically cleaves 
versican (at the site of Glu441-Ala442) and aggrecan (Glu1480-Gly1481 and 
Glu1871-Leu1872) [179, 200 and 201] while ADAMTS4 and 5 also mainly cleave 
after Glu (Glu-Ala, Glu-Gly and Glu-Leu) [202-204], the whole picture of the S3 and 
S1 subsite will be a major advance of the mechanism of scissile bond cleavage by the 
ADAMTS family. In addition, my findings on the S3 and S1 subsites of ADAMTS13 
can give a hint for the investigation of the corresponding subsites of the ADAMTS1, 4 
and 5. This should be readily achievable because all the crystal structures of the 
ADAMTS1, 4 and 5 have been determined [69-71]. If successful, it will further 
confirm my findings and eventually depict a more precise framework of how the 
ADAMTS family members interact with their individual substrates.  
7.2 Mutation within VWF could also potentially play a role in 
microvascular thrombosis 
An absence of cleavage of VWF, caused by either congenital or acquired deficiencies 
of ADAMTS13, can result in TTP. Congenital TTP is a result of mutations in the 
ADAMTS13 gene and numerous mutations in the ADAMTS13 gene have now been 
reported in patients with this disorder. Acquired TTP is caused by patients’ 
autoantibodies against ADAMTS13 (mainly directed to its Spacer domain). While 
ADAMTS13 mutations reduce the synthesis/secretion of ADAMTS13 and cause 
lower concentration of ADAMTS13 in plasma, autoantibodies against ADAMTS13 
can directly impair the activity of the enzyme to proteolyse VWF. Under such 
conditions, ultra large VWF multimers, due to lacking processed by ADAMTS13 
accumulate, contribute to the acute microvascular thrombotic occlusions by forming 
platelet clumps. Obviously, previous pathological studies and classifications on TTP 
have more focused on ADAMTS13 itself rather than its substrate VWF. My results 
suggest that residue substitutions within VWF could also potentially contribute to 
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microvascular thrombosis. I found that the synthesis/secretion/multimers distribution 
of full length VWF with either L1603A or L1603S mutation behaves very similar to 
that of wild type full length VWF. However, L1603A or L1603S substitution in full 
length VWF inhibits its proteolysis by ADAMTS13. This discovery raises interesting 
questions about how mutations in VWF might contribute to thrombosis under various 
circumstances. It will be meaningful to screen patients with microvascular thrombosis 
for genetic mutations in the VWF, particularly for those known to be without gene 
mutations in ADAMTS13. 
7.3 Crystal structure of ADAMTS13 MP domain 
My work was based on the model of structure of ADAMTS13 catalytic domain. 
Whether other residues play an important role in the interaction between VWF and 
ADAMTS13 remains unknown. Therefore, it will be interesting to crystallize 
ADAMTS13 for that purpose. I attempted to optimise expression of the correctly 
folded ADAMTS13 catalytic domain for crystal structure trials during the work of my 
thesis. I have explored using several alternative approaches such as bacterial 
expression system (pET SUMO protein expression system) and insect cells expression 
system (Drosophila expression system), and various purification strategies and 
methods involving in Ni2+ column, heparin column, gel filtration, and hydrophobic 
interaction chromatography based on FPLC. Now I have established a stable line of 
insect cells, which I confirmed to be capable of expressing comparatively high yields 
of ADAMTS13 MP-Dis domains. The generation of larger amounts of protein using 
the strategies outlined above raises the prospect of determining a number of 
ADAMTS13 MP and MP-Dis crystal structures. Crystallography can be high risk. 
Nevertheless, given the successful crystallisation of ADAMTS1, 4 and 5 and non-
catalytic domains of ADAMTS13, and the extremely interesting structures that could 
be determined would transform our understanding of ADAMTS13 and its interaction 
with VWF. This is a worthy goal. The crystallisation of: (i) wild type ADAMTS13 
MP-Dis; (ii) ADAMTS13 MP-Dis with active-site catalytic Glu (E225A) mutated to 
prevent autolysis; (iii) the ADAMTS13 MP domain (with and without E225A); (iv) 
these proteins (i-iii) in complex with VWF115 mutant with Y1605A-M1606A; (v) 
these proteins (i-iii) in complex with VWF115 mutant with L1603A;  (vi) these 
proteins (i-iii) in the presence and absence of Ca2+ [76, 205]; and (vii) these proteins 
(i-iii) containing a mutation in a Ca2+-binding site (e.g. Glu83 or Asp173) [76, 206] 
will all be attempted. These experiments, if successful, will provide structures for 
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ADAMTS13 MP domain, show how the metalloprotease can bind and interact with its 
substrates, and will further undoubtedly illustrate the mechanism of VWF scissile 
bond cleavage by this interesting metalloprotease, ADAMTS13.   
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APPENDIX 
Appendix I:  VWF 115 pET100/D-TOPO vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5764 bp
(Invitrogen)
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Appendix II: Primers used for site-directed mutagenesis  
L1603A: 5'- GAGCAGGCGCCCAACGCGGTCTACATGGTCACC -3' 
L1603Ar: 5'- GGTGACCATGTAGACCGCGTTGGGCGCCTGCTC -3' 
L1603K:  5'- GAGCAGGCGCCCAACAAGGTCTACATGGTCACC -3' 
L1603Kr: 5'- GGTGACCATGTAGACCTTGTTGGGCGCCTGCTC -3' 
L1603N:  5'- GGGAGCAGGCGCCCAACAACGTCTACATGGTCACCGG-3' 
L1603Nr: 5'- CCGGTGACCATGTAGACGTTGTTGGGCGCCTGCTCCC-3' 
L1603S:   5'- GAGCAGGCGCCCAACTCGGTCTACATGGTCACCGG -3' 
L1603Sr: 5'- CCGGTGACCATGTAGACCGAGTTGGGCGCCTGCTC -3' 
DREQ/SSSS:   5'- TCGTCGGCGCCCAACCTGGTCTACATG-3' 
DREQ/SSSSr:  5'-CGAGCTACCCTGGCTGACCAAGAAGC-3' 
N1602A:   5'- CGAGCAGGCGCCCGCCCTGGTCTACATG -3' 
N1602Ar: 5'- CATGTAGACCAGGGCGGGCGCCTGCTCG -3' 
V1604S:   5'- GCAGGCGCCCAACCTGTCCTACATGGTCACCGG -3' 
V1604Sr:  5'- CCGGTGAC ATGTAGGACAGGTTGGGCGCCTGC -3' 
Y1605A:   5'-GGCGCCCAACCTGGTCGCCATGGTCACCGGAA-3' 
Y1605Er: 5'-GGATTTCCGGTGACCATGGCGACCAGGTTGGC-3' 
L152A:   5'- CTCAC TCGTCCCTGGCGAGCGTCTGTGGGTGG -3' 
L152Ar: 5'- CCACCCACAGACGCTCGCCAGGGACGAGGTGAG -3' 
L152R:  5'- CTCACCTCGTCCCTGCGGAGCGTCTGTGGGTGG -3' 
L152Rr: 5'- CCACCCACAGACGCTCCGCAGGGACGAGGTGAG -3' 
W206A:   5'- GCCTGCTCCCCAACGCGAGCTGCCTCATTACC -3' 
W206Ar: 5'- GGTAATGAGGCAGCTCGCGGTTGGGGAGCAGGC -3' 
W206R:  5'- GCCTGCTCCCCAACCCGGAGCTGCCTCATTACC -3' 
W206Rr: 5'- GGTAATGAGGCAGCTCCGGGTTGGGGAGCAGGC -3' 
L198A:  5'- GGCGTCACCCAGGCGGGCGGTGCCTGC -3' 
L198Ar: 5'- GCAGGCACCGCCCGCCTGGGTGACGCC -3' 
L198S:  5'- GGCGTCACCCAGTCGGGCGGTGCCTGC -3' 
L198Sr: 5'- GCAGGCACCGCCCGACTGGGTGACGCC -3' 
L198E:  5'- GGCGTCACCCAGGAGGGCGGTGCCTGC -3' 
L198Er: 5'- GCAGGCACCGCCCTCCTGGGTGACGCC -3' 
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The platelet-tethering function of von Willebrand factor (VWF) is
proteolytically regulated by ADAMTS13 (a disintegrin and metal-
loproteinase with a thrombospondin type 1 motif, member 13),
which cleaves the Tyr1605-Met1606 (P1-P1′) bond in the VWF A2
domain. To date, most of the functional interactions between
ADAMTS13 and VWF that have been characterized involve VWF
residues that are C terminal to the scissile bond. We now demon-
strate that the substrate P3 position in VWF, Leu1603, is a critical
determinant of VWF proteolysis. When VWF Leu1603 was sub-
stituted with Ser, Ala, Asn, or Lys in a short VWF substrate,
VWF115, proteolysis was either greatly reduced or ablated (up to
400-fold reduction in kcat/Km). As Leu1603 must interact with resi-
dues proximate to the Zn2+ ion coordinated in the active center of
ADAMTS13, we sought the corresponding S3 interacting residues.
Substitution of 10 candidate residues in the metalloprotease do-
main of ADAMTS13 identiﬁed two spatially separated clusters cen-
tered on Leu198 or Val195 (acting with Leu232 and Leu274, or with
Leu151, respectively), as possible subsites interacting with VWF.
These experimental ﬁndings using the short VWF115 substrate
were replicated using full-length VWF. It is hypothesized that VWF
Leu1603 interacts with ADAMTS13 Leu198/Leu232/Leu274 and
that Val195/Leu151 may form part of a S1 subsite. The recognition
of VWF Leu1603 by ADAMTS13, in conjunction with previously
reported remote exosites C terminal of the cleavage site, suggests
a mechanism whereby the VWF P1-P1′ scissile bond is brought into
position over the active site for cleavage. Together with recently
characterized remote exosite interactions, these ﬁndings provide
a general framework for understanding the ADAMTS family sub-
strate interactions.
microvascular thrombosis | thrombotic thrombocytopenia purpura
Von Willebrand factor (VWF) is a large multimeric glyco-protein that is essential for normal hemostasis (1). Following
vessel injury, VWF binds to exposed subendothelial collagen.
Thereafter, in response to the shear forces exerted by the ﬂowing
blood, it unfolds from its inactive globular conformation into an
active string-like form that can speciﬁcally recruit platelets (2–4).
VWF multimeric size is a primary determinant of its platelet-
tethering function and is proteolytically controlled by the plasma
metalloprotease ADAMTS13 (a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13) (5–8). The phys-
iological importance of this system is highlighted by the clinical se-
quelae associated with dysfunction of the VWF/ADAMTS13 axis.
Whereas ADAMTS13 deﬁciency can cause fatal microvascular
thrombosis-thrombotic thrombocytopenic purpura (7), excessive
VWF proteolysis causes bleeding (i.e., type 2A von Willebrand
disease) (1).
ADAMTS13 circulates in plasma as a constitutively active en-
zyme, which is unusual. Despite this behavior, plasma VWF
remains essentially resistant to ADAMTS13 proteolysis in free
circulation. This resistance is because shear-dependent unfolding
of the VWF A2 domain is ﬁrst required to expose both ADA-
MTS13 binding sites and the Tyr1605-Met1606 scissile bond
before cleavage can occur. Once the A2 domain has unraveled,
however, multiple exosite interactions contribute to the approxi-
mation of ADAMTS13 metalloprotease domain with the VWF
Tyr1605-Met1606 scissile bond (9–16). The characterized func-
tionally important interactions include the binding of the
ADAMTS13 spacer domain with amino acids in the C-terminal
region of the VWF A2 domain (9, 12, 14), and the interaction of
the ADAMTS13 disintegrin-like domain with Asp1614 in VWF
(11). Remarkably, little is known of the molecular interactions
between the substrate and the metalloprotease domain of
ADAMTS13. A quantitative study of cleavage of VWF short and
full-length substrates showed the importance of the P1 and P1′
residues (Tyr1605 and Met1606, respectively), as substitution of
these appreciably reduced proteolysis by ADAMTS13 (17). We
recently provided further evidence for the importance of the ac-
commodation of the P1′ residue, Met1606, within the S1′ pocket
adjacent to the active site (10).
Most attention to date has been paid to regions and residues of
VWF that are C terminal to the cleavage site. We hypothesized
that a necessary feature of enzymatic cleavage of VWF will be
a docking point for ADAMTS13 that is N terminal to the scissile
bond. This ﬁnding is essential because cleavagemust be associated
with a reduction in binding afﬁnity of the substrate to enable the
protease to recycle, a reduction that will then be provided by bond
cleavage. To investigate further the VWF residues important for
cleavage by ADAMTS13, we have considered the activities of
previously reported short VWF A2 domain fragments that span
the cleavage site. One, VWF64 (1605–1668), could not be cleaved
by ADAMTS13 (13), but others, such as VWF73 (1596–1668),
VWF76 (1593–1668), and VWF115 (1554–1668) are all proteo-
lysed efﬁciently (14, 18, 19). The difference between the substrates
that are and those that are not cleaved resides in the sequence N
terminal to the scissile bond. Therefore, we conjectured that the
VWF1596–1604 N-terminal sequence must contain a structural
determinant that is essential for proteolysis.
Results
We introduced a panel of single and multiple amino acid sub-
stitutions into the shortA2domain substrate,VWF115,which spans
residues Glu1554-Arg1668 (Fig. S1). The synthetic peptide desig-
natedN-terminal peptide (NTP) that spansAsp1596-Tyr1605 is also
shown.VWF115 and its variants were expressed, puriﬁed, and quan-
tiﬁed as previously described, before functional analyses (11, 18).
Cleavage of WT VWF115 by ADAMTS13 was rapid when ex-
amined by SDS/PAGE to visualize the cleavage products (Fig.
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1A). TheVWF115 variants inwhich the P10-P7 residues,VWF115
Asp1596-Gln1599, were all replaced by Ser (DREQ1596-9SSSS),
or the P4 residue, VWF115Asn1602, was substituted forAla, were
both cleaved rapidly, very similar toWTVWF115 (Fig. 1A). Point
substitution of VWF115 Val1604 (the P2 residue) to Ser resulted
in a modest reduction in proteolysis, whereas substitution of the
P1 residue, VWF115 Tyr1605, to Ala predictably reduced ap-
preciably the rate of cleavage (Fig. 1A). However, substitution of
VWF115 Leu1603 (at the P3 position) with Ser abolished pro-
teolysis (Fig. 1A). In additional experiments, VWF115 Leu1603
was also substituted with Ala, Asn, and Lys: all of these variants
had severely reduced (Leu1603Ala) or undetectable (Leu1603Asn
and Leu1603Lys) cleavage (Fig. 1B, Upper). In contrast, sub-
stitution of VWF Leu1603 with large hydrophobic residues Met
and Phe had minimal inﬂuence on cleavage (Fig. 1B, Lower).
Cleavage of selected variants was studied quantitatively by HPLC
under conditions in which the catalytic efﬁciency, kcat/Km, could be
determined (Fig. 1C). Minimal cleavage of VWF115 Leu1603Ser
was observed (Fig. 1C). Table 1 summarizes the speciﬁcity con-
stants derived from replicate experiments. The proteolysis of the
VWF115 Leu1603Ser mutant was essentially ablated (>400 fold
reduction in catalytic efﬁciency).Although this reduction in kcat/Km
was appreciably larger even than the 38-fold reduction of the
VWF115 Tyr1605Ala variant with the substituted P1 residue, the
P1 residue substitution to Ser in a VWF115 Tyr1605Ser variant
also had barely detectable cleavage when examined by SDS/
PAGE (Fig. S2). In additional quantitative experiments, the
cleavage of VWF115 Leu1603Ala was studied by HPLC. Time-
course experiments with 1 nM ADAMTS13 indicated that even
this conservative residue change produced ∼100-fold reduction in
cleavage efﬁciency (Fig. 1C); however, quantitation of such low
level of proteolysis is imprecise. Using higher concentrations (10
nM) of ADAMTS13 to induce sufﬁcient cleavage of the VWF115
Leu1603Ala variant, substrate titration of the initial rate of pro-
teolysis (Fig. 1D) of the variant demonstrated reduced (n=3) kcat
of 0.11 ± 0.07 (compare with WT ADAMTS13, 0.33 ± 0.18) s−1
and increased Km of 6.8 ± 3.6 (compare with WT ADAMTS13,
0.91 ± 0.51) μM.
Results from the literature are summarized in the lower part
of Table 1. The reduction in cleavage constant for the VWF115
Leu1603Ser variant is appreciably greater than the 18-fold re-
duction for the VWF115 Met1606Ala variant in which the P1′
residue was substituted (10), the 6.5-fold reduction for the
VWF115 Asp1614Ala that disrupts the disintegrin-like domain
binding exosite (11), and the 12.5- to 15-fold reduction for the
Δ1660–1668 C-terminal deletion variant that abolishes the
spacer domain binding exosite (9, 13). Together, these results
clearly demonstrate an essential role for VWF residue Leu1603,
which is N terminal to the scissile bond, acting with VWF P1
residue, Tyr1605, in the cleavage process.
Further evidence for an important docking site within VWF
Asp1596-Tyr1605 was obtained using an NTP containing this
sequence to inhibit ADAMTS13 cleavage of VWF115. Addition
of 1 mM WT NTP clearly reduced cleavage of VWF115 by
ADAMTS13 when visualized by SDS/PAGE (Fig. 2A). In con-
trast, an NTP variant containing the Leu1603Ala substitution
was without apparent effect, conﬁrming Leu1603 as the key
residue in this sequence. The inﬂuence of the NTP upon the
initial rate of VWF115 proteolysis by ADAMTS13 was quanti-
ﬁed by HPLC (Fig. 2B). Although WT NTP produced a large
Fig. 1. Cleavage of VWF115 and its variants by ADAMTS13. (A) Composite
and point substitution variants of VWF115 (6μM), N terminal to and in-
cluding the scissile bond, are incubated with 3.5 nM ADAMTS13 and reaction
products visualized by SDS/PAGE. (B) Proteolysis of different point sub-
stitution variants of VWF115 Leu1603 by ADAMTS13 was analyzed as in A.
(Upper) Cleavage of VWF115 Leu1603Ala, -Asn, and -Lys; (Lower) Cleavage
of VWF115 Leu1603Met and -Phe. (C) Graph showing the time course of
cleavage of 2.5 μM VWF115 point and composite substitution variants by
1nM ADAMTS13. VWF115 proteolysis was quantiﬁed by HPLC. (D) De-
termination of kcat and Km for WT VWF115 and for the VWF115 Leu1603Ala
variant. High concentrations of ADAMTS13 (10 rather than 1 nM) were used
to induce proteolysis of VWF Leu1603Ala, the initial rates of which were
determined by HPLC, corrected for protease concentration and plotted as
a function of substrate concentration.
Table 1. Quantitative analysis of scissile bond cleavage by
ADAMTS13 for WT VWF and its variants
VWF115 kcat/Km (×10
5 M−1s−1) Fold reduction
WT 9.3 ± 2.3 —
DREQ/SSSS 6.4 ± 0.7 1.4
N1602A 4.3 ± 0.4 2.2
L1603S <0.02 >400
L1603A 0.1 ± 0.04 100
V1604S 1.8 ± 0.1 5.1
Y1605A 0.2 ± 0.05 38
M1606A * 18
D1614A ** 6.5
Δ1660–8 *** 12.5–15
Speciﬁcity constants, kcat/Km, (±SD) were determined by HPLC quantitation
of VWF115 proteolysis by ADAMTS13 (n ≥ 3). Values for VWF115 Leu1603
variants must be regarded as approximate because of very low cleavage
rates. Results indicated by asterisks are from the literature: *, ref. 10; **,
ref. 11; ***, refs. 9 and 13.
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concentration dependent reduction in cleavage rate, the effect of
NTP Leu1603Ala was very modest.
The VWF P3 residue, Leu1603, is located within ∼10 Å of the
scissile bond. It must therefore interact with residues on the
surface of the ADAMTS13 metalloprotease domain in close
proximity to the catalytic Zn2+ ion coordinated within the active
site. Using a model of ADAMTS13, we identiﬁed 10 candidate
S3 residues in ADAMTS13 (Leu151, Leu152, Val195, Thr196,
Gln197, Leu198, Trp206, Leu232, L273, and L274) that might
interact with VWF Leu1603 because of their proximity to the
active site (Fig. 3A). ADAMTS13 residues Thr196 and Gln197
were substituted in a recent report and the variants found to
have normal proteolytic activity against VWF115 (10), and
therefore were excluded from further investigation. When the
activities of ADAMTS13 variants Leu151Ser, Leu152Arg,
Val195Ser, Leu198Ser, Trp206Arg, Leu232Asn, Leu273Asn,
and Leu274Ser were examined by SDS/PAGE using WT
VWF115 (Fig. 3B), we found that ADAMTS13 variants
Leu151Ser, Val195Ser, Leu198Ser, Leu232Asn, and Leu274Ser
exhibited reduced ability to cleave VWF115. The activities of
these selected variants were therefore examined quantitatively
by HPLC (Fig. 3C). This experiment revealed an approximately
ﬁvefold reduction in kcat/Km for ADAMTS13 Leu198Ser com-
pared with WT ADAMTS13 (9.3 ± 2.3 × 105 M-1·s−1, n = 3) and
a 13- to 16-fold, reduction in kcat/Km for ADAMTS13 variants
Val195Ser and Leu274Ser. No proteolytic cleavage fragments
could be detected for the ADAMTS13 Leu232Asn and
Leu151Ser variants, which had poor secretion. The ADAMTS13
residues which, when substituted resulted in reduced protease
activity, fall into two clusters: Leu198/Leu232/Leu274 and
Val195/Leu151.
The approximately ﬁvefold reduction in kcat/Km for proteolysis
of VWF115 by the ADAMTS13 Leu198Ser variant is very similar
to that for the cleavage of VWF115 Val1604Ser by WT
ADAMTS13 (Table 1). This ﬁnding raised the possibility that
ADAMTS13 Leu198 might interact with VWF Val1604 (P2 resi-
due) rather than VWF Leu1603 (P3 residue). However, this con-
tention was excluded by experiments in which WT VWF115 and
VWF115 Val1604Ser were proteolysed by catalytic amounts (1–3
nM) of WT ADAMTS13 or ADAMTS13 Leu198Ser (Fig. S3).
These results clearly suggest that the effects of both of these sub-
stitutions were independent of each other, making the interaction
between the residues unlikely.
In a similar manner, we next examined whether the
ADAMTS13 variants Leu198Ser, Val195Ser, and Leu274Ser in-
duce cleavage of the VWF115 Leu1603Ser variant, which is of
decreased magnitude compared with that of WT ADAMTS13.
For these experiments, it was necessary to use high concentrations
(30 nM) of the ADAMTS13 variants, as the usual catalytic con-
centrations (1–3 nM) failed to induce proteolysis of VWF115
Leu1603Ser. For the ADAMTS13 Leu198Ser variant, similar,
minimal cleavage of the VWF115 Leu1603Ser occurred to that
observed for WT ADAMTS13 (Fig. S4). For the ADAMTS13
Val195Ser and Leu274Ser variants, there was a suggestion of less
cleavage of the VWF115 Leu1603Ser variant.
To verify our ﬁndings of the importance of the P3 residue
in VWF proteolysis by ADAMTS13, we introduced both the
Leu1603Ala and Leu1603Ser substitutions into full-length re-
combinantVWF. These variants were expressed normally and had
normal multimer distribution (Fig. 4A). Full-lengthWTVWFwas
Fig. 2. Inhibition of cleavage of VWF115 by the NTP. (A) Proteolysis of 6 μM
VWF115 by 3.5 nM ADAMTS13 in the presence and absence of 1 mM NTP
and NTP(Leu1603Ala). VWF115 cleavage is visualized by SDS/PAGE. (B) In-
hibition of the initial rate of cleavage of 2.5 μM VWF115 by 1 nM ADAMTS13
in the presence of 0 to 1 mM NTP or NTP(Leu1603Ala). The initial rate of
proteolysis was quantiﬁed using HPLC.
Fig. 3. Determinants of VWF cleavage by ADAMTS13 and its variants. (A)
Model of the metalloprotease domain of ADAMTS13 showing 10 candidate
S3 residues: the catalytic Zn2+ ion and proposed S1′ pocket are also labeled.
The VWF sequence around the scissile bond is indicated below the model. (B)
Proteolysis of 6 μM VWF115 by 1 nM WT ADAMTS13 and ADAMTS13 var-
iants Leu151Ser, Leu152Arg, Val195Ser, Leu198Ser, Trp206Arg, Leu232Asn,
Leu273Asn, and Leu274Ser. VWF proteolysis is visualized by SDS/PAGE. (C)
HPLC quantitation of 2.5 μM VWF115 proteolysis by 3 nM WT ADAMTS13
and by ADAMTS13 variants Leu151Ser, Val195Ser, Leu198Ser, Leu232Asn,
and Leu274Ser.
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rapidly and effectively cleaved byADAMTS13 (Fig. 4B, visualized
on SDS/PAGE and Western blotting following reduction of the
protein), whereas minimal cleavage was observed with the VWF
Leu1603Ala and Leu1603Ser variants (Fig. 4B). Additional ex-
periments examining the ability of ADAMTS13 Leu198Ser,
Val195Ser, andLeu274Ser variants to cleave full-lengthWTVWF
were also performed. These experiments showed a small reduction
inVWF cleavage byADAMTS13 Leu198Ser, but large reductions
for the other two ADAMTS13 variants (Fig. 4C).
Further support for an essential role of VWF Leu1603 and
ADAMTS13 Leu198 and Val195 residues in the cleavage re-
action is provided by species alignments showing their structural
conservation. VWF Leu1603 is perfectly conserved in all species
(Fig. S5). Interestingly, complete conservation of the functionally
important P9′ residue in VWF, Asp1614, can also be noted.
Similar regional alignment of the ADAMTS13 metalloprotease
domains also shows strong conservation of Leu151, Val195,
Leu198, Leu232, and Leu274 (Fig. S6).
Discussion
Cleavage of VWF by ADAMTS13 requires approximation of the
substrate and protease. As ADAMTS13 circulates as a constitu-
tively active enzyme, VWF cleavage is not driven by changes in
the protease, such as an activation step that characterizes most
zymogen to protease transitions in blood coagulation factors.
Rather, proteolysis is uniquely inﬂuenced by changes in the con-
formation of VWF, which must ﬁrst unfold. A critical feature of
VWF unfolding has been shown to be the unfolding of the A2
domain itself. This domain is stabilized by a hydrophobic plug
comprised of vicinal Cys residues located at the C terminus of
the domain, which is inserted in the center of the domain near to
the scissile bond (3, 20). This hydrophobic plug must ﬁrst be
removed for the A2 domain. Only once unfolded does VWF
reveal the Tyr1605-Met1606 scissile bond and enable access of
ADAMTS13. As with many reactions in hemostasis, remote
exosites assist the cleavage process by bringing the active center
of the protease into position over the scissile bond (9–11, 13, 14,
21). These exosite interactions which are C terminal to the
scissile bond, either directly or indirectly facilitate the P1-P1′
bond positioning and cleavage. We recently provided evidence
that P1′ residue, VWF Met1606, interacts with ADAMTS13
metalloprotease domain residues Asp252-Pro256 that form the
S1′ pocket, and that speciﬁcity of ADAMTS13 can be altered by
substituting these residues (10).
A small number of residues N terminal to the VWF scissile
bond have previously been examined for their inﬂuence on
cleavage by ADAMTS13, although this has been done in the
context of polymorphisms that might inﬂuence VWF function
rather than exploring speciﬁc exosite interactions (17). In-
terestingly, the report containing these results also demonstrated
the requirement for the P1 residue to have an aromatic side
chain, which is a determinant of its accommodation in the S1
pocket. This ﬁnding very likely explains the 38-fold reduction in
proteolysis of the VWF115 Tyr1605Ala variant and minimal
proteolysis of the VWF115 Tyr1605Ser variant. We reasoned
that an N-terminal docking site other than the P1 residue must
also be essential for scissile bond cleavage. Our systematic in-
vestigation reported here of the inﬂuence of residues N terminal
to the scissile bond, prompted by examination of the reported
activities of small VWF substrates, enabled us to identify the
functional importance of VWF Leu1603 at the P3 substrate
position. Remarkably, substitution of this single residue has the
largest effect of any prior reported residue change in VWF. In-
deed, the reduction in cleavage speciﬁcity of the variant VWF
Leu1603Ser is far greater (>400-fold) than those of composite
substitutions or deletions of prior identiﬁed exosites within the
VWF sequence (Table 1). This ﬁnding is further supported by
strict sequence conservation of VWF Leu1603 between species,
which is greater even than the cleavage site residues (Fig. S5).
The functional importance of VWF Leu1603 points to an im-
portant role in the cleavage mechanism, acting together with the
P1 residue, Tyr1605, to orient and anchor the scissile bond. To
identify potential interacting residues for the P3 residue on the
ADAMTS13 protease domain, we substituted potential hydro-
phobic interacting partners close to the active center and ex-
amined VWF cleaving activity of these variants, which suggested
that two separate clusters of ADAMTS13 residues involving
residues Leu198 and Val195 may provide interaction sites for
VWF. Although mutation of these residues did not induce
a comparable reduction in cleaving activity as replacement of
VWF Leu1603, mutation of adjacent residues Leu274, Leu232,
and Leu151 in ADAMTS13 either reduced or abolished
cleavage. The very low expression levels of these two latter
ADAMTS13 mutants suggests that mutation-induced misfolding
of the ADAMTS13 metalloprotease domain cannot be excluded
as a contributor to reduced activity.
We now propose a provisional mechanism for cleavage of VWF
usingamodel of theADAMTS13metalloprotease anddisintegrin-
like domains (Fig. 5). Thismechanism showsADAMTS13Arg349
(green) thatprovides adockingpoint forVWFAsp1614Cterminal
to the catalytic center (orange with Zn2+ shown). Based on our
results, two potential VWF interaction sites, involving Leu198 and
Val195, are shown. We postulate that ADAMTS13 Val195 and
Leu151 may be positioned to form part of the S1 rather than S3
subsite andmight therefore interactwith the aromatic ringofVWF
Tyr1605, rather than with VWF Leu1603. If so, we propose that
ADAMTS13 Leu198, Leu232, and Leu274 contribute to the S3
subsite for VWF Leu1603. Based on a prior report, the likely po-
sition of the S1′ pocket ﬂanked by ADAMTS13 Asp252-Pro256
(purple) is shown: this subsite is predicted to accommodate
Met1606 (10). Underneath is shown the VWF1603-1614 poly-
Fig. 4. Proteolysis of full-length VWF by ADAMTS13. (A) Recombinant WT
VWF and VWF Leu1603Ala and Leu1603Ser were examined for their multi-
mer composition using SDS-agarose gel electrophoresis and Western blot-
ting for VWF. (B) Proteolysis of recombinant full-length WT VWF, VWF
Leu1603Ala, and Leu1603Ser (1.0 μg/mL) by 20 nM ADAMTS13. Changes in
VWF were examined by SDS/PAGE under reducing conditions with Western
blotting for VWF. (C) Proteolysis of full-length WT VWF (1.0 μg/mL) by 15 nM
WT ADAMTS13 and ADAMTS13 Val195Ser, Leu198Ser, and Leu274Ser var-
iants examined by SDS/PAGE with Western blotting, as in B.
4 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1018559108 Xiang et al.
peptide with potentially complementary interacting residues color
coordinated. It is proposed, therefore, that VWF Leu1603,
Tyr1605, and Asp1614 contact ADAMTS13 Leu198, Val195, and
Arg349 in ADAMTS13, respectively, ensuring that the scissile
bond is brought into position over the active center for cleavage to
occur. Our results suggest that VWF Leu1603 interaction with the
metalloprotease is absolutely essential forproteolysis tooccur.The
interactions ofADAMTS familymemberswith their substrates are
generally not well understood and the detailed understanding
of how VWF is positioned and cleaved by ADAMTS13 may
provide a useful general model for this multidomain metal-
loprotease family.
Cleavage of the VWF scissile bond by ADAMTS13 is essential
for normal hemostasis. An absence of cleavage, caused by
inherited or acquired deﬁciencies of ADAMTS13, predisposes to
thrombotic thrombocytopenic purpura. Numerous point muta-
tions in the ADAMTS13 gene have now been identiﬁed in
patients with this disorder. Mostly, these mutations reduce the
synthesis/secretion of ADAMTS13 and it is believed that accu-
mulation of ultra large VWF multimer contributes to the acute
microvascular thrombotic occlusions by forming platelet clumps.
The present results suggest that residue substitutions within
VWF could also potentially play a role in microvascular throm-
bosis. It will be of interest to screen families and individuals
suffering from microvascular thrombosis for mutations in the
VWF gene around the cleavage site, particularly any cases of
thrombosis known to be without gene mutations in ADAMTS13.
Materials and Methods
Expression and Puriﬁcation of VWF115 and VWF115 Variants. An expression
vector for the VWF A2 domain cleavage fragment, VWF115 (spanning VWF
residues 1554–1668), its mutagenesis, and expression have been previously
described (18).
Expression of Recombinant Full-Length VWF and the VWF(Leu1603Ser and
Leu1603Ala) Mutants. An expression vector for full-length human VWF and
its mutagenesis have been previously described (22). Recombinant full-length
WT VWF and these variants were expressed transiently in HEK293T cells
(23). The concentration of VWF was determined by a speciﬁc ELISA (24), and
VWF multimer analysis was assessed as previously described (24).
Expression of Recombinant ADAMTS13 and ADAMTS13 Variants. The expression
vector forWTADAMTS13 and its mutagenesis have been described elsewhere
(25). WT ADAMTS13 and ADAMTS13 variants were transiently expressed
in HEK293T cells (23). Expression and secretion of ADAMTS13 was conﬁrmed
by Western blotting using a polyclonal rabbit anti-ADAMTS13 antibody
(26). After 3 to 4 d, conditioned medium was harvested, cleared, and con-
centrated using 50-kDa molecular weight centrifugal ﬁlter devices (Milli-
Fig. 5. Model of the ADAMTS13 active center aligned with VWF. ADAMTS13 metalloprotease (MP, light blue) and disintegrin-like (Dis, gray) domains is
shown with the area in the box enlarged to illustrate speciﬁc positioning of the scissile bond and potential docking points for the VWF peptide around the
scissile bond. ADAMTS13 residues implicated in VWF proteolysis derived from the present and other reports are highlighted; Leu198, Leu232, Leu274 (dark
blue), Val195, Leu151 (dark brown), Arg349 (green), active center (light blue, with Zn2+ shown in brown) with catalytic Glu225 and residues ﬂanking the S1′
pocket (purple). The S1 pocket that harbors the P1 residue Tyr1605 is predicted to lie around the Val195/Leu151 cluster in this model. We propose that the
cluster of Leu198, Leu232, and Leu274 provides the S3 subsite for VWF Leu1603. Beneath the ﬁgure is the VWF1603-1614 polypeptide (shown to scale), with
identiﬁed interacting residues (P3, P1, P1′, and P9′) highlighted in complementary colors.
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pore). ADAMTS13 concentration was determined using a speciﬁc in-house
ADAMTS13 ELISA, as previously described (26, 27).
VWF115 Cleavage by ADAMTS13. WT ADAMTS13 or ADAMTS13 variant (1 or
3.5 nM, unless otherwise indicated) in 20 mM Tris, 150 mM NaCl (pH 7.8) was
incubated for 1 h with 5 mM CaCl2. Next, 6 μM VWF115, or VWF115 variant
was added and at regular intervals aliquots of 15 μL were removed and
stopped with 5 μL 30 mM EDTA. Thereafter, proteolysis of VWF115 was vi-
sualized by SDS/PAGE with Coomassie staining to detect cleavage products.
Quantitative analysis of VWF115 proteolysis was performed by reactions
that were set up similarly, except 2.5 μM VWF115 were used and samples
were analyzed by HPLC from which the catalytic efﬁciencies for proteolysis
(kcat/Km) were derived, as previously described (18). Determination of in-
dividual catalytic constants, kcat and Km, were also performed as described
(18), using 1 nM ADAMTS13 with WT VWF115 and 10 nM ADAMTS13 with
VWF Leu1603Ala. The protease was titrated with increasing concentrations
of the substrates, initial rates of proteolysis determined by HPLC, and these
were corrected for differences in protease concentrations. All functional
assays were repeated a minimum of three times and with different prepa-
rations of VWF115 and ADAMTS13.
Cleavage of Full-Length Multimeric VWF by ADAMTS13. To compare the
cleavage of full-length WT VWF and VWFLeu1603Ser and Leu1603Ala var-
iants, ADAMTS13 (20 nM) was preincubated for 30 min in 20 mM Tris, 0.5%
BSA, 5 mM CaCl2. Recombinant WT VWF or VWF variant, 1.0 μg/mL, were
preincubated in the presence of 3.0 M urea (ﬁnal concentration 1.0 M) at
37 °C. For the analysis of the ADAMTS13 Val195Ser, Leu198Ser, and
Leu274Ser variants, WT VWF (1.0 μg/mL) and 15 nM of the variants were
used. Subsamples were removed reactions were stopped with EDTA.
Changes in VWF resulting from ADAMTS13 proteolysis were analyzed by
SDS/PAGE under reducing conditions and Western blotting for VWF, as
previously described (14).
Peptide Inhibition Assay. For peptide inhibition assay, 1 mM synthetic peptide
containing VWF Asp1596-Tyr1605 sequence (termed NTP) (Alta Bioscience) or
NTP(Leu1603Ala) was incubated with 3.5 nM ADAMTS13 and 5 mM CaCl2 at
37 °C for 30 min, and 6 μM VWF115 was then added. The reaction was
stopped (from 0–60 min) with EDTA and analyzed by SDS/PAGE with Coo-
massie staining. To quantify the effect of peptides on VWF115 proteolysis by
ADAMTS13, 0 to 1 mM NTP or NTP(Leu1603Ala) were individually incubated
with 1 nM ADAMTS13 and CaCl2 at 37 °C for 30 min, and 2.5 μMVWF115 was
then added. After 15 min, the reaction was stopped with EDTA. Thereafter,
VWF115 proteolysis was quantiﬁed by HPLC.
Sequence Alignments and Molecular Modeling. Amino acid sequences of either
VWF or ADAMTS13 from different species retrieved from PubMed were
aligned using AlignX software (Informax).
The ADAMTS13 metalloprotease domain was initially modeled using the
HHPred server based on its sequence homology to ADAMTS1, -4, and -5, for
which the crystal structures are available (28–30). Models were manipulated
with Pymol software (Delano Scientiﬁc LLC).
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Fig. S1. Partial primary sequence of the ADAMTS13 substrate VWF115. VWF amino acids are shown as single letter, the ADAMTS13 cleavage site is indicated,
substitutions/deletions referred to in the text are annotated below the sequence, and the N-terminal peptide (NTP) is represented by the horizontal arrow.
VWF115 spans residues 1554Glu–1668Arg, but residues shown are only for VWF73, spanning1596Asp–1668Arg.
Fig. S2. Cleavage of WT VWF115, VWF115 Leu1603Ser, and VWF115 Tyr1605Ser by ADAMTS13. Cleavage of 6 μM WT VWF115 and variants was performed
with 1 nM (Upper) and 10 nM (Lower) WT ADAMTS13 and reactions visualized by SDS/PAGE.
Fig. S3. Studies with VWF115 Val1604Ser, the P2 residue, and ADAMTS13 Leu198Ser. Cleavage of 6 μM WT VWF115 and VWF115 Val1604Ser by 1 nM WT
ADAMTS13 and ADAMTS13 Leu198Ser visualized by SDS/PAGE.
Fig. S4. Cleavage of VWF115 Leu1603Ser by ADAMTS13 Val195Ser, Leu198Ser, and Leu274Asn. Cleavage of 6 μM VWF115 Leu1603Ser by 30 nM WT
ADAMTS13 and ADAMTS13 Val195Ser, Leu198Ser, and Leu274Ser are visualized by SDS/PAGE.
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Fig. S5. Regional alignment of the VWF sequence in different species. The amino acid residues within VWF1593–1615 were aligned to identify highly con-
served residues. The position of the scissile bond, Leu1603, and Asp1614 are indicated at the top of the ﬁgure.
Fig. S6. Regional alignment surrounding the active site of the ADAMTS13 sequence in different species. The active site, conserved Ca2+ binding site and
residue Arg349 are indicated, along with hydrophobic residues implicated in ADAMTS13 function, Leu151, Val195, Leu198, Leu232, and Leu274.
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Review article
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves
von Willebrand factor
James T. B. Crawley,1 Rens de Groot,1 Yaozu Xiang,1 Brenda M. Luken,1 and David A. Lane1
1Centre for Haematology, Imperial College London, London, United Kingdom
von Willebrand factor (VWF) is a large
adhesive glycoprotein with established
functions in hemostasis. It serves as a
carrier for factor VIII and acts as a vascu-
lar damage sensor by attracting platelets
to sites of vessel injury. VWF size is
important for this latter function, with
larger multimers being more hemostati-
cally active. Functional imbalance in mul-
timer size can variously cause microvas-
cular thrombosis or bleeding. The
regulation of VWF multimeric size and
platelet-tethering function is carried out
by ADAMTS13, a plasma metalloprotease
that is constitutively active. Unusually,
protease activity of ADAMTS13 is con-
trolled not by natural inhibitors but by
conformational changes in its substrate,
which are induced when VWF is subject
to elevated rheologic shear forces. This
transforms VWF from a globular to an
elongated protein. This conformational
transformation unfolds the VWF A2 do-
main and reveals cryptic exosites as well
as the scissile bond. To enable VWF pro-
teolysis, ADAMTS13 makes multiple inter-
actions that bring the protease to the
substrate and position it to engage with
the cleavage site as this becomes ex-
posed by shear. This article reviews re-
cent literature on the interaction between
these 2 multidomain proteins and pro-
vides a summary model to explain proteo-
lytic regulation of VWF by ADAMTS13.
(Blood. 2011;118(12):3212-3221)
Many of the coordinated processes involved in hemostasis are
driven by proteolytic reactions in which proteases cleave specific
substrate bonds. Bond cleavage can lead to activation, propagation,
or inactivation of a biochemical process. Control of proteolytic
reactions is complex and, in its broadest sense, embraces localiza-
tion of the protease and substrate, recruitment of cofactors for the
purpose of acceleration of cleavage and then, direct or indirect
inhibition of the protease to terminate its action. The plethora of
proteolytic reactions in hemostasis provides examples of both
general and process-specific mechanisms of control, which are all
needed to ensure effective coordination. The proteolytic regulation
of von Willebrand factor (VWF) function by its cleaving protease,
ADAMTS13, falls into the latter category (ie, process-specific
control), as it has certain unique features that set it apart from other
hemostatic reactions. VWF is a large adhesive glycoprotein,
necessary for initial platelet tethering and subsequent platelet
adhesion.1 It is a multiadhesive protein that can interact with cell
surface, extracellular matrix, and plasma protein ligands through
specific domain binding sites.2-6 VWF is synthesized as a multi-
meric protein, which is central to its physiologic role. VWF function as a
vessel wall damage sensor and initiator of primary hemostasis is highly
dependent on its multimeric size.7 The larger VWF multimers in plasma
are the most hemostatically reactive not only because they contain more
ligand binding sites, but also because they are more conformationally
responsive to vascular shear forces.1
In circulation, a first level of functional control of VWF is
provided by its adoption of a globular conformation.8 The conse-
quence of a globular fold is that certain interaction sites are buried
and inaccessible to their ligands, which enables VWF to patrol the
intact vasculature without binding unnecessarily to platelets or to
plasma proteins. The functional quiescence of circulating VWF is
perturbed by vessel damage, which results in the exposure of the
collagen-rich matrix that normally underlies the protective endothe-
lial cell monolayer. Globular VWF recognizes this newly exposed
collagen leading to its specific recruitment to the damaged vessel
wall. VWF then undergoes a unique structural transition whereby it
is unfolded by local shear forces exerted on the tethered molecule
by the flowing blood.8 In this way, VWF adopts an elongated,
“active” conformation that exposes previously hidden platelet
binding sites that mediate the capture of circulating platelets to the
site of vascular injury. These first steps in the genesis of the primary
platelet plug illustrate the importance of VWF conformation for its
hemostatic function. Intriguingly, this same process of shear-
dependent unfolding that activates VWF into a functional hemo-
static protein also represents a primary determinant of the proteo-
lytic regulation that controls VWF function.9
VWF is synthesized in a multimeric form that is essentially too
large and thus too reactive for its routine functions. Although the
largest plasma VWF multimers have generally been considered to
range from 20- to 40-mers, more recent measurements have
estimated that 100- or 200-mers may also exist, suggesting that
stored endothelial and platelet VWF multimers may even exceed
this.10 Control of VWF size, therefore, requires a specific regula-
tory mechanism. The plasma metalloprotease, ADAMTS13, pro-
vides this function by cleavage of a single peptide bond (Tyr1605-
Met1606) located within the central VWF A2 domain (Figure
1A-B).11,12 However, while in its globular conformation VWF is
essentially resistant to proteolysis, and only when VWF unfolds in
response to shear does the scissile bond become accessible for
ADAMTS13 to cleave. Proteolysis reduces VWF multimer size
and, consequently, also its hemostatic function. The clinical
importance of the regulation of VWF multimeric size by
ADAMTS13 is exemplified by the clinical manifestation of
dysfunction of the VWF-ADAMTS13 axis. ADAMTS13 defi-
ciency (with consequent loss of VWF proteolysis) is associated
with thrombotic thrombocytopenia purpura (TTP),13 a disease
caused by clumping of platelets by ultra large (UL)–VWF and
defined clinically by microangiopathic hemolytic anemia and
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thrombocytopenia.14 In contrast, excessive ADAMTS13-mediated
VWF proteolysis precipitates type 2A von Willebrand disease15 in
persons carrying mutations in VWF that increase the cleavage
susceptibility of the scissile bond. There have also been sugges-
tions that the hemostatic imbalance caused by reduced ADAMTS13
cleavage of VWF may contribute to thrombosis associated with
cardiovascular diseases, but the evidence is currently conflicting.16,17
Control of VWF function by proteolysis depends on themes that
are well rehearsed in hemostasis, including both the interaction of
remote exosites and recognition of the scissile bond by the
substrate-binding pocket of the protease. However, unlike the vast
majority of hemostatic proteases, ADAMTS13 activity is not
subject to direct regulation by a specific inhibitor. Although free
hemoglobin18 and IL-619 can both inhibit ADAMTS13 function,
these do not represent normal physiologic regulators (but may
inhibit ADAMTS13 under pathophysiologic circumstances). Cer-
tain coagulation proteases, such as thrombin and plasmin,20 might
play a role in controlling activity because ADAMTS13 is sensitive
to proteolysis by these serine proteases at defined cleavage
inactivation sites.21 However, as evidence of ADAMTS13 proteol-
ysis in vivo has only been observed in patients with severe sepsis22
or in a very rare case of 2-antiplasmin deficiency,23 it is probable
that this remains a pathologic phenomenon rather than a normal
control mechanism. The absence of a specific inhibitor, therefore,
implies that in the normal physiologic context, ADAMTS13 is
essentially unregulated and that its activity is primarily controlled
by both the availability of the scissile bond of VWF and the
specificity of the VWF-ADAMTS13 interaction. Substrate control
of protease function represents an intriguing and less familiar
mechanism in the setting of hemostasis, and yet this is central to
control and coordination of platelet tethering. Over the past decade,
much attention has been paid to the molecular mechanisms
underlying the control of VWF function by ADAMTS13, the focus
of this review.
The substrate, VWF
Synthesis of VWF is restricted to endothelial cells and megakaryo-
cytes.24,25 The nascent polypeptide monomer ( 310 kDa) contains
a signal peptide, a propeptide and the now familiar mature VWF
domain organization that contains a variety of specific ligand
binding sites (Figure 1A). Covalent dimerization of VWF mono-
mers takes place in the endoplasmic reticulum, mediated through
intermolecular disulphide pairing of Cys residues in the cysteine
knot domain.26,27 Multimerization of the dimers in the Golgi, in a
process catalyzed by the propeptide (D1 and D2 domains), which
acts as a protein disulphide isomerase to form disulphide bonds
between the N-termini of VWF dimers.28,29 During its synthesis,
VWF undergoes extensive glycosylation with 12 N-linked and
10 O-linked glycan side chains on each mature monomer unit
(Figure 1A-C). Glycosylation is essential for secretion of the
protein and 4 N-linked sites (Asn99, Asn857, Asn2400, and
Asn2790) have been identified that are of particular importance for
Figure 1. The substrate, VWF. (A) Domain organization
of VWF. N-linked and O-linked glycosylation sites are
represented by green and orange lollipops, respectively.
The propeptide (yellow represents D1 and D2) is marked.
S-S indicates sites of intermolecular disulphide bond
pairing. Vertical arrows indicate the location of cleavage
sites (furin and ADAMTS13). Ligand binding sites (FVIII,
GPIb, collagen, and IIbIII) are labeled below. (B) Sche-
matic representation of the VWF A1, A2, and A3 do-
mains. The paired cysteines in A1 and A3 are shown. The
vicinal disulphide bond that forms the molecular plug in
the A2 domain and the Tyr1605-Met1606 (YM)
ADAMTS13 cleavage site are also represented. (C) Struc-
ture of the VWF A2 domain highlighting the N-linked
glycosylation sites (green), vicinal disulphide bond (blue),
and the ADAMTS13 cleavage site (red) hidden in the
center of the folded domain. (D) Molecular models of the
unfolding of the VWF A1-A2-A3 domains. In globular
VWF, the A3 domain collagen binding site is exposed.
Elevated shear forces on VWF cause uncoupling of the A
domains, extraction of the Cys1669-Cys1670 vicinal
disulphide plug, and unraveling of the A2 domain. This
exposes the GPIb binding site in the A1 domain, cryptic
ADAMTS13 binding sites, and the cleavage site in the A2
domain (red).
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synthesis/secretion.30,31 A small proportion of the N- and O-linked
glycans contain the ABO(H) blood sugars.32 Not only do these
influence plasma VWF levels, their presence also influences VWF
proteolysis by ADAMTS13, as shown by the increased proteolysis
of patients with the rare Bombay blood group.33 The most
important N-linked glycan in this respect is that attached to
Asn1574 within the A2 domain (Figure 1C), which, if removed,
appreciably increases the susceptibility of the VWF A2 domain to
unfold and be proteolysed.30 This glycan may help stabilize the
folding of the VWF A2 domain and therefore also influence the
domain unfolding necessary for proteolysis. The O-linked glycans
are clustered either side of the VWF A1 domain and probably play
a role in stiffening the hinge between the adjacent domains.34
After glycosylation, furin removes the VWF propeptide, which
then assists in the trafficking of both the mature multimeric VWF
and cleaved propeptide to Weibel-Palade bodies of endothelial cells
or -granules of platelets.35 VWF is stored in these organelles in
UL form. These UL-VWF multimers can be released constitutively
from the endothelium into the bloodstream,36 or on demand in
response to a variety of different physiologic agonists capable of
activating the endothelium or platelet.
On secretion, a proportion of VWF released from endothelial
cells remains tethered to the cell surface, from which it is
proteolytically cleaved and released by ADAMTS13.37 Once in
free circulation, VWF adopts its globular conformation. In this
respect, the behavior of the VWF A1-A2-A3 domains is central to
VWF function. In its globular form, one can envisage that the
collagen-binding site within the A3 domain is constitutively
exposed on the surface, as it must provide the initial contact point
for the newly exposed collagen. Conversely, the glycoprotein Ib
(GPIb) binding site in the VWF A1 domain remains largely
hidden until required to prevent spontaneous or unnecessary
platelet binding. The intervening VWF A2 domain that harbors the
ADAMTS13 cleavage site (Tyr1605-Met1606) is folded such that
the cleavage site and VWF A2 domain exosites are hidden/buried
(Figure 1B-C). While in this globular form, VWF exhibits func-
tional quiescence.
Mechanical shear forces in the bloodstream act on the VWF
molecule, thereby stretching it and changing its conformation. This
modulates the exposure of both VWF A1 domain platelet binding
sites and the VWF A2 domain ADAMTS13 binding/cleavage
site(s).38,39 Larger VWF multimers unravel more readily under high
shear.38 Furthermore, attachment of VWF multimers to collagen
and/or platelets further facilitates unfolding because of increased
tensile force acting on the VWF molecule. VWF unfolding is
thought to involve both the uncoupling of the VWF A1-A2-A3
tridomain cluster, and conformational changes within individual
domains,39 most notably the VWF A2 domain40 (Figure 1D).
The protease, ADAMTS13
ADAMTS13 is synthesized in hepatic stellate cells41 and vascular
endothelial cells42 as an  180-kDa glycoprotein. Its domain
structure is depicted in Figure 2A. ADAMTS13 is a member of the
ADAMTS family of Zn2-dependent metalloproteases, which all
contain (from the mature N-terminus) a metalloprotease, disintegrin-
like, thrombospondin type 1 (TSP) repeats, cysteine-rich and
spacer domains.13,43-45 Thereafter, different family members con-
tain variable numbers and types of domains.
The metalloprotease domains of the ADAMTS family are
characterized by a reprolysin-type Zn2 binding signature (HEXX-
HXXGXXHD) involving 3 perfectly conserved His residues
(Figure 2B). This sequence also contains an active-site Glu residue
(at position 225 in ADAMTS13), which polarizes a water molecule
that is stabilized by the coordinated Zn2 ion, and is part of the
proteolytic machinery. The Zn2-binding motif is followed in all
ADAMTS metalloprotease domains by a tight “Met-turn,” which is
a further structural characteristic of these metalloproteases.
Whereas these common structural features in ADAMTS family
members are critical for substrate recognition and hydrolysis of the
scissile bond, differences in the substrate binding exosites and in the
architecture of the catalytic site allow eachADAMTS family member to
recognize and proteolyse its physiologic substrate at a particular site.
Figure 2. The protease, ADAMTS13. (A) Domain organization of
ADAMTS13. From the N-terminus are the metalloprotease domain (MP;
red), disintegrin-like domain (Dis; yellow), TSP repeats (1-8; green),
cysteine-rich domain (Cys; blue), spacer domain (purple), and CUB
domains (orange). Binding sites and function of specific domains are
labeled below. (B) Structure of ADAMTS13 N-terminal domains (MDTCS)
based on the crystal structure of DTCS and homology modeling of the MP
domain. Surface representation is shown. Domains are colored according
to panel A. (Insets) Cartoon representation of the location of the high-
affinity calcium binding site and coordinating residues (green) in the MP
domain, the active site containing 3 His residues (red) and catalytic
Glu225 (mauve), the disintegrin-like domain exosite, and spacer domain
exosite.
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ADAMTS13 requires divalent cations for its activity.12 In
addition to the Zn2 ion in the active center, Ca2 ions are also
required for enzyme function. On the basis of ADAMTS family
sequence conservation and structural analyses of the metallopro-
tease domains of ADAMTS1, ADAMTS4, and ADAMTS5,46-48 a
double Ca2 binding site within the ADAMTS13 metalloprotease
domain coordinated by Glu83, Asp173, Cys281, and Asp284 was
predicted.49,50 However, functional evaluation of this Ca2 binding
site revealed that mutating either Glu83 or Asp173 to Ala did not
appreciably diminish proteolysis of a short VWF substrate.50 This
suggests that the binding of Ca2 to this site is not of major
importance for ADAMTS13 function. Conversely, mutation of
another candidate site composed of Asp182, Asp187, and Glu212
had a major influence on ADAMTS13 activity.50 Single point
substitutions of these residues increased the KD(app) for Ca2 from
 72M (for wild-type ADAMTS13) up to 720M, indicating a
large reduction in functional binding affinity for Ca2. That these
residues are present in a loop adjacent to the ADAMTS13 active
site (Figure 2B) suggests that Ca2 binding provides structural
integrity to this loop that is necessary for efficient proteolysis of the
VWF substrate.
Adjacent to the metalloprotease domain in ADAMTS family
members are disintegrin-like domains, which share similarity with
snake venom disintegrins but lack the canonical cysteine arrange-
ment. Despite its name, the disintegrin-like domain of ADAMTS
family members does not appear to function like a disintegrin and
bears greater structural similarity to the cysteine-rich domains51:
this is evident from the recently published crystal structure of the
ADAMTS13 noncatalytic domains spanning the disintegrin to
spacer domains.52 In addition, and unlike the ADAM family
metalloproteases, the disintegrin-like domain of the ADAMTS
family contains a linker region that extends around the back of the
metalloprotease domain and positions the disintegrin-like domain
at one end of the active-site cleft.
The TSP repeats of ADAMTS13 are homologous to the type
1 repeat of thrombospondin-1 and -2. The first TSP repeat (48-
54 residues) is very similar in all members and generally contains
6 cysteines. The downstream TSP repeats (after the spacer domain) are
much more variable in sequence. The 4th TSP repeat of ADAMTS13
contains just 4 Cys residues, 2 of which are predicted to remain
unpaired. Four TSP domains in ADAMTS13 contain a CSVSCG motif
in which the second serine is O-linked glycosylated and forms a
consensus binding sequence for the CD36 cell surface receptor.53
The cysteine-rich domain of ADAMTS13 demonstrates high
sequence homology with the other ADAMTS family members,
which contain 10 conserved cysteines (except ADAMTS10). This
precedes the spacer domain, which contains no cysteines and is of
highly variable length among family members. It is the least
homologous of all the domains and is globular with 10 -strands in
a jelly roll topology, forming 2 antiparallel -sheets.
ADAMTS13 is the only member of theADAMTS family to contain
CUB domains, of which there are 2 located at the C-terminus. CUB
domains are present on proteins known to be important for developmen-
tal regulation, such as bone morphogenetic protein-1.
ADAMTS13 recognition of globular VWF
Recognition of VWF by ADAMTS13 is complex, yet highly
specific and involves multiple interactions between distinct do-
mains of both ADAMTS13 and VWF, with some of the interaction
sites on VWF only becoming exposed during shear. Much of the
structure-function work on ADAMTS13 has used domain deletion
mutants that retained the metalloprotease domain but were progres-
sively truncated from the C-terminus. Despite the limitations of
potential conformational changes induced by domain deletion,
these mutants have provided valuable initial tools for exploring
ADAMTS13 domain function. Early results with deletion mutants
of ADAMTS13, however, provided inconsistent and condition-
dependent evidence for a functional role for the C-terminal TSP
repeats and CUB domains. For example, it was widely held that
truncation mutants of ADAMTS13 with deletions after the spacer
domain (MDTCS) retained most of their activity in cleaving VWF
under static denaturing conditions, implying that these domains
might be dispensable.54-56 Another study reported activity of
deletion mutants in flow based, but not in static assays.57 However,
the C-terminal TSP and CUB domains have been claimed to be
important for optimal cleavage activity of ADAMTS13 under flow
conditions,58 against full-length murine VWF59 and for cleaving
platelet decorated strings in vivo.60 Finally, a peptide sequence
from first CUB domain was found to inhibit VWF proteolysis
under flow conditions.61 To resolve such conflicting results,
Zanardelli et al prepared deletion mutants of both VWF and of
ADAMTS13 and performed binding and activity studies under
both static and flow conditions.62 These experiments showed
that full-length ADAMTS13 could bind with a KD  86nM to
VWF in its quiescent/globular (as opposed to its unraveled)
conformation. This binding is mediated in part by the VWF D4
domain and the TSP5-8 and/or the CUB domains of ADAMTS13.
Similar conclusions were drawn by Feys et al using immunopre-
cipitation of VWF-ADAMTS13 complexes in solution to deter-
mine a KD  79nM.63 This interaction was dependent on the
ADAMTS13 TSP2-8 repeats. Both studies demonstrated the
specific binding of ADAMTS13 to globular VWF, and that in the
absence of shear-induced unfolding of VWF this interaction is
nonproductive in terms of VWF proteolysis.
Feys et al demonstrated that a proportion of globular VWF
and ADAMTS13 normally circulate in plasma in complex with
each other.63 The stoichiometry of ADAMTS13 to globular
VWF is low ( 1 ADAMTS13 molecule per 250 VWF mol-
ecules).63 This suggests that the larger, more hemostatically
active VWF multimers are the most probably globular VWF
forms to circulate in complex with ADAMTS13.64 It is also
these larger species that contribute most to platelet plug
formation. Consequently, although only a small percentage of
plasma ADAMTS13 ( 3%) actually circulates bound to VWF,
this pool may be particularly effective at colocalizing VWF and
ADAMTS13 to the site of vessel damage. Evidence that this
may be of functional significance was provided by Banno et al,65
who examined mice with an Adamts13 gene that expresses a
truncated form of the enzyme (ADAMTS13S) that lacks the
TSP(7/8) and CUB domains.66 Neither the Adamts13/ nor
Adamts13S/S mice had discernible differences in their plasma
VWF multimers, suggesting that the TSP(7/8) and the CUB
domains may not be necessary for modulating normal plasma
VWF size.65 However, mice expressing the truncated
ADAMTS13 were more thrombogenic in experimental throm-
bus formation under high shear conditions, suggesting that the
loss of the TSP(7/8) and CUB domains impaired the ability of
ADAMTS13 to regulate VWF-dependent development of the
platelet plug.
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VWF A2 domain unfolding is required for
proteolysis by ADAMTS13
Although ADAMTS13 can bind globular VWF, it cannot cleave it12
because further binding sites and the scissile bond are hidden inside
the folded VWF A2 domain.67,68 The folded VWF A2 domain
adopts an atypical Rossman fold in which amphipathic -helices
surround a central -sheet in which the ADAMTS13 cleavage site
is buried67 (Figure 1B-C). Although the VWF A2 domain is highly
homologous to the VWF A1 and A3 domains, it is more prone to
unfolding because it lacks an intradomain disulphide bond that
connects the N- and C-termini and further destabilized because one
of the amphipathic -helices has been replaced by a less-ordered
loop (4-less loop)67 (Figure 1B-C). The VWF A2 domain crystal
structure has also revealed a very rare vicinal disulphide bond
between adjacent Cys1669 and Cys1670 at the C-terminus of the
last -helix in the A2 domain. This vicinal disulphide bond forms
an 8-membered ring that bends the peptide backbone in an
unusually strained conformation and forms a “molecular plug” that
directly interacts with hydrophobic residues in the core of the
domain.67 This disulphide bond was therefore hypothesized to
stabilize the VWF A2 domain fold. Luken et al indeed showed that
when this disulphide bond is removed by mutagenesis, the VWF
A2 domain more readily unfolds and is more susceptible to
proteolysis by ADAMTS13.69 When VWF encounters elevated
rheologic shear forces, this “molecular plug” is pulled out,
allowing water molecules to enter and destabilize the hydrophobic
core resulting in VWF A2 domain unfolding (Figure 1D).
Of all the VWF A2 domains that are present in a long VWF
multimer, it is those in the middle that are most likely to unfold and
therefore be cleaved. Under shear the tensile forces that are applied
on VWF increase with the distance from the nearest end of the
multimer.38 This means that the force is highest in the middle, but
also that an VWF A2 domain in the middle of a large multimer is
more prone to unfolding than one in the middle of a short multimer.
This provides a mechanism that distinguishes VWF multimers that
need to be cleaved (larger ones) from those that do not (shorter
ones).
Zhang et al investigated the forces necessary to unfold the VWF
A2 domain using laser tweezers.38 They applied force to a single
VWF A2 domain and measured the increase in length at different
forces. They found that the VWF A2 domain typically unfolds at
approximately 11pN. Their analysis predicted that this tensile force
might correspond to that encountered in the middle of a free
flowing 200-mer VWF multimer in arterioles and capillaries. Apart
from during transit through arterioles and capillaries, such high
shear rates are also encountered when VWF is bound to platelets,
collagen or during secretion from endothelial cells. VWF bound to
platelets has indeed be shown to be more susceptible to cleavage by
ADAMTS13,70 and VWF multimers are cleaved by ADAMTS13
on secretion from endothelial cells.37
Zhang et al also found that when force was relaxed after domain
unfolding, the VWF A2 domains could refold.38 Refolding after a
high shear encounter in the circulation is probably important in
preventing excessive cleavage. Interestingly, the VWF A2 domain
contains a cis-proline (Pro1645) that when exposed to high forces
(eg, when VWF is bound to platelets) could potentially become a
trans-proline, which could last long enough (100-1000 seconds) to
delay refolding and, in turn, enhance the opportunity for proteoly-
sis by ADAMTS13. The biophysical balance between unfolding
and refolding represents a key determinant of VWF function.
The ADAMTS13 spacer domain binds to a
cryptic VWF A2 domain exosite that is
revealed on unfolding
Once the VWF A2 domain is unfolded, additional binding sites for
ADAMTS13 on VWF are revealed. To investigate where within the
VWF A2 domain these binding sites reside, short VWF A2 domain
fragments, such as VWF115 and VWF73, have been used as
substrates.68,71 C-terminal deletion mutants of these fragments
demonstrated that VWF A2 domain residues Glu1660-Arg1668
appreciably contribute to the cleavage of the Tyr1605-Met1606
scissile bond.71 Gao et al found that the ADAMTS13 spacer
domain binds to this sequence, referred to as a VWF A2 domain
exosite, and that deletion of either the spacer domain from
ADAMTS13, or deletion of the VWF A2 domain exosite reduced
cleavage of VWF73 by approximately 20-fold.72 Wu et al isolated
short peptides containing the VWF A2 domain exosite that were
able to inhibit cleavage of short substrates and of full-length
multimeric VWF.72,73 This VWF A2 domain exosite is cryptic
inasmuch as it is not exposed in the isolated folded VWF A2
domain or in globular VWF.62,69 Exposure of this cryptic exosite
requires the extraction of the adjacent molecular plug formed by
the vicinal disulphide bond, Cys1669-Cys1670 (Figure 1D) and
Figure 3. ADAMTS13 recognition of the VWF cleavage site. (A) Molecular model
of the ADAMTS13 metalloprotease (MP; light red) and disintegrin-like (Dis; yellow)
domains. (Inset) The active site cleft. Active site residues (Zn2 ion, its 3 coordinating
His residues His224, His228, and His234, as well as the catalytic Glu225 residue)
and disintegrin-like domain exosite residues are labeled. The high-affinity functional
Ca2-binding loop is also marked. Regions of the metalloprotease domain that are
predicted to harbor the S3, S2, S1, S1, and S2 subsites are labeled marked in
different colors. (B) Below the active site cleft, VWF A2 domain residues Leu1603-
Asp1614 are depicted as sticks and transparent spacefill. The P3, P2, P1, P1, P2,
and P9 residues in VWF that are important for proteolysis are labeled and colored
according to their predicted complementary subsites (S) in the metalloprotease
domain.
3216 CRAWLEY et al BLOOD, 22 SEPTEMBER 2011  VOLUME 118, NUMBER 12 personal use only.
For at IMPERIAL COLLEGE LONDON on September 23, 2011. bloodjournal.hematologylibrary.orgFrom 
uncoupling of the C-terminal -helix in which residues Glu1660-
Arg1668 reside. As this region is predicted to unfold first, even
partial unfolding of the VWF A2 domain could be sufficient for the
spacer to bind.
Further insight into the nature of the ADAMTS13 spacer
domain exosite that binds this VWF A2 domain site came from the
study of autoantibodies that arise in acquired TTP. The ADAMTS13
Cys and spacer domains were shown to be the primary autoimmune
target in TTP.74 Using both monoclonal and polyclonal antibodies
isolated from patients with acquired TTP, Pos et al demonstrated
that ADAMTS13 spacer domain residues Arg660, Tyr661, and
Tyr665 represent a core binding site for autoantibodies.75 The
ADAMTS13 spacer domain residues Arg660, Tyr661, and Tyr665
reassuringly align as a surface cluster on the structure of the
noncatalytic domains,52 available for both antibody and VWF A2
exosite interactions75 (Figure 2B). Substitution of these amino
acids resulted in a 12-fold reduction in catalytic efficiency (kcat/Km)
of VWF115 proteolysis and a 25-fold reduction in VWF115
binding.75 This suggested that the core binding site for TTP
autoantibodies overlapped with a functional spacer domain exosite.
Jin et al used similar mutagenesis approaches and suggested that
Arg659 of ADAMTS13 might also contribute to ADAMTS13
spacer-VWF A2 interactions.76 Although ADAMTS13 can bind
globular VWF with a KD of  80nM via interactions of the
C-terminal TSP and CUB domains, once VWF is unfolded this
binding increases appreciably (KD  5-10nM) because of the
cooperative effects of the spacer domain and the C-terminal TSP
and CUB domains.
An interesting point is that, although the ADAMTS13 spacer
domain exosite undoubtedly engages with the cryptic VWF A2
exosite and is a major determinant of short substrate binding and
proteolysis, mutation of this exosite in full-length ADAMTS13
(rather than in the ADAMTS13 truncation, MDTCS) does not
greatly influence proteolysis of full-length multimeric VWF.75
Therefore, the interaction between the ADAMTS13 spacer domain
and the VWF A2 domain exosites makes a modest, rather than
pivotal, contribution to the proteolysis of full-length VWF. This
may suggest some functional redundancy between the spacer
domain and C-terminal TSP and CUB domain binding sites and
further highlights the importance of additional functional exosites
in both molecules.
The ADAMTS13 disintegrin-like domain
interacts with a VWF exosite to orient the
scissile bond toward the active-site
The shear induced extraction of the vicinal Cys1669-Cys1670 plug
from the hydrophobic core of the VWF A2 domain not only
exposes the VWF Glu1660-Arg1668 A2 domain exosite, but also
destabilizes the domain fold to enable exposure of additional
sequences that act as additional exosites. Gao et al used deletion
mutants of VWF73 to propose a number of discreet interactions
between ADAMTS13 domains and the VWF polypeptide.77 Simi-
lar conclusions were drawn by Akiyama et al based on their crystal
structure of the ADAMTS13 DTCS domains and functional
analyses of ADAMTS13 mutants.52 Both studies suggested that the
cysteine-rich domain contains a functional exosite that may interact
with residues adjacent to the VWF A2 domain exosite that binds the
spacer domain.52,77 However, at the time of writing, it is not yet
clear what the nature of this interaction is, or what its relative
contribution to the proteolysis of full-length VWF might be.
The role of the ADAMTS13 disintegrin-like domain was
investigated in detail by de Groot et al using both deletion and
substitution mutagenesis.78 A role for this domain had been
suggested by earlier reported domain deletion studies54,55 and
confirmed by de Groot et al.78 The use of molecular modeling and
sequence homology alignments with ADAMTS family members
helped identify potential exosite residues in this domain that might
make interactions with VWF. Kinetic analysis of point substitu-
tions revealed that mutation of Arg349 or Leu350 in the ADAMTS13
disintegrin-like domain reduced cleavage of VWF115 by approxi-
mately 10- to 20-fold because of both an increase in Km and
decrease in kcat, suggesting changes in both functional substrate
binding and substrate turnover.78 The effect of mutating this exosite
is very similar to the magnitude of the disruption of the spacer
domain exosite in proteolysis of short A2 domain fragments, but
appreciably greater when examining the proteolysis of full-length
multimeric VWF.75
The proximity of these amino acids in the disintegrin-like
domain to the active site in the adjacent ADAMTS13 metallopro-
tease domain (Figures 2B, 3A) suggested that they would likely
interact with VWF residues approximately 26Å C-terminal to the
scissile bond.78 Fortuitously, previous work by Zanardelli et al had
identified Asp1614 (located 9 residues C-terminal to the cleavage
site) in the VWF A2 domain as functionally important to the
cleavage of VWF115.68 Based on this, de Groot et al explored
whether Asp1614 in VWF forms a charged interaction with
Arg349. They showed that substituting either residue produced an
equivalent reduction in VWF115 cleavage, suggesting a mutual
and dependent interaction between these residues. This defined a
functional exosite on the ADAMTS13 disintegrin-like domain that
interacts with a complementary exosite on VWF involving Asp1614
and that this helps orientate the scissile bond toward the active
center of ADAMTS1378 (Figure 3).
Role of the VWF P1-P1 scissile bond
residues and the ADAMTS13 S1-S1 pockets
Notwithstanding the importance of the aforementioned remote
exosite interactions for binding and for guiding the substrate to the
active site of ADAMTS13, the metalloprotease domain itself must
also necessarily interact with the substrate in the vicinity of the
cleavage site and therefore harbor sites that contribute to scissile
bond specificity. Indeed, interactions between the metalloprotease
domain and VWF scissile bond have been demonstrated to be
critical for VWF proteolysis, as mutagenesis of the Tyr1605 (P1)
and Met1606 (P1) residues to alanine predictably greatly reduce
proteolytic efficiency.79,80 The comparatively normal proteolysis of
VWF115 Tyr1605Phe and Tyr1605Trp variants79 demonstrated the
importance of the aromatic side chain of the P1 residue. Undoubt-
edly, the P1 and P1 residues must be accommodated in specific
complementary binding pockets on ADAMTS13. The ADAMTS13
S1 pocket that accommodates the P1 residue probably involves
hydrophobic residues Leu151 and Val195.80 Furthermore, molecu-
lar modeling has suggested that this may also be made up by
elements of the loop containing the high-affinity Ca2 binding site
(Figure 3).
Similar analysis using VWF115 Met1606Leu highlighted the
requirement for a large and hydrophobic amino acid in the P1
position.79 The nature of the S1 subsite that accommodates the P1
residue of the substrate has been recently investigated by de Groot
et al.81 This report showed that a VWF115 P1 variant, Met1606Ala,
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was proteolysed 15- to 18-fold less efficiently than wild-type
VWF115. However, when ADAMTS13 residues Asp252-Pro256
were substituted with the corresponding residues of ADAMTS1,
the variant exhibited ADAMTS1-like P1 specificity by efficiently
cleaving a VWF115 mutant with Ala at the P1 site.81 This strongly
implied that amino acids Asp252-Pro256 of ADAMTS13 are
important in shaping the docking site of the P1 (Met) residue of the
VWF scissile bond and contribute to the S1 pocket (Figure 3).
Positioning of the VWF scissile bond: role of
the P3 residue
It is interesting to note that, in the literature to date, most attention
has been paid to regions and residues of VWF that are C-terminal to
the cleavage site. This approach has successfully identified the
importance of the VWF cleavage site residues, the ADAMTS13
disintegrin-like domain binding site and the VWF A2 domain
exosite that binds the spacer domain. Xiang et al hypothesized that
another necessary feature of enzymatic cleavage of VWF must be a
docking point for ADAMTS13 that is N-terminal to the scissile
bond.80 They considered the cleavage susceptibilities of previously
reported short VWF A2 domain fragments that span the cleavage
site. One, VWF64 (1605-1668), cannot be cleaved by
ADAMTS13,77 whereas others, such as VWF73 (1596-1668),
VWF76 (1593-1668), and VWF115 (1554-1668) are all proteoly-
sed efficiently.68,71,82 The difference between the substrates that are,
and those that are not cleaved, resides in the sequence N-terminal to
the scissile bond. Therefore, Xiang et al conjectured that the
VWF1596-1604 sequence immediately N-terminal to the cleavage
site must contain a structural determinant that is essential for
proteolysis.80 Accordingly, by systematic substitution of all of the
amino acids in this region, they showed that VWF P3 residue,
Leu1603, has an essential role in proteolysis of the scissile bond,
and the adjacent P2 residue (Val1604) plays an additional minor
role. Remarkably, substitution of Leu1603 alone to Ser, Asn, or Lys
all reduced the cleavage efficiency, up to ADAMTS13  400-
fold.80 Molecular modeling identified candidate interacting resi-
dues for VWF Leu1603 on the surface of ADAMTS13 adjacent to
the active site. Mutagenesis studies identified ADAMTS13 resi-
dues Leu198, Leu232, and Leu274 as elements that together may
make up the S3 subsite (Figure 3).
Because the VWF P3 residue is functionally so important, it
suggested a role in the cleavage mechanism of the VWF scissile
bond. Xiang et al have proposed a model of cleavage in which the
VWF P3 (Leu1603), P2 (Val1604), and P9 (Asp1614) residues act
Figure 4. Proteolysis of VWF by ADAMTS13. VWF
circulates in plasma as a multimeric molecule (A) that
adopts a quiescent globular conformation. Each multi-
mer is composed of disulphide linked VWF monomers
(B). In its globular conformation, the A3 domain colla-
gen binding site is exposed. ADAMTS13 can bind to
this globular VWF via its TSP (5-8) and CUB domains
(C), step 1. This enables VWF and ADAMTS13 com-
plexes to form and circulate in plasma. Under elevated
shear forces (which can occur on secretion, collagen
binding, or passage through the microvasculature),
VWF can unravel to expose A1 domain binding site for
GPIb. These shear forces also remove molecular plug
formed by the vicinal disulphide bond in the A2 domain,
which causes A2 domain unfolding (D), step 2 (see
Figure 1). This unfolding reveals cryptic exosites that
enable residues in the ADAMTS13 spacer domain to
bind to the unfolded A2 domain (E), step 3 (see Figures
1D, 2B). Thereafter, a critical low-affinity interaction
between D1614 and the Dis domain helps approximate
and position the cleavage site (F), step 4 (see Figure 3).
This enables further interactions between the MP
domain to occur, including an essential interaction via
an S3 subsite with L1603 in VWF (G), step 5 (see
Figure 3). Together, these interactions allow the MP
to engage via S1 and S1 subsites with the cleavage
site (YM; H), step 6, after which proteolysis can
occur, step 7.
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as docking sites on either side of the scissile bond.80 This brings the
P1 and P1 residues into position over the active site-coordinated
Zn2 ion and the catalytic Glu225 of ADAMTS13 for cleavage. A
model of the ADAMTS13 metalloprotease-disintegrin domains
aligned with the VWF sequence, including and surrounding the
scissile bond, is shown in Figure 3.
A multidomain, conformation-driven model of
VWF bond proteolysis by ADAMTS13
A summary model of VWF and ADAMTS13 interactions, encom-
passing binding at multiple sites, ultimately leading to scissile bond
cleavage can now be proposed that involves 7 potentially distinct
steps. Under normal physiologic conditions, VWF circulates in
plasma in a globular conformation in which the VWF A2 domain is
hidden within the core of the molecule. A binding site for
ADAMTS13 within the D4-cysteine knot domains of VWF is
nevertheless constitutively exposed, and a small proportion of
ADAMTS13 can reversibly associate with the globular protein
(step 1), with binding mediated by its TSP5-CUB domains
(KD  80nM; Figure 4A-C). When shear forces begin to induce the
transition of VWF from a globular to a fibrillar conformation (ie,
when secreted, when tethered to the site of vessel injury by its A3
domain or during passage through the microvasculature under high
shear), additional exosite binding sites on VWF are revealed that
present themselves (step 2) to complementary sites on ADAMTS13.
The ADAMTS13 spacer domain recognizes residues VWF resi-
dues Glu1660-Arg1668 (step 3), revealed when the vicinal Cys
disulphide bond plug is extracted from the hydrophobic core of the
A2 domain. This increases the affinity of ADAMTS13 for VWF
(KD  10nM). An ADAMTS13 disintegrin-like domain exosite
involving Arg349 recognizes a complementary exosite on VWF
composing Asp1614 in a critical, but low affinity, interaction (step
4). Thereafter, an essential contact is made between VWF Leu1603
and a complementary S3 subsite in ADAMTS13 involving Leu198,
Leu232, and Leu274 (step 5). Together, these interactions bring the
Tyr1605-Met1606 scissile bond over the ADAMTS13 active site.
This allows the P1 and P1 residues to engage with their respective
S1 and S1 subsite pockets, involving ADAMTS13 Leu151/Val195
(S1) and Asp252-Pro256 (S1), respectively (step 6). Steps 3 to 6
can be envisaged to represent a “molecular zipper” that ends in the
precise delivery of the scissile bond to the active site. Once
cleavage has taken place (step 7), there is a consequent reduction in
affinity of protease and substrate, enabling the protease to recycle.
Location specific cleavage of VWF by
ADAMTS13
Three distinct locations of VWF proteolysis by ADAMST13 can be
considered: (1) newly secreted VWF strings from the endothelial
cell surface, (2) UL-VWF in free circulation, and (3) unraveled
VWF at sites of platelet plug formation (Figure 5). Although
proteolysis in each of these instances could fulfill a somewhat
different purpose, the cleavage reaction is driven by local shear
forces that reveal the VWF A2 exosites that enable productive
ADAMTS13 binding. That ADAMTS13 proteolysis is dependent
on shear-induced unfolding may seem paradoxical inasmuch as the
very unfolding process that is required for platelet tethering is also
the primary determinant of proteolysis that counteracts this func-
tion. However, the recent advances in our understanding of the
biochemistry of the interactions of ADAMTS13 and VWF have
provided a potential explanation for this.
Vessel damage exposes collagen, to which VWF binds and
subsequently unravels in response to shear forces. This, in turn,
allows circulating platelets to bind. The binding of GPIb to VWF
occurs rapidly, involving both fast on- and off-rates that exceed the
rate of VWF proteolysis by ADAMTS13.39,83 It should be noted
that, despite the high-affinity binding of ADAMTS13 to VWF
(KD  10nM), the Km for proteolysis is appreciably higher
(Km  0.16-1.6M).38,68,78,81 Moreover, at sites of vessel damage,
the presence of collagen and thrombin generated by activation of
the coagulation cascade can act as potent local activators of
Figure 5. Location of VWF cleavage by ADAMTS13. Cartoon depicting the sites of VWF proteolysis by ADAMTS13. (UL)VWF is synthesized by the endothelium and stored
within Weibel-Palade bodies (WPB; green). VWF multimers of various sizes, including UL-VWF, can be secreted directly into the circulation. (1) Alternatively, a proportion of
UL-VWF may attach to the endothelial surface during exocytosis and unravel in response to shear forces. Under such circumstances, the VWF A2 domain unfolds to enable
ADAMTS13 (red scissors) to cleave VWF and release the VWF string. Whether directly secreted or proteolytically released, VWF can adopt a globular fold in the plasma
circulation. However, during passage through the microvasculature, globular UL-VWF in free circulation will probably unravel (at least partially/transiently). (2) Such unraveling
permits the processing of the largest, most hemostatically active forms of VWF, resulting in their conversion to smaller plasma VWF multimers. Mutations in VWF that
precipitate type 2A von Willebrand disease are particularly influenced by such proteolysis. This group of mutations enhances the propensity of VWF to unfold in free circulation,
leading to excessive proteolysis and loss of hemostatically functional VWF. Conversely, ADAMTS13 deficiency results in the loss of such plasma processing. Under these
circumstances, platelets (Pl) can become bound to transiently unraveled VWF, leading to the accumulation of VWF-platelet aggregates that occlude the microvasculature, as
seen in patients presenting with TTP. At sites of vessel damage, endothelial damage results in exposure of subendothelial collagen. Plasma VWF binds to this, unravels, and, in
turn, recruits platelets. The presence of collagen and thrombin induces rapid platelet activation, which consolidates the platelet plug. Thrombin further stabilizes this through the
deposition of fibrin and the proteolytic inactivation of ADAMTS13. (3) Downstream of the site of injury (ie, in the absence of collagen and thrombin), VWF-platelet strings may
still be proteolysed by ADAMTS13, which in turn limits/regulates platelet plug formation. Low or reduced ADAMTS13 levels may impair this process and consequently influence
the pathophysiology of arterial thrombosis.
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recruited platelets that prompt further VWF-independent adhesion
and aggregation. These recruited platelets can thereby become
resistant to the consequences of ADAMTS13-mediated VWF
proteolysis. As the platelet plug develops, however, it grows
beyond the site of injury (and also the primary source of collagen
and thrombin). In these locations, although unraveled VWF may
tether platelets through GPIb, binding is not consolidated as
effectively by the effects of collagen and thrombin. This probably
provides more time for ADAMTS13 to cleave VWF, and so
regulate platelet plug growth by confining it to the site of vessel
damage. This is further supported by the visualization of
ADAMTS13 function on the surface of developing thrombi using
whole blood flow models.84
The scenario is different for VWF that is either newly secreted
from the endothelium, or larger VWF multimers that are present in
free circulation, which may naturally unravel to expose their
GPIb binding site. In these cases, such unraveling takes place in
the absence collagen or thrombin that could otherwise activate
bound platelets. As platelet tethering in these instances is not
consolidated by the effects of such agonists, and, furthermore, as
this process also promotes VWF A2 domain unfolding, the
proteolysis of VWF by ADAMTS13 can occur, albeit relatively
slowly. The consequent decrease in VWF multimer size reduces the
shear forces exerted on the proteolysed molecules, enabling them
to adopt a quiescent globular conformation. This plasma proteoly-
sis thereby counteracts the formation of unwanted platelet-rich
thrombi in the microvasculature, thrombi such as occurs in persons
with TTP/ADAMTS13 deficiency.
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